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PEO    Poly Ethylene Oxide 
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PVP    Poly Vinyl Pyrrolidone 
PMMA   Polymethyl Methacrylate 
EC    Ethyl Cellulose 
PEG 400   Poly Ethylene Glycol 400 
DBP    Dibutyl Phthalate 
DCM    Dichloromethane 
BX    Betaxolol 
%    Percentage 
FTIR    Fourier Transform Infrared 
UV    Ultra Violet 
HPLC    High Performance Liquid Chromatography 
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cm    Centimeter 
µL    Micro liter 
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µg, mcg   Microgram 
mM                           Millimolar 
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w/w    Weight by weight 
w/v    Weight by volume 
h, hr    Hour, Hours 
Min    Minutes 
Sec    Seconds 
o
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C    Degree centigrade 
t    Time 
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Aim of present work 
Eye being a most delicate organ, ocular drug delivery is a challenge for the 
formulator. A drop of an aqueous solution, irrespective of instilled volume is 
eliminated completely from the eye within 5 to 6 minutes of its application and 
only a small amount (1-3%) actually penetrates the cornea and reaches the 
intraocular tissue. 
Ophthalmic inserts offer many advantages over conventional dosages forms, 
like increased ocular residence, possibility of releasing drug at a slow and 
constant rate, accurate dosing, exclusion of preservatives and increased shelf 
life. Design, construction and technology of ocular insert in a controlled and 
sustained ocular delivery device are gaining rapid improvement to overcome 
these constraints. 
Recent trend in ocular research is to formulate a dosage 
form which not only prolongs the residence of system in eye but also helps to 
reduce the elimination of the drug. In the same area many drug delivery 
systems including insitu gel, microemulsions, nanoparticles, liposome, 
niosomes, ocular inserts etc. are being investigated worldwide by many 
researchers.  
Niosomes in topical ocular delivery are preferred over other vesicular systems 
because of the following reasons: (1) chemical stability; (2) low toxicity 
because of their non-ionic nature; (3) handling surfactants with no special 
precautions or conditions; (4) the ability to improve the performance of the 
drug via better availability and controlled delivery at a particular site; (5) being 
biodegradable, biocompatible and non-immunogenic. 
There are only a few ocular inserts available on the market, made of EVA as a 
rate controlling membrane. Likewise, poly (methylmethacrylate) (PMMA) is 
also an excellent film-forming polymer but the films of PMMA alone are brittle. 
It offers more resistance to the diffusion of drug molecules, and is less 
explored as a polymer for ocular delivery of drugs. The current literatures 
indicate that no inserts are made of hydrophobic monolithic systems using 
betaxolol. Therefore, varying the ratio of these polymers in the composition of 
the films provides better control of drug release characteristics. Betaxolol is 
selective beta-1-adrenegic receptor blocker and used in the treatment of 
ocular hypertension and chronic open angle glaucoma.  Ocular administration 
of Betaxolol has the disadvantage of low bioavailability due to extensive and 
Aim of present work 
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highly variable defense mechanisms of the eye. In addition, Betaxolol eye 
drops requires bid dosing. Owing to these disadvantages, an Ocular patch of 
Betaxolol was designed and developed.  
The advantage of vesicular systems does not only reside in providing 
prolonged and controlled action at the corneal surface but also involves 
providing controlled ocular delivery by preventing the metabolism of the drug 
from the enzymes present at the tear/corneal epithelial surface. Moreover, 
vesicles offer a promising avenue to fulfill the need for an ophthalmic drug 
delivery system that has the convenience of a drop, but will localize and 
maintain drug activity at its site of action. The penetration of drug molecules 
into the eye from a topically applied preparation is a complex phenomenon. In 
vesicular dosage forms, the drug is encapsulated in lipid vesicles, which can 
cross cell membrane. Vesicles, therefore, can be viewed as drug carriers 
which can change the rate and extent of absorption as well as the disposition 
of the drug. 
Hence this investigation has been designed to study the drug release kinetics 
of betaxolol from a hydrophobic matrix system of PMMA cast with 
incorporating different proportions of PEO. Various niosomal formulations of 
betaxolol are formulated and evaluated in this study. New ocular insert 
devices - Nioserts are designed and developed.  
 
It was our prime objective to develop ocular drug delivery system that: 
1. Release the drug for prolonged period of time preferably 24 hr. 
2. Provide an increased ocular residence time resulting in prolonged drug 
delivery in eye. 
3. Reduce precorneal drug loss and thereby obtaining greater therapeutic 
efficacy.   
4. Show better in-vivo performance than conventional dosage forms. 
5. Avoid the systemic side effects. 
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1. INTRODUCTION 
In the recent years considerable attention has been focused on the 
development of new drug delivery systems. The therapeutic efficacy and 
safety of drugs administered by conventional methods can be improved by 
more precise spatial and temporal placement with in the body through a 
controlled drug delivery. Basically, there are three modes of drug delivery i.e. 
Targeted Delivery, Controlled Delivery and Modulated Delivery. 
1) Targeted delivery refers to the systemic administration of drug carrier with 
the goal of delivering the drug to specific cell types, tissues or organ. 
2) Controlled release refers to the use of delivery device with the objective of 
releasing the drug into the patient’s body at a predetermined rate, or at a 
specific time or with specific release profiles. 
3) Modulated release of a drug delivery device refers to the release of drug at 
a variable rate, controlled by environmental conditions, biofeedback, sensor 
input or an external control device(1)
1.1  Ocular drug delivery system 
.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
For many decades, treatment of an acute disease or a chronic illness has 
been mostly accomplished by delivery of drugs to patients using various 
pharmaceutical dosage forms, including tablets, capsules, pills, suppositories, 
creams, ointments, liquids, aerosols and injectables as drug carriers. Even 
today, these conventional drug deliveries are the primary pharmaceutical 
products commonly seen in the prescription and over the counter drug market 
place. These types of conventional dosage systems are known to provide a 
prompt release of drug. Therefore, to achieve as well as to maintain the drug 
concentration within the therapeutically effective range needed for treatment, 
it is often necessary to take this type of drug delivery system several times a 
day. This results in a significant fluctuation in drug levels.    
Recently, several new techniques for drug delivery are made which are 
capable of controlling the rate of drug delivery, sustaining the duration of 
therapeutic activity or targeting the delivery of the drug to a tissue. These 
advancements have led to the development of several novel drug delivery 
systems that could revolutionize the method of medication and provide a 
number of therapeutic benefits(2). 
Chapter 1  Introduction 
                                       Hitesh B. Gevariya 2                                   Ph. D. Thesis 
 
Ophthalmic products are preparations designed for application to the eye 
either for the treatment of disease, for the relief of symptoms, for diagnostic 
purpose or an adjuvant to surgical procedure. The conventional ocular 
preparations are eye drops and ophthalmic ointments. As soon as the eye 
drop solution is instilled into cul-de-sac, it is rapidly drained away from the 
precorneal cavity by constant tear flow and lachrymal-nasal drainage. Only 
about 1-2% of instilled dose is absorbed into the target tissues and relatively 
concentrated solution is required for installation to achieve an adequate level 
of therapeutic effect. The frequent periodic instillation of eye drops becomes 
necessary to maintain a continuous sustained level of medication. 
A basic concept in ophthalmic research and development is that the 
therapeutic efficacy of an ophthalmic drug can be greatly improved by 
prolonging its contact with the corneal surface. The viscosity enhancing 
agents such as methylcellulose are added to eye drop preparations or 
ophthalmic drug is formulated in water-insoluble ointment formulation to 
sustain the duration of intimate drug-eye contact. But these dosage forms give 
only marginally more sustained drug-eye contact than eye drop solutions and 
do not yield a constant drug bioavailability as originally hoped. The ocusert 
system has succeeded in significantly reducing dosing and also in remarkably 
improving the therapeutic efficacy of ophthalmic drugs(2)
Drugs that could be considered for delivery by log-acting inserts, in addition to 
anti glaucoma drugs, are antibiotics and anti-bacterials which require several 
applications daily in standard vehicles for treatment of Acanthamoeba 
Keratitis, trachoma etc. Other drugs selected for topical administration with 
inserts are antiviral, antifungal, anti-filarial, anti-allergenic, anti-inflammatory 
(Steroidal and NSAID), fibrinolytes, immuno suppressant and growth 
factors
. 
The ocusert systems are the only medicated inserts marketed in western 
countries. The prolonged constant-rate release pattern achieved by inserts 
such as ocusert and ocufit type can be considered as most desirable 
condition for long term therapy; both because of efficiency as well as the 
reduction of ocular and systemic side effects. 
(3). 
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1.2 Anatomy and physiology of the eye 
Eye is the most marvelous of the sense organs as it makes us aware of 
various objects all around us, near and far away. Eye is nearly spherical in 
shape except that its front portion i.e., transparent cornea bulges a bit 
forward. The eye is protected by the eyelashes, eyelids, tears and blinking. 
The eyelashes catch foreign materials as the blink reflex prevents injury by 
closing the lids, blinking occurs frequently during waking hours to keep the 
corneal surface free of mucous and moistened by the tears secreted by the 
lacrimal glands. Tears wash away irritating agents and are bactericidal, 
preventing infections. The protective operations of the eye lids and lacrimal 
system are such that, there is a rapid removal of material instilled into the eye 
unless the material is suitably small in volume, chemically and physiologically 
compatible with surface tissues. The eye is one of the most delicate and yet 
most valuable of the sense organs and is a challenging subject for topical 
administration of drugs to the eye(4)
1.2.1 Accessory structures of the eye 
. 
The accessory structures of the eye include the eyelids, eyelashes, eyebrows, 
the lacrimal (tearing) apparatus and extrinsic eye muscles. The lacrimal 
apparatus is a group of structures that produces and drains lacrimal fluids or 
tears(5)
The eyeball measures about 2.5 cm in diameter, only a small portion (about 
1/6
. 
1.2.2    Anatomy of the eyeball 
th part) of the globular eye is exposed in front, the rest is hidden in bony 
socket of the orbit on a cushion of fat and connective tissue. The wall of the 
human eyeball consists essentially of three layers: Fibrous tunic, Vascular 
tunic and Retina(5, 6). 
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Figure 1.1: Anatomy of the eye 
 
1. Fibrous tunic 
Fibrous tunic, the outermost coat of the eyeball, consists of the anterior 
cornea and posterior sclera.  
The cornea is a transparent coat that covers the colored iris. Cornea mainly 
consists of the following structures from the front to back, (I) Epithelium, (II) 
Bowman’s membrane, (III) Stroma, (IV) Descemet’s Membrane, (V) 
Endothelium. The cornea is 0.5 to 1mm in thickness and normally it 
possesses no blood vessels except at the corneosclerar junction. The 
sclera, the “white” of the eye, is a layer of dense connective tissue made up 
densely of collagen fibers and fibroblasts. The sclera covers the entire 
eyeball except the cornea. At the junction of the sclera and cornea is an 
opening known as the scleral venous sinus (canal of Schelmm).  
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2. Vascular tunic 
This middle layer is mainly vascular, consisting of the choroid, ciliary body and 
iris.  
Choroid lines the posterior five-sixths of the inner surface of the sclera. It is 
very rich in blood vessels. 
Ciliary body is the anterior continuation of the choroids consisting of ciliary 
muscle and secretary epithelial cells. The major function of the ciliary body is 
the production of aqueous humor. Systemic drugs enter the anterior and 
posterior chambers largely by passing through the ciliary body vasculature 
and then diffusing in to the iris where they can enter the aqueous humor. The 
ciliary body is one of the major ocular sources of drug-metabolizing enzymes, 
responsible for drug detoxification and removal from the eye. 
Iris is the visible colored part of the eye and extends interiorly from the ciliary 
body lying behind the cornea and in front of the lens. The pigment granules of 
the iris epithelium absorb light as well as lipophilic drugs. This type of binding 
is characteristically reversible, allowing release of drug overtime. As a result, 
the iris can serve as a reservoir for some drugs, concentrating and then 
releasing them for longer than otherwise expected(5, 7)
The innermost layer is the retina, consisting of the essential nervous system 
responsible for vision. Retina lines the posterior three quarters of the eyeball 
and is the beginning of the visual pathway
. 
3. Retina 
(5). The retina is situated between 
the clear vitreous humor in its inner surface and the choroids on its outer 
surface. Retina consists of two distinct chambers, anterior and posterior 8( )
Behind the pupil and iris, within the cavity of the eyeball, is the lens. Protein 
called crystallins, arranged like the layers of an onion, make up the lens. The 
lens is held in place by the zonules, which run from the ciliary body and fuse 
into the outer layer of the lens capsule. The lens tends to develop cataract or 
opacities with age, interfering with vision
. 
1.2.3   Lens 
(8). 
1.2.4   Interior of the eyeball 
The lens divides the interior of the eyeball into two cavities; Anterior cavity 
and Vitrous chamber. 
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The anterior cavity consists of two chambers 
The anterior chamber that lies between the cornea and the iris. 
The posterior chamber that lies behind the iris and in front of the lens. 
Aqueous humor is formed by ciliary bodies and occupies the posterior and 
anterior chambers, having a volume of about 0.2mL. The fluid is constantly 
generated by pigmented and non- pigmented epithelium of ciliary body(5, 7)
The Vitreous chamber is filled with a viscous fluid, vitreous humor, which is a 
viscoelastic connective tissue composed of small amounts of 
glycosaminoglycans, including of hyaluronic acid and proteins such as 
collagen
. 
(8)
The conjunctiva membrane covers the outer surface of the white portion of the 
eye and the inner surface of the eyelids. In most places it is loosely attached 
and thereby permits free movement of the eyeball, this makes possible sub-
conjunctival injection. The conjunctiva forms an inferior and a superior sac 
except for the cornea, the conjunctiva is the most exposed portion of the 
eye
. 
1.2.5   Conjunctiva 
(8)
1.3 Common eye disorders 
. 
A number of disorders can affect the structure of the eye, with outcomes 
ranging from moderate discomfort to significant loss of vision. The health care 
provider should be familiar with the signs and symptoms of common eye 
disorders and understand the decision making process behind treatment(9)
Glaucoma is a group of diseases of the eye characterized by damage to the 
ganglion cells and the optic nerve. If left untreated, these effects may lead to 
. 
1.3.1   Inflammatory conditions 
1. Hordeolum and Chalazion 
2. Blepharitis 
3. Dacryocystitis 
4. Conjunctivitis 
5. Trachoma 
6. Anterior Uveitis   
1.3.2   Corneal ulcer 
1.3.3   Glaucoma 
Chapter 1  Introduction 
                                       Hitesh B. Gevariya 7                                   Ph. D. Thesis 
 
various degrees of loss of vision and blindness. Increased intraocular 
pressure (IOP) remains the most important risk factor for the development of 
glaucoma. Glaucoma is typically classified as either open angle or angle 
closure (closed angle), based upon causes of increased intraocular 
pressure(10)
1.3.3.1 Glaucoma classified according to etiology 
. 
A)  Primary glaucoma 
 1. Open angle glaucoma 
a) Primary open angle glaucoma (chronic open angle 
glaucoma, chronic simple glaucoma) 
b) Normal pressure glaucoma (low pressure glaucoma) 
 2. Angle-closure glaucoma 
a) Acute 
b) Sub acute 
c) Chronic 
d) Plateau iris 
B)  Congenital glaucoma 
1. Primary congenital glaucoma 
2. Glaucoma associated with other development ocular 
abnormalities 
a) Anterior chamber cleavage syndromes 
Axenfeld’s  syndrome 
Sieger’s syndrome 
Peter’s anomaly 
b) Aniridia 
3. Glaucoma associated with extraocular development 
abnormalities 
a) Sturge-Weber syndrome 
b) Marfen’s syndrome 
c) Neurofibromatosis 
d) Lowe’s syndrome 
e) Congenital rubella 
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C) Secondary glaucoma. 
1. Pigmentary glaucoma 
2. Exfoliation syndrome 
3. Due to lens changes (phacogenic) 
a) Dislocation 
b) Intumescence 
c) Phacolytic 
4. Due to uveal tract changes 
a) Uveitis 
b) Posterior synechiae (seclusio pupillae) 
c) Tumor 
5. Iridocorneoendothelial (ICE) syndrome 
6. Trauma 
a) Hyphema 
b) Angle contusion / recession 
c) Peripheral anterior synechiae 
7. Postoperative  
a) Ciliary block glaucoma (malignant glaucoma) 
b) Peripheral anterior synechiae 
c) Epithelial downgrowth 
d) After corneal graft surgery 
e) After retinal detachment surgery 
8. Neovascular glaucoma 
a) Diabetes mellitus 
b) Central retinal vein occlusion 
c) Intraocular tumor 
9. Raised episclera venous pressure 
a) Carotid-cavernous fistula  
b) Sturge-Weber syndrome 
10. Steroid-induced 
D) Absolute glaucoma: The end result of any uncontrolled glaucoma is a 
hard, sightless, and often painful eye. 
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1.3.3.2 Etiology (Study of causes of disease) 
Optic nerve damage caused by the different types of glaucoma is a result of a 
variety of initiating factors.  Genetic predisposition, physical changes, 
systemic diseases, or medications may increase a person’s risk of developing 
damage that may be broadly classified as intraocular pressure dependent 
(most commonly) or intraocular pressure independent.  Increased intraocular 
pressure remains the major etiologic risk factor for the development of 
glaucoma.  Myopia may be an additional risk factor, especially in younger 
patients.  Glaucoma can occur as a secondary manifestation of systemic 
disorders or trauma.   
1.3.3.3 Pathogenesis 
There are five stages in the pathogenesis of glaucoma: (1) a variety of initial 
events, causing (2) Changes in aqueous outflow, resulting in (3) Increased 
IOP, which leads to (4) Optic nerve atrophy, and finally, (5) Progressive loss 
of vision.  This description highlights the importance of aqueous humor 
production and elimination in the progression of glaucoma and subsequent 
complications.  
1.3.3.4 Open-angle glaucoma 
In open-angle glaucoma, a physical blockage occurs within the trabecular 
meshwork that retards elimination of aqueous humor.  The obstruction is 
presumed to be between the trabecular sheet and the episcleral veins, into 
which the aqueous humor ultimately flows. The impairment of aqueous 
drainage elevates the intraocular pressure to between 25 and 35 mm Hg 
(normal intraocular pressure is 10 to 20 mm Hg), indicating that the 
obstruction is usually partial.  This increase in intraocular pressure is sufficient 
to cause progressive cupping of the optic disk and eventually visual field 
defects. 
1.3.3.5 Angle-closure glaucoma 
In angle-closure glaucoma, increased intraocular pressure is caused by 
papillary blockage of aqueous humor outflow and is more severe.  The basic 
requirements leading to an acute attack of angle closure are a papillary block, 
a narrowed anterior chamber angle and a convex iris. When a patient has a 
narrow anterior chamber or a pupil that dilates to a degree where the iris 
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comes in greater contact with the lens, there is interference with the flow of 
aqueous humor from the posterior to the anterior chamber.  Because aqueous 
humor is continually secreted, pressure from within the posterior chamber 
forces the iris to bulge forward. This may progress to complete blockage.  
The pathologic complications of angle closure and open angle glaucoma 
include the formation of cataracts, adhesion of the iris to the cornea, atrophy 
of the optic nerve and retina, complete blockage of aqueous outflow, and 
ultimately, blindness. 
1.3.3.6 Congenital glaucoma 
Congenital glaucoma is a rare disorder in which intraocular pressure is 
increased as a result of developmental abnormalities of the ocular structures 
in the newborn or infant.  It may occur in association with other congenital 
abnormalities and anomalies such as homocystinuria and Marfan’s syndrome. 
1.3.3.7 Normal-tension glaucoma  
The etiology and pathogenesis of normal tension glaucoma remain to be 
completely understood.  Normal tension glaucoma is thought to be related, at 
least in part, to decreased blood flow to the optic nerve.  This may eventually 
cause neuronal damage.  In addition, these eyes appear to be more 
susceptible to pressure related damage within the normal or high normal 
range, and therefore a pressure lower than normal is often necessary to 
prevent further visual loss.  
1.3.3.8 Drug-induced glaucoma 
Several therapeutic classes of drugs, such as those with anti-cholinergic, 
adrenergic, or corticosteroid effects, have been implicated in inducing or 
worsening glaucoma.  Medications affect open angle and closed angle 
glaucoma differently.  Drugs that dilate the pupil, for instance, may precipitate 
an acute attack of angle closure glaucoma but usually do not produce harmful 
effects in those with open angle glaucoma.  Dilation of the pupil in angle 
closure glaucoma may cause the peripheral iris to bulge forward, blocking the 
trabecular meshwork.  The aqueous humor is prevented from reaching the 
outflow channels, which results in increased IOP.  Because excessive 
resistance to outflow in open angle glaucoma is caused primarily by changes 
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within the trabecular outflow channels, dilation of the pupil usually will not 
increase the intraocular pressure.                                                                                                                                                                                                                                                                                                                                                                                                           
1.4 Absorption of drugs in eye(11)
It is often assumed that drugs administered into the eye are rapidly and totally 
absorbed. However, contrary to this belief, the moment drug is placed in lower 
cul-de-sac of eye, several factors immediately begins to affect the 
bioavailability of drug. Absorption of drugs takes place either through corneal 
or non corneal routes. The non-corneal route involves absorption across the 
sclera and conjunctiva into the intraocular tissues. This route is however, not 
productive as it restrains the entry of drug into aqueous humor. Maximum 
absorption thus takes place through cornea, which leads the drug into 
aqueous humor. The goal of ophthalmic drug delivery system has traditionally 
been to maximize ocular drug absorption rather than to minimize the systemic 
absorption. 
 
1.5   Drug elimination from lacrimal fluid(11)
a) Spillage of drug by overflow. 
 
Ophthalmic liquid dosage form like solutions, suspensions or liposome is 
either drained from conjunctival sac into nasolacrimal duct or is cleared from 
precorneal area resulting in poor bioavailability of drugs. Drugs are mainly 
eliminated from the precorneal lacrimal fluid by solution drainage, lacrimation 
and non productive absorption to the conjunctiva of the eye. These factors 
and the corneal barrier limit the penetration of the topically administered drug 
into the eye. Only a few percentage of applied dose is delivered into 
intraocular tissue, while the major part (50-100%) of the dose is absorbed in 
systemic route.  Precorneal constraints include,  
b) Dilution of drug by tear turnover. 
c) Nasolacrimal drainage / systemic drug absorption. 
d) Conjunctival absorption. 
e) Enzymatic metabolism. 
1.5.1 Transcorneal penetration 
Transcorneal penetration of drug is mainly affected by corneal barriers, 
physiochemical properties of drugs and active ion transport systems present 
at cornea. 
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1.5.1.1 Corneal barriers 
Corneal epithelium is the main barrier for drug absorption into eye. Corneal 
epithelium acts as a protective barrier against foreign molecules and also as a 
barrier to ion transport. The corneal epithelium consists of a basal layer of 
columnar cells, squamous cells, and polygonal shaped superficial cells.  
In a healthy corneal epithelium, intracellular tight junctions completely 
surrounds the most superficial cells, nevertheless the intracellular spaces are 
wider between wing cells and basal cells. These allow the paracellular 
diffusion of large molecules through these layers of cell only. Tight junctions 
serve as a selective barrier  for small  molecules and they completely  prevent  
the diffusion  of macro molecules via the paracellular route. Corneal stroma is 
a highly hydrophilic tissue; it acts as a rate limiting barrier for ocular 
absorption of most lipophilic drugs. The corneal endothelium is responsible for 
maintaining normal corneal hydration. 
1.5.1.2   Physiochemical properties of drug 
Transcellular or paracellular pathway is the main route for drugs to penetrate 
across corneal epithelium. Hydrophilic drugs penetrate primarily through the 
paracellular pathway, which involves passive or altered diffusion through 
intracellular spaces while lipophilic drugs prefer the transcellular route. For 
topically applied drugs passive diffusion along their concentration gradients, 
either transcellular or paracellular permeation, is the main permeation 
mechanism. Lipophilicity, solubility, molecular size and shape, charge and 
degree of ionization also affect the route and rate of penetration in cornea.  
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Figure 1.2: Factors and corneal barrier limitations for penetration of  
topically administered drug 
 
1.5.2 Non–corneal absorption 
Apart from corneal route topically applied ocular drugs may be absorbed 
through non-corneal route. This route involves drug penetration across the 
bulbar conjunctiva and underlying sclera in to the uveal tract and vitreous 
humor. This route is important for hydrophilic and large molecules, such as 
insulin and p-aminoclonidine, which have poor corneal permeability. 
1.6 Drawback of traditional ophthalmic formulations (11)
a) Rapid precorneal elimination 
 
 1. They have poor bioavailability because of   
b) Conjunctival absorption 
c) Solution drainage by gravity 
d) Induced lacrimation 
e) Normal tear turnover 
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2. Frequent instillation of concentrated medication is required to achieve a 
therapeutic effect.  
3. Systemic absorption of the drug and additives drained through 
nasolacrimal duct may result in undesirable side effects. 
4. The amount of drug delivered during external application may vary. The 
drop size of ocular medication is not uniform and those delivered is 
generally not correct. 
5. Presence of viscous vehicles can cause blurred vision. 
1.7    Novel ophthalmic delivery systems 
To overcome the drawbacks of conventional ophthalmic dosage form, many 
progresses have been done to improve the pre-corneal drug absorption and 
minimize pre-corneal drug loss. 
1.7.1 Mucoadhesives 
Mucoadhesives are retained in the eye by virtue of non-covalent bonds 
established with the corneal conjunctival mucin for extending pre-ocular 
residence time(12, 13)
1.7.2 Phase transition system 
. 
These are liquid dosage forms which shift to the gel or solid phase when 
instilled in the cul-de-sac. After converting into gel it remains in contact with 
the cornea of the eye for prolonged period of time due to which drug 
elimination also slow down(14, 15)
1.7.3 Niosomes 
. 
Niosomes are the vesicles, containing non-ionic surfactants, that can entrap 
both hydrophilic and lipophillic drugs either in aqueous layer or in vesicular 
membrane made of lipid materials(16). It helps in preventing the metabolism of 
the drug by enzymes present at the tear/corneal surface 17( )
1.7.4 Liposomes  
. 
Liposomes are microscopic vesicles composed of membrane like lipid layers 
surrounding aqueous compartments. The lipid layers are comprised mainly of 
phospholipids(18). They have the ability to entrap hydrophilic compound in the 
aqueous compartment and to incorporate hydrophobic molecule in the lipid 
bilayers 19( ). 
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1.7.5 Nanoparticles 
Nanoparticles are solid particles of polymeric nature ranging in size from 10-
1000 nm. The drugs are bound to small particles, which are then dispersed 
into aqueous vehicle(20). Due to very small in size these are not washed away 
with tears quickly 21( )
1.7.6 Contact lenses 
. 
Contact lenses are substitutes for spectacles and are enjoying a certain 
degree of popularities. Use of soft contact lenses soaked in drug solution 
have been suggested for slow but prolonged drug delivery but particularly to 
corneal tissue(22)
1.7.7 Pharmacosomes 
. 
They are the vesicles formed by the amphiphilic drugs. Any drug possessing a 
free carboxyl group can be esterified  to the hydroxyl group of a lipid molecule 
thus generating an amphiphillic prodrug. These are converted to 
pharmacosomes on dilution with tear(23)
1.7.8 Ophthalmic inserts 
. 
Inserts are defined as a thin disks or small cylinders made with appropriate 
polymeric material and fitting into the lower or upper conjunctival sac. Their 
long persistence in preocular area can result in greater drug availability with 
respect to liquid and semisolid formulation(24).
1.8 Requisites of controlled ocular delivery systems
  
1. To overcome the side effects of pulsed dosing (frequent dosing and high    
concentration) produced by conventional systems. 
(11)  
2. To provide sustained and controlled drug delivery. 
3. To increase the ocular bioavailability of drug by increasing corneal 
contact time. This can be achieved by effective coating or adherence to 
corneal surface, so that the released drug effectively reaches the anterior 
chamber. 
4. To provide targeting within the ocular globe so as to prevent the loss to 
other ocular tissues. 
5. To circumvent the protective barriers like drainage, lacrimation and 
diversion of exogenous chemicals into the systemic circulation by the 
conjunctiva.  
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6. To provide comfort and compliance to the patient and yet improve the 
therapeutic performance of the drug over conventional systems. 
7. To provide the better housing of the delivery system in the eye so as the 
loss to other tissues besides cornea is prevented. 
Ocular drugs and delivery systems are currently undergoing a process of 
design optimization due to inherent physiological and anatomical constraint of 
the eye leading to limited absorption of topically applied drugs. 
Two major approaches are being undertaken to improve topical delivery of 
drugs which are: 
1. Approaches to prolong the contact time of drug with corneal surface. 
2. Approaches to enhance corneal permeability either by mild or transient 
structural alteration of corneal epithelium or by modification of chemical 
structure of the drug molecules. 
1.9    Ophthalmic inserts  
Ophthalmic inserts are defined as elliptical flexible wafer, multilayered system 
consisting of drug as core surrounded by rate controlling membrane and 
designed to be placed in cul-de-sac between sclera and eyelid(11)
1.9.1 Advantages of ophthalmic insets
. 
1. Increasing the contact time and thus improve bioavailability. 
(3, 11) 
2. Providing prolonged drug release and thus a better efficacy. 
3. Reduction of systemic side effects and thus reduces adverse effects. 
4. Reduction of the number of administration and thus better patient 
compliance. 
5. Administration of an accurate dose in the eye and thus a better therapy. 
6. Increased shelf life with respect to aqueous solutions. 
7. Exclusion of preservative, thus reducing the risk of sensitivity reactions. 
8. A possibility of incorporating various novel chemical technological 
approaches such as pro-drugs, micro particulates, salts acting as 
buffers. 
1.9.2 Disadvantages of ocular inserts
1. Initial discomfort, their movement around the eye. 
(3) 
2. Occasional inadvertent loss during sleep or while rubbing the eye. 
3. Interference with vision and a difficult placement. 
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1.9.3 Desired criteria for ocular insert are(3, 12)
1. Comfort 
 
2. Lack of explosion 
3. Ease of handling and insertion 
4. Non-interference with vision and oxygen permeability 
5. Reproducibility of release kinetics 
6. Sterility 
7. Stability 
8. Ease of manufacture 
1.9.4   Classification of ophthalmic inserts(11)
As long as gradient exist, there is zero-order drug delivery through the 
membrane. Second one is the rate of release of the drug outside the 
membrane. The eye (cul-de-sac) provides an excellent environment for this 
type of drug delivery system and prevents a build up of stagnant drug around 
the module. Thus the gradient and force are preserved and drug continues to 
 
Ophthalmic inserts, based upon their solubility behaviour, are classified as 
given below; 
A.  Insoluble ophthalmic inserts 
B.  Soluble ophthalmic inserts 
C.  Bio erodible ophthalmic inserts 
A.    Insoluble ophthalmic inserts  
     They have been sub-classified into:  
a) Diffusion Inserts,  E.g. ‘Ocuserts’ 
b) Osmotic inserts 
c) Contact lenses presoaked in drug solution 
a)  Diffusion inserts or ocuserts 
Ocusert system is a novel ocular drug delivery system based on porous 
membrane. A central reservoir of drug is surrounded by the polymeric 
membrane, which allows a constant movement of the drug in to the tissue by 
diffusion. A controlled rate of delivery is provided by interaction between the 
membrane molecule and the drugs. The first major important factor in the rate 
of drug release is the driving force, which is maintained by saturated 
concentration of the drug in the reservoir.  
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move out of reservoir. Pilocarpine ocusert has been marketed in U.S. by Alza 
Corporation for the treatment of glaucoma. It is 13.4mm long, 5.7 mm broad, 
0.3 mm thick and weighs 19mg to be placed in cul-de-sac between sclera and 
eyelid. The ocusert system provides nearly steady zero-order delivery rate of 
pilocarpine from the unit for 7 days in the aqueous tear environment of the 
cul-de-sac. 
When the insert placed in the eye, water from the tear fluid begins to 
penetrate the matrix, then swelling and consequently polymer chain relaxation 
and drug diffusion take place. The dissolution of the matrix, which follows the 
swelling process, depends on polymers structure, linear amorphous polymer 
dissolve much faster than cross-linked or partially crystalline polymers. 
The release rate of diffusional devices present three distinct regions as shown 
under    
  
Figure 1.3: Release rate from diffusion inserts 
 
Region A: An initial usually high drug release rate corresponding to the     
establishment of equilibrium between the reservoir and the eye 
surface.  
Region B: Rate decreases to a plateau corresponding to a steady drug   
release rate. 
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Region C: A final decrease of the release rate corresponding to the 
exhaustion of the drug. 
E.g. Pilocarpine Ocusert 
The principle for its operation can be described by the Fick’s diffusion 
equation.  
J = -DA dc/dx                                                [1.1] 
                     Where,  
                          J – Solute flux 
 D – Diffusion coefficient for the drug within the polymer                            
membrane  
 A – Area of membrane 
                            dc/dx – drug concentration gradient within the membrane 
along the direction of drug flow. 
The use of a hydrophobic membrane that does not interact with the 
environment so as to change the shape (area) or diffusional characteristics as 
well as reservoir with excess drug (saturated solution) to provide 
thermodynamic force for the drug to diffuse continuously through the rate- 
controlling membrane should provide a steady zero-order release rate. Two 
kinds of this drug delivery system are available as ocusert Pilo 20 (5mg of 
pilocarpine with release rate of 20 mcg/hr) and as ocusert pilo 40 (11mg of 
pilocarpine with release rate of 40mcg/hr).  
b)  Osmotic insert 
The osmotic inserts are generally composed of a centre part surrounded by a 
peripheral part and are of two types. 
Type 1: The central part is composed of a single reservoir of a drug with or 
without an additional osmotic solute dispersed throughout polymeric matrix, 
so that the drug is surrounded by the polymer as discrete small deposits. The 
second peripheral part of this inserts compresses a covering film made up of 
insoluble semi permeable polymer. The osmotic pressure against the polymer 
matrix causes its rupture in the form of apertures. Drug is then released 
through these apertures from the deposits near the surface of the devices. 
Type 2:  The central part is composed of two distinct compartments. The drug 
and  the  osmotic  solutes  are  placed  in  two  separate  compartments,  the  
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drug reservoir being surrounded by an elastic impermeable membrane and 
the osmotic solute reservoir by a semi permeable membrane. The second 
peripheral part is similar to that of type 1. The tears diffuse into the osmotic 
compartment inducing an osmotic pressure that stretches the elastic 
membrane and contracts the compartment including drug, so that the active 
component is forced to the single drug release aperture. 
c)   Contact lenses  
Contact lenses are shaped structures comprising covalently cross linked 
hydrophilic or hydrophobic polymer that forms a three dimensional network or 
matrix capable of retaining water, aqueous drug solution or solid components.  
Contact lenses are classified into 5 groups. 
a) Rigid 
b) Semi-rigid 
c) Elastomeric 
d) Soft hydrophilic  
e) Bio-polymeric 
 The soft hydrophilic contact lenses are very popular because they are easy to 
fit and are tolerated better. The drug incorporation in to contact lens depends 
on whether its structure is hydrophilic or hydrophobic. When contact lens 
(including 35-80% water) is soaked in solution, it absorbs the drug. Drug 
release depends markedly on the amount of drug, the soaking time of the 
contact lens and the drug concentration in the soaking solution.  
Advantages 
1. Concerning the high cost of contact lenses it should be mentioned that 
disposable contact lenses have been commercially available and it 
should be possible to incorporate a drug into such devices at an 
acceptable cost. 
2. The contact lenses are the only class of ophthalmic inserts that have the 
ability to correct any refractive error that the patient may have and there 
by provide improved visual acuity, while the medication is being 
administered. 
Disadvantages 
1. Cleaning and rinsing procedures can induce deterioration of the devices.  
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2. The cost of medicated contact lens is high. 
B. Soluble ophthalmic inserts 
They can be broadly divided in to two types, the first one being based on 
natural polymers and the other one synthetic or semi synthetic polymers. 
I. Natural polymers 
Natural polymer used to produce soluble ophthalmic inserts is collagen. The 
therapeutic agent is preferably absorbed by soaking the insert in a solution 
containing the drug, drying and rehydrating it before use on the eye. The 
amount of drug loaded will depend on the amount of binding agent present, 
concentration of the drug solution in to which the composite is soaked as well 
as duration of soaking. As the collagen dissolves, the drug is gradually 
released from the interstices between the collagen molecules.  
II. Synthetic or semi-synthetic polymer 
The soluble ophthalmic inserts, containing synthetic and semi-synthetic 
polymers, offer the additional advantages of being of a generally simple 
design, of being based on products well adapted for ophthalmic use and 
easily processed by conventional methods. The main advantage is decreased 
release rate, but still controlled by diffusion. 
C. Bioerodible ophthalmic inserts 
These are composed of matrix of homogenous dispersion of a drug coated 
with hydrophobic material, which is substantially impermeable to the drug. 
The main components used for the production of this type of inserts are the 
so-called Bioerodible polymers i.e., materials that undergo hydrolysis of 
chemical bonds and hence dissolution.     
Bioerosion is defined here as the property of a material to innocuously 
disintegrate or breakdown from a unit structure or entity, over a prolonged 
period of time, in response to the environment in the eye. When bioerosion 
process takes place geometrically of inserts is modified and it is difficult to 
adequately control the release. The bioerodible polymers used in erodible 
inserts are carboxymethylcellulose, hydrophobic polyacrylic acids, 
hydroxypropylmethylcellulose, and silicone based pro-polymers. There are 
three devices, which are marketed to date namely Lacrisert, Soluble Ocular 
Drug Inserts (SODI) and Minidisc. 
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1.10 Niosomes 
Vesicles prepared from self-assembly of hydrated non-ionic surfactants 
molecules are called niosomes. Niosomes and liposomes are equiactive in 
drug delivery potential and both increase drug efficacy as compared with that 
of free drug. Niosomes are preferred over liposomes because the former 
exhibit high chemical stability and economy. 
These types of vesicles were first reported in the cosmetic industries. Non-
ionic surfactants used in formation of niosomes are polyglyceryl alkyl ether, 
glucosyl dialkyl ether, crown ether, polyoxyethylenealkyl ether, ester-linked 
surfactants, and steroid-linked surfactants and spans, and tweens series. 
Niosomes preparation is affected by processes variables, nature of 
surfactants, and presence of membrane additives and nature of drug to be 
encapsulated(25)
1.10.1 Structure of niosomes 
.  
Niosomes are microscopic lamellar structures, which are formed on the 
admixture of non-ionic surfactant of the alkyl or dialkyl polyglycerol ether class 
and cholesterol with subsequent hydration in aqueous media(16). 
Structurally, niosomes are similar to liposomes, in that they are also made up 
of a bilayer. However, the bilayer in the case of niosomes is made up of non-
ionic surface active agents rather than phospholipids as seen in the case of 
liposomes. Most surface active agents when immersed in water yield micellar 
structures; however some surfactants can yield bilayer vesicles which are 
niosomes. 
Niosomes may be unilamellar or multilamellar depending on the method used 
to prepare them. The niosome is made of a surfactant bilayer with its 
hydrophilic ends exposed on the outside and inside of the vesicle, while the 
hydrophobic chains face each other within the bilayer. Hence, the vesicle 
holds hydrophilic drugs within the space enclosed in the vesicle, while 
hydrophobic drugs are embedded within the bilayer itself. The figure below 
will give a better idea of what a niosome looks like and where the drug is 
located within the vesicle. 
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Figure 1.4: Structure of niosomes 
A typical niosome vesicle would consist of a vesicle forming ampiphile i.e. a 
non-ionic surfactant such as Span-60, which is usually stabilized by the 
addition of cholesterol and a small amount of anionic surfactant such as 
diacetyl phosphate, which also helps in stabilizing the vesicle(26)
1.10.2 Advantages of niosomes 
. 
Use of niosomes in cosmetics was first done by L’Oreal as they offered the 
following advantages(16)
• The vesicle suspension being water based offers greater patient 
compliance over oil based systems 
 
• Since the structure of the niosome offers place to accommodate 
hydrophilic, lipophilic as well as amphiphilic drug moieties, they can be 
used for a variety of drugs. 
• The characteristics such as size, lamellarity etc. of the vesicle can be 
varied depending on the requirement. 
• The vesicles can act as a depot to release the drug slowly and offer a 
controlled release. 
Other advantages of niosomes are 
• They are osmotically active and stable. 
• They increase the stability of the entrapped drug. 
• Handling and storage of surfactants do not require any special 
conditions. 
• Can increase the oral bioavailability of drugs. 
• Can enhance the skin penetration of drugs. 
• They can be used for oral, parenteral as well topical use. 
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• The surfactants are biodegradable, biocompatible, and non-
immunogenic. They improve the therapeutic performance of the drug 
by protecting it from the biological environment and restricting effects to 
target cells, thereby reducing the clearance of the drug. 
• The niosomal dispersions in an aqueous phase can be emulsified in a 
non-aqueous phase to control the release rate of the drug and 
administer normal vesicles in external non-aqueous phase. 
1.10.3 Salient features of niosomes 
• Niosomes can entrap solutes in a manner analogous to liposomes. 
• Niosomes are osmotically active and stable. 
• Niosomes possess an infra structure consisting of hydrophobic and 
hydrophilic mostly together and so also accommodate the drug 
molecules with a wide range of solubility. 
• Niosomes exhibits flexibility in their structural characteristics 
(composition, fluidity and size) and can be designed according to the 
desired situation. 
• Niosomes can improve the performance of the drug molecules by 
delayed clearance from the circulation. 
• Improve bioavailability to the particular site, just by protecting the drug 
from biological environment. 
• Offer controlled delivery of drug at a particular site. 
• No special conditions are required for handling and storage of 
Niosomes. 
1.10.4 Types of niosomal systems(16)
1. 
 
Small unilamellar vesicles
2. 
 (SUV, size 0.025-0.05 μm) are commonly 
produced by sonication, and French Press procedures. Ultrasonic 
electrocapillary emulsification or solvent dilution techniques can be used to 
prepare SUVs. 
Multilamellar vesicles
3. 
 (MLV, size >0.05 μm) exhibit increased-trapped 
volume and equilibrium solute distribution, and require hand-shaking 
method. They show variations in lipid compositions. 
Large unilamellar vesicles (LUV, size >0.10 μm), the injections of lipids 
solubilised in an organic solvent into an aqueous buffer, can result in 
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spontaneous formation of LUV. But the better method of preparation of 
LUV is Reverse phase evaporation, or by Detergent solubilisation method.  
1.10.5 Methods/ techniques of preparation of niosomes 
By using following general steps niosomes can be prepared: 
• Hydration of mixture of the surfactants/lipids at elevated temperature, 
• Sizing of niosomes, 
• Removal of the unentrapped material from the vesicles by different methods. 
1.10.5.1 Hydration stage 
Niosomes widely differ in their properties depending on the method used for 
production and composition of bilayer. The method of preparation of niosome 
is based on liposome technology. The basic process of preparation is the 
same i.e. hydration by aqueous phase of the lipid phase which may be either 
a pure surfactant or a mixture of surfactant with cholesterol. The bioactive 
material, which is to be entrapped, is dissolved in the aqueous phase/organic 
phase. The methods used for preparation of niosomes are listed as follows. 
1.10.5.2 Ether injection method 
This method was reported in 1976 by Deamer and Bangham, in which a lipid 
solution in di-ethyl ether is slowly introduced into warm water typically the lipid 
mixture is injected into an aqueous solution of the material to be encapsulated 
(using syringe type infusion pump) at 55-65 oC and under reduced pressure. 
Vaporization of ether leads to the formation of single layered vesicles (SLVs) 
depending upon the conditions used, the diameter of vesicles varies. Baillie et 
al.,(27) used this method for entrapment of 5, 6 carboxy florescein whereas, 
Hunter et al., 25( ) used it for the entrapment of sodium stibogluconate 
(pentosam). The particle size of the niosomes formed depends on the 
conditions used, and can range anywhere between 50-1000µm 28( )
In this method a mixture of the vesicle forming agents such as the surfactant 
and cholesterol are dissolved in a volatile organic solvent such as diethyl 
ether or chloroform in a round bottom flask. The organic solvent is removed at 
room temperature using a rotary evaporator, which leaves a thin film of solid 
mixture deposited on the walls of the flask. This dried surfactant film can then 
be rehydrated at 50-60 
. 
1.10.5.3 Thin film hydration technique (Hand shaking method) 
oC using the aqueous phase, with gentle agitation to 
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yield multilamellar niosomes. The multilamellar vesicles thus formed can 
further be processed to yield unilamellar niosomes or smaller niosomes using 
sonication, microfluidization or membrane extrusion techniques(28)
Baillie et al reported Hand shaking method for the entrapment of 5, 6 carboxy 
fluorescein
. 
(27). Chandraprakash et al entrapped methotrexate in niosomes 
prepared by Hand shaking method using lipophilic surfactants like span 40, 
span 60 and span 80, cholesterol and di-cetyl phosphate in ratio of 47.5: 47.5: 
5. The tissue distribution of methotrexate was improved after entrapping with 
niosomes 29( ). Rogerson et al prepared doxorubicin entrapped niosomes using 
pure surfactant or a mixture of surfactants and cholesterol 30( ). Azmin et al 
modified this method for preparation of methotrexate entrapped niosomes 26( )
The novel key in this method is the removal of solvent from an emulsion by 
evaporation. Water in oil emulsion is formed by bath sonication of a mixture of 
two phases, and then the emulsion is dried to a semi-solid gel in a rotary 
evaporator under reduced pressure. The next step is to bring about the 
collapse of certain portion of water droplets by vigorous mechanical shaking 
with a vortex mixture. In these circumstances, the lipid monolayer, which 
encloses the collapse vesicles, is contributed to adjacent intact vesicles to 
form the outer leaflet of the bilayer of large unilamellar niosomes. The vesicles 
formed are unilamellar and have a diameter of 0.5 μm. Recently a great deal 
of interest is being shown in formulation of proniosomes. Proniosomes are dry 
formulations of surfactant coated carrier, which on rehydration and mild 
agitation give niosomes. Proniosomes have the advantage of circumventing 
the problems of physical stability such as aggregation, fusion and leaking, 
chemical stability such as hydrolysis, providing the convenience of 
transportation, distribution, storage and dosing. Proniosomes are usually 
prepared by dissolving spray coated surfactant in a organic solvent on to inert 
carriers such as sorbitol and maltodextrin
. 
1.10.5.4 Reverse phase evaporation 
(31, 32)
Briefly, method involves the creation of a solution of cholesterol and surfactant 
(1:1 ratio) in a mixture of ether and chloroform. An aqueous phase containing 
the drug to be loaded is added to this, and the resulting two phases are 
sonicated at 4-5 °C. A clear gel is formed which is further sonicated after the 
. 
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addition of phosphate buffered saline (PBS). After this the temperature is 
raised to 40 °C and pressure is reduced to remove the organic phase. This 
results in a viscous niosome suspension which can be diluted with PBS and 
heated on a water bath at 60 °C for 10 min to yield niosomes(33, 34)
In this method, a solution of surfactant and cholesterol is made in chloroform. 
The solvent is then evaporated under reduced pressure to get a thin film on 
the wall of the round bottom flask, similar to the hand shaking method. This 
film is then hydrated using citric acid solution (300mM, pH 4.0) by vortex 
mixing. The resulting multilamellar vesicles are then treated to three freeze 
thaw cycles and sonicated. To the niosomal suspension, aqueous solution 
containing drug is added and vortexed. The pH of the sample is then raised to 
7.0-7.2 using 1M disodium phosphate (this causes the drug which is outside 
the vesicle to become non-ionic and can then cross the niosomal membrane, 
and once inside it is again ionized thus not allowing it to exit the vesicle). The 
mixture is later heated at 60 °C for 10 min to give niosomes
. 
1.10.5.5 Trans membrane pH gradient (inside acidic) / Drug uptake 
process (remote loading) 
(35)
It is a technique which has only recently been developed and which allows the 
preparation of niosomes without the use of organic solvents. The bubbling unit 
consists of a round bottom flask with three necks, and this is positioned in a 
water bath to control the temperature. Water-cooled reflux and thermometer is 
positioned in the first and second neck, while the third neck is used to supply 
nitrogen. Cholesterol and surfactant are dispersed together in a buffer (pH 
7.4) at 70 °C. This dispersion is mixed for a period of 15 sec with high shear 
homogenizer and immediately afterwards, it is bubbled at 70 °C using the 
nitrogen gas to yield niosomes
. 
1.10.5.6 The “Bubble” method 
(36)
To create proniosomes, a water soluble carrier such as sorbitol is first coated 
with the surfactant. The coating is done by preparing a solution of the 
surfactant with cholesterol in a volatile organic solvent, which is sprayed onto 
the powder of sorbitol kept in a rotary evaporator. The evaporation of the 
organic solvent yields a thin coat on the sorbitol particles. The resulting 
. 
1.10.5.7 Formation of niosomes from proniosomes 
Chapter 1  Introduction 
                                       Hitesh B. Gevariya 28                                   Ph. D. Thesis 
 
coating is a dry formulation in which a water soluble particle is coated with a 
thin film of dry surfactant. This preparation is termed Proniosome(37). 
 
Figure 1.5: Formation of niosomes from proniosomes 
 
The niosomes can be prepared from the proniosomes by adding the aqueous 
phase with the drug to the proniosomes with brief agitation at a temperature 
greater than the mean transition phase temperature of the surfactant. 
1.10.5.8 Microfludisation 
This is a recent technique to prepare small MLVS. A Microfludizer is used to 
pump the fluid at a very high pressure (10,000 psi) through a 5 µm screen. 
Hereafter; it is forced along defined micro channels, which direct two streams 
of fluid to collide together at right angles, thereby affecting a very efficient 
transfer of energy. The lipids can be introduced into the fluidizer. The fluid 
collected can be recycled through the pump until vesicles of spherical 
dimensions are obtained. This results in greater uniformity, small size and 
better reproducible niosomes. 
1.10.6 Sizing of niosomes(38)
1. Probe sonication 
 
The size ranges of niosomes have a major effect on their fate in-vivo and in-
vitro. Hence, size reduction stage of niosome is essential after hydration 
stage. The more commonly used methods for niosome size reduction found in 
literature are given below 
(26, 27): produced C16G3
2. Extrusion through 100 nm Nucleopore filters
 niosomes in the 100–140 nm size 
range. 
(39) yielded sodium 
stilbogluconate C16G3
3. In some instances the combination of sonication and filtration (220 nm 
Millipore® filter) has been used like DOX loaded Span 60 niosomes in the 
200 nm size range
 niosomes in the 140 nm size range. 
(40). 
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4. The achievement of sub-50 nm sizes is possible by the use of a 
microfluidizer. 
5. High-pressure homogenization also yields vesicles below 100 nm in 
diameter. 
1.10.7 Removal of unentrapped materials 
Lipophilic drugs are fully associated with niosomes due to their high affinity to 
the lipid bilayer. But other drugs exhibit less attachment tendency to lipid 
bilayer hence has entrapment efficiency less than 100%. Small fraction of 
unentrapped drugs can cause unacceptable side effects (anti-cancer drugs). 
The methods that have been used for the removal of unentrapped material 
identified in literature are listed below. 
1. Exhaustive dialysis(27, 41)
2. Separation by gel filtration (eg. Sephadex G50)
 
(40, 42)
3. Centrifugation (7000 g for 30 min)
 
(30, 43)
4. Ultracentrifugation (150000 g for 1.5 h)
  
(44)
more exposed
 
1.10.8 Components of niosomes 
Niosomes mainly contains following types of components: 
1.10.8.1 Non-ionic surfactants 
The non-ionic surfactants orient themselves in bilayer lattices where the polar 
or hydrophobic heads align facing aqueous bulk (media) while the 
hydrophobic head or hydrocarbon segments align in such a way that the 
interaction with the aqueous media would be minimized. To attain 
thermodynamic stability, every bilayer folds over itself as continuous 
membrane i.e. forms vesicles so that hydrocarbon /water interface remains no 
(38). Mainly following types of non-ionic surfactants are used for 
the formation of niosomes:- 
a) Alkyl ethers: L’Oreal described some surfactants for the preparation of 
niosomes containing drugs/chemicals as 
1) Surfactant-I (Mol.Wt.473) is C16 monoalkyl glycerol ether with average of 
three glycerol units. 
2) Surfactant-II (Mol.Wt.972) is diglycerol ether with average of the seven 
glycerol units. 
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3) Surfactant III (Mol.Wt.393) is ester linked surfactant. Other than alkyl 
glycerol, alkyl glycosides and alkyl ethers bearing polyhydroxyl head 
groups are also used in formulation of niosomes(27, 45)
b) Alkyl esters: Sorbitan esters are most preferred surfactant used for the 
preparation of niosomes amongst this category of surfactants. Vesicles 
prepared by the polyoxyethylene sorbitan monolaurate are relatively soluble 
than other surfactant vesicles. For example polyoxyethylene (polysorbate 
60) has been utilized for encapsulation of diclofenac sodium
. 
(33)
c) Alkyl amides: Alkyl amide (e.g. galactosides and glucosides) have been 
utilized to produce niosomal vesicles
.  
(46)
Sterols are important components of the cell membrane and their presence in 
membrane affect the bilayer fluidity and permeability. Cholesterol is a sterol 
derivative, which is mainly used for the formulation of niosomes. Although it 
may not show any role in the formation of bilayer, its importance in formation 
of niosomes and manipulation of layer characteristics cannot be discarded. In 
general, incorporation of cholesterol affect properties of niosomes like 
membrane permeability, rigidity, encapsulation efficiency, ease of rehydration 
of freeze dried niosomes and their toxicity. It prevents the vesicle aggregation 
by the inclusion of molecules that stabilize the system against the formation of 
aggregates by repulsive steric or electrostatic forces that leads to the 
transition from the gel to the liquid phase in niosome systems. As a result of 
this, the niosome become less leaky in nature
. 
d) Fatty acid and amino acid compounds: Long chain fatty acids and amino 
acid moieties have also been used in some niosomes preparation. 
1.10.8.2 Cholesterol 
(46)
Some charged molecules are added to niosomes to increase stability of 
niosomes by electrostatic repulsion which prevents coalescence. The 
negatively charged molecules used are diacetyl phosphate (DCP) and 
phosphotidic acid. Similarly, stearylamine (STR) and stearyl pyridinium 
chloride are the well known positively charged molecules used in niosomal 
preparations. These charged molecules are used mainly to prevent 
aggregation of niosomes. Only 2.5-5 mol percentage concentration of charged 
. 
1.10.8.3 Charged molecule 
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molecules is tolerable because high concentration can inhibit the niosome 
formation. 
1.10.9 Formulation aspects of niosomes 
Niosomes are formed by self‐assembly of non‐ionic surfactants in aqueous 
media as spherical, unilamellar, multilamellar system and polyhedral 
structures in addition to inverse structures which appear only in non‐aqueous 
solvent(40)
Van Abbe
. 
1.10.9.1 Nature of surfactants 
(47) explained that the non‐inonic surfactants are preferred because 
the irritation power of surfactants decreases in the following order: cationic> 
anionic> ampholytic> non‐ionic. The ether type surfactants with single alkyl 
chain as hydrophobic tail, is more toxic than corresponding dialkylether chain. 
The ester type surfactants are chemically less stable than ether type 
surfactants and the former is less toxic than the latter because ester‐linked 
surfactant is degraded by esterase to triglycerides and fatty acid in vivo 25( ). 
The surfactants with alkyl chain length from C12‐C18 are suitable for the 
preparation of niosomes. Span series surfactants having hydrophilic lipophilic 
balance (HLB) number of between 4‐8 can form vesicles 42( ). Guinedi et al. 17( )
Charge inducer is used to impart charge on the vesicles to increase its 
stability by preventing fusion of vesicles and providing higher value of zeta 
potential. The commonly used positively charge inducers are stearylamine, 
cetyl pyridinium chloride and negatively charge inducers are lipoamino acid 
and dicetyl phosphate. Aggarwal and his coworkers
 
prepared niosomes from Span 60 and Span 40 to encapsulate acetazolamide 
(ACZ). Highest drug entrapment efficiency was obtained with Span 60 in a 
molar ratio of 7: 6 with cholesterol. They found that both the surfactants were 
nonirritant with ocular tissues however; only reversible irritation of substantia 
propia was observed in the rabbit eye.  
1.10.9.2 Charge inducer 
(48) formulated niosomes 
by reverse phase evaporation method to encapsulate ACZ using Span 60, 
cholesterol, positively (stearyl amine), and negatively (dicetyl phosphate) 
charge inducers. Drug entrapment efficiency varied with the charge and the 
percent entrapment efficiency was found to be 43.75%, 51.23% and 36.26% 
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for neutral, positively charged and negatively charged niosomes, respectively. 
The positively charged niosomes, although showed good corneal permeability 
and IOP lowering capacity, were however seemed to be inappropriate in 
terms of the corneal cell toxicity. 
1.10.9.3 Bioadhesive polymer 
Bioadhesive polymers are the other membrane additives that are used to 
provide some additional properties to the niosomes. Carbopol 934P‐coated 
niosomal formulation of ACZ, prepared from Span 60, cholesterol, 
stearylamine or dicetyl phosphate exhibited more tendency for the reduction 
of intraocular pressure compared to that of a marketed formulation 
(Dorzox)(48). Aggarwal and Kaur 49( )
Some researchers
 prepared chitosan and carbopol‐coated 
niosomes to entrap antiglaucoma agent timolol maleate by reverse phase 
evaporation method. Polymer coating extended the drug release up to 10 hr 
(releasing only 40‐43% drug). However, in comparison, chitosan coated 
niosomes showed a better sustained effect. 
1.10.9.4 Steric barrier 
(50)
Development of a topically effective formulation of ACZ is difficult because of 
its unfavorable partition coefficient, solubility, permeability coefficient, and 
poor stability at the pH of its maximum solubility. Based on these factors and 
the ability of niosomes to come into complete contact with corneal and 
conjunctival surfaces, niosomal drug delivery system has been investigated to 
 examined the aggregation behavior of 
monomethoxypoly (ethylene glycol) cholesteryl carbonates in mixture with 
diglycerol hexadecyl ether and cholesterol. They obtained non‐aggregated, 
stable, unilamellar vesicles at low polymer levels with optimal shape and size 
homogeneity at cholesteryl conjugate/lipids ratios of 5‐10 mol%. Higher levels 
up to 30 mol% led to the complete solubilization of the vesicles into disk‐like 
structures of decreasing size with increasing polyethylene glycol content. This 
study revealed the bivalent role of the derivatives; while behaving as 
solubilizing surfactants, they provided an additional efficient steric barrier, 
preventing the vesicles from aggregation and fusion over a period of at least 2 
weeks.  
1.10.9.5 Isotonic stabilizer 
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enhance the corneal absorption of ACZ. Boric acid solution (2%) is isotonic 
with tears and could be used as a vehicle for the ACZ niosomal formulations 
because the pH of maximum stability for ACZ is 4.0. A recent study revealed 
that boric acid solution can maintain the pH between 4.0 and 5.0. In addition, 
the pharmacodynamic studies showed more than 30% fall in IOP which was 
sustained up to 5 hr(51).  
1.10.10 Factors affecting formation of niosomes 
1.10.10.1 Structure of surfactants 
The geometry of vesicle to be formed from surfactants is affected by its 
structure, which is related to critical packing parameters. On the basis of 
critical packing parameters of Surfactants can predict geometry of vesicle to 
be formed. Critical packing parameters can be defined using following 
equation,  
CPP (Critical Packing Parameters) = v/lc ×a0                     [1.2] 
                  Where v = hydrophobic group volume 
                              lc = the critical hydrophobic group length 
                              a0
The stable niosomes can be prepared with addition of different additives along 
with surfactants and drugs. Niosomes formed have a number of morphologies 
and their permeability and stability properties can be altered by manipulating 
membrane characteristics by different additives. In case of polyhedral 
niosomes formed from C
= the area of hydrophilic head group 
From the critical packing parameter value type of miceller structure formed 
can be ascertained as given below, 
If CPP < ½ then formation of spherical micelles 
If ½ < CPP < 1 formation of bilayer micelles 
If CPP > 1 formation of inverted micelles 
1.10.10.2 Membrane composition 
16G2, the shape of these polyhedral niosome remains 
unaffected by adding low amount of solulan C24 (cholesteryl poly-24-
oxyethylene ether), which prevents aggregation due to development of steric 
hindrance. In contrast spherical Niosomes are formed by C16G2: 
cholesterol:solulan (49:49:2). The mean size of niosomes is influenced by 
membrane composition such as polyhedral niosomes formed by C16G2: 
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solulan C24 in ratio (91:9) having bigger size (8.0 ± 0.03µm) than 
spherical/tubular niosomes formed by C16G2: cholesterol:solulan C24 in ratio 
(49:49:2) (6.6±0.2µm)(44). Addition of cholesterol molecule to niosomal system 
provides rigidity to the membrane and reduces the leakage of drug from 
noisome 43( )
The physico-chemical properties of encapsulated drug influence charge and 
rigidity of the niosome bilayer. The drug interacts with surfactant head groups 
and develops the charge that creates mutual repulsion between surfactant 
bilayers and hence increases vesicle size
. 
1.10.10.3 Nature of encapsulated drug 
(39)
Hydration temperature influences the shape and size of the niosome. For 
ideal condition it should be above the gel to liquid phase transition 
temperature of system. Temperature change of niosomal system affects 
assembly of surfactants into vesicles and also induces vesicle shape 
transformation
. The aggregation of vesicles is 
prevented due to the charge development on bilayer. 
1.10.10.4 Temperature of hydration 
(38, 44). Arunothayanun et al. reported that a polyhedral vesicle 
formed by C16G2: solulan C24 (91:9) at 25 °C which on heating transformed 
into spherical vesicle at 48 °C, but on cooling from 55 °C, the vesicle 
produced a cluster of smaller spherical niosomes at 49 °C before changing to 
the polyhedral structures at 35 °C. In contrast vesicle formed by C16G2
38
: 
cholesterol: solulanC24 (49:49:2) shows no shape transformation on heating 
or cooling( )
Shape of niosomes assumed to be spherical, their mean diameter can be 
determined by using laser light scattering method
. 
Along with the above mentioned factors, volume of hydration medium and 
time of hydration of niosomes are also critical factors. Improper selection of 
these factors may result in formation of fragile niosomes or creation of drug 
leakage problems. 
1.10.11 Characterization of niosome 
1.10.11.1 Size 
(31). Also, diameter can be 
determined by using electron microscopy, molecular sieve chromatography, 
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ultracentrifugation, photon correlation microscopy and optical microscopy(26, 
52)
Assembly of non-ionic surfactants to form bilayer vesicle is characterized by 
X-cross formation under light polarization microscopy
. 
1.10.11.2 Bilayer formation 
(53)
It is determined by using NMR spectroscopy, small angle X-ray scattering and 
electron microscopy
. 
1.10.11.3 Number of lamellae 
(52)
Membrane rigidity can be measured by means of mobility of fluorescence 
probe as function of temperature
. 
1.10.11.4 Membrane rigidity 
(53)
The entrapment efficiency (EE) is expressed as EE = amount entrapped/total 
amount added * 100. It is determined after separation of unentrapped drug, on 
complete vesicle disruption by using about 1mL of 2.5% sodium lauryl sulfate, 
briefly homogenized and centrifuged and supernatant assayed for drug after 
suitable dilution
. 
1.10.11.5 Entrapment efficiency (EE) 
(54)
The chain length and hydrophilic head of non-ionic surfactants affect 
entrapment efficiency, such as stearyl chain C18 non-ionic surfactant vesicles 
show higher entrapment efficiency than lauryl chain C12 non-ionic surfactant 
vesicles. The tween series surfactants bearing a long alkyl chain and a large 
hydrophilic moiety in the combination with cholesterol at 1:1 ratio have highest 
entrapment efficiency for water soluble drugs
. Entrapment efficiency is affected by following factors: 
Surfactants 
(53). HLB value of surfactants 
affects entrapment efficiency, such as HLB value of 14 to 17 is not suitable for 
niosomes but HLB value of 8.6 has highest entrapment efficiency and 
entrapment efficiency decreases with decrease in HLB value from 8.6 to 
1.7 55( ). The entrapment efficiency is affected by phase transition temperature 
of surfactants, i.e. span 60 exhibits highest entrapment efficiency in series 
having highest transition temperature (Tc) 56( )
The incorporation of cholesterol into bilayer composition of niosome induces 
membrane-stabilizing activity and decreases the leakiness of membrane
. 
Cholesterol contents 
(30). 
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Hence, incorporation of cholesterol into bilayer increases entrapment 
efficiency. The permeability of vesicle bilayer to 5, 6-carboxy flourescein (CF) 
is reduced by 10 times due to incorporation of cholesterol(41)
Rambhau et al., reported that ascorbyl palmitate in combination with 
cholesterol and negatively charged lipid diacetyl phosphate forms vesicles 
called aspasome. The film hydration method was used for preparation of 
aspasomes, followed by sonication. The aqueous solution of azidothymidine 
was entrapped in aqueous region of bilayers. The cholesterol content in 
aspasomes exhibits very less effect for vesicle size and percent entrapment 
that affect release rate of azidothymidine. Aspasome with 45% of cholesterol 
shows maximum retardation in release rate than other composition. 
Aspasomes have inherent antioxidant properties that have potential 
applications toward disorder caused by reactive oxygen species. Transdermal 
permeation of aspasomal drug is much higher than aqueous dispersion and 
aqueous solution of drug
. 
1.10.12 Specialized systems 
1.10.12.1 Aspasomes (Ascorbyl palmitate vesicles) 
(57)
Niosomes prepared from nimesulide, span and cholesterol and incorporated 
in carbopol-934 gel (1%w/w) base contain propylene glycol (10%w/w) and 
glycerin (30%w/w). In vitro diffusion studies of such niosomal gel, plain drug 
gel and marketed gel were carried out in diffusion cell using human cadaver 
skin. The mean flux value and diffusion co-efficient were found to be 5 to 7 
times lower for niosomal gel as compared to plain drug gels. Skin retention of 
drug was maximum (58.19%) in niosomal gel formulation after 24 hr of 
diffusion studies. This formulation also evaluated for inhibition of edema using 
carrageenan-induced rat paw edema method. It was found that the percent of 
inhibition of edema in niosomal gel i.e.66.68±5.19% is high as compared to 
plain gel
. 
1.10.12.2 Niosomes in carbopol gel 
(55)
Polyhedral niosomes can be obtained from mixture of C
. 
1.10.12.3 Polyhedral niosomes 
16EO5 and solulan-
C24 in low concentration of cholesterol. A.T.Florence et al., worked on 
extrusion of polyhedral niosomes by capillary and studied some properties of 
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extruded polyhedral niosomes(58). When polyhedral niosomes extruded under 
certain condition into aqueous media fuse to produce long continuous stable 
tubules by controlling factor such pressure need to extrude niosomes and 
composition of vesicles. The applied shear stress on vesicle affects its release 
pattern such as increasing sheer stress by narrowing size of micropipette 
aperture increases higher release pattern of entrapped materials 59( )
Yoshioka et al., reported that the emulsification of an aqueous niosomes into 
an oil phase form vesicle in water in oil emulsion (V/W/O)
. 
1.10.12.4 Vesicles in water and oil system (V/W/O) 
(42). On addition of 
niosomes suspension formed from mixture of sorbitol mono stearate, 
cholesterol and solulan C24 to oil phase at 60 oC. There is formation of 
vesicle in water in oil emulsion but cooling to room temperature forms vesicle 
in water in oil gel (V/W/O gel). The (V/W/O gel) can entrap protein and also 
protect it from enzymatic degradation after oral administration and controlled 
release. The release of entrap material is lowest in case of V/W/O gel as 
compared to W/O gel and niosomal suspension 60( )
Reddy et al., studied on anti-inflammatory effect of noisome after 
incorporating into hydroxypropyl methyl cellulose semi-solid base containing 
10% glycerin. The bio availability and reduction of carageenan induced higher 
rat paw edema in case of noisome formulated in hydroxylpropyl methyl 
cellulose as compared to plain formulation of flurbiprofen
. Florence et al., studied on 
immunogenic properties of V/W/O gel and (W/O) gel, reported that both 
exhibit immunoadjuvant tendency. 
1.10.12.5 Niosomes in hydroxypropyl methylcellulose 
(61)
1.10.13 Applications of niosomes 
. 
The application of niosomal technology is widely varied and can be used to 
treat a number of diseases. There are very less niosomal formulations found 
in market. But some experimentally evaluated application of niosomal 
formulation identified in literatures, either proven or under research, are listed 
below. 
1.10.13.1 Drug targetting 
One of the most useful aspects of niosomes is their ability to target drugs. 
Niosomes can be used to target drugs to the reticulo-endothelial system. The 
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reticulo-endothelial system (RES) preferentially takes up niosome vesicles. 
The uptake of niosomes is controlled by circulating serum factors called 
opsonins. These opsonins mark the niosome for clearance. Such localization 
of drugs is utilized to treat tumors in animals known to metastasize to the liver 
and spleen. This localization of drugs can also be used for treating parasitic 
infections of the liver(16)
Niosomes can also be utilized for targeting drugs to organs other than the 
RES. A carrier system (such as antibodies) can be attached to niosomes (as 
immunoglobulins bind readily to the lipid surface of the niosome) to target 
them to specific organs. Many cells also possess the intrinsic ability recognize 
and bind specific carbohydrate determinants, and this can be exploited by 
niosomes to direct carrier system to particular cells
. 
(62)
Niosomal daunorubicin hydrochloride exhibited an enhanced anti-tumor 
efficacy when compared to free drug. The niosomal formulation was able to 
destroy the Dalton’s ascitic lymphoma cells in the peritoneum within the third 
day of treatment, while free drug took around six days and the process was 
incomplete. The hematological studies also prove that the niosomal 
formulation was superior to free drug treatment. An enhanced mean survival 
time was achieved by the niosomal formulation that finally substantiates the 
overall efficacy of the niosomal formulation
. 
1.10.13.2 Anti-neoplastic treatment 
Most antineoplastic drugs cause severe side effects. Niosomes can alter the 
metabolism; prolong circulation and half life of the drug, thus decreasing the 
side effects of the drugs.  
Daunorubicin HCl 
(54)
Rogerson et al., studied distribution of niosomal doxorubicin prepared from 
C16 monoalkyl glycerol ether with or without cholesterol. Niosomal 
formulation exhibited an increased level of doxorubicin in tumor cells, serum 
and lungs, but not in liver and spleen. Doxorubicinloaded cholesterol-free 
niosomes decreased the rate of proliferation of tumor and increased life span 
of tumorbearing mice. The cardio toxicity effect of doxorubicin was reduced by 
. 
Doxorubicin 
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niosomal formulation. Niosomal formulation changes the general metabolic 
pathway of doxorubicin(30)
Azmin et al., quoted in their research article that niosomal formulation of 
methotrexate exhibits higher AUC as compared to methotrexate solution, 
administered either intravenously or orally. Tumoricidal activity of niosomally-
formulated methotreaxate is higher as compared to plain drug solution
. 
Methotrexate 
(26)
Niosomal formulation of bleomycin containing 47.5% cholesterol exhibits 
higher level drug in the liver, spleen and tumor as compared to plain drug 
solution in tumor bearing mice. There is no significant difference in drug 
concentration with niosomal formulation in lung as compared to plain drug 
solution. Also, there is less accumulation of drug in gut and kidney in case of 
niosomal formulation
. 
Bleomycin 
(63)
Niosomal formulation of vincristine exhibits higher tumoricidal efficacy as 
compared to plain drug formulation
. 
Vincristine 
(64). Also, niosomal formulation of 
carboplatin exhibits higher tumoricidal efficacy in S-180 lung carcinoma-
bearing mice as compared to plain drug solution and also less bone marrow 
toxic effect 65( )
Leishmaniasis is a disease in which a parasite of the genus Leishmania 
invades the cells of the liver and spleen. Commonly prescribed drugs for the 
treatment are derivatives of antimony (antimonials), which in higher 
concentrations can cause cardiac, liver and kidney damage. Use of niosomes 
in tests conducted showed that it was possible to administer higher levels of 
the drug without the triggering of the side effects, and thus allowed greater 
efficacy in treatment
. 
Leishmaniasis 
(25)
Oral peptide drug delivery has long been faced with a challenge of bypassing 
the enzymes which would breakdown the peptide. Use of niosomes to 
successfully protect the peptides from gastrointestinal peptide breakdown is 
being investigated. In an in vitro study conducted by Yoshida et al, oral 
. 
1.10.13.3 Delivery of peptide drugs 
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delivery of a vasopressin derivative entrapped in niosomes showed that 
entrapment of the drug significantly increased the stability of the peptide(56)
Due to their immunological selectivity, low toxicity and greater stability; 
niosomes are being used to study the nature of the immune response 
provoked by antigens
. 
1.10.13.4 Use in studying immune response 
(66)
Niosomes can be used as carriers for haemoglobin within the blood. The 
niosomal vesicle is permeable to oxygen and hence can act as a carrier for 
haemoglobin in anemic patients
. 
1.10.13.5 Niosomes as carriers for haemoglobin 
(67)
One of the most useful aspects of niosomes is that they greatly enhance the 
uptake of drugs through the skin. Transdermal drug delivery utilizing niosomal 
technology is widely used in cosmetics; in fact, it was one of the first uses of 
the niosomes. Topical use of niosome entrapped antibiotics to treat acne is 
done. The penetration of the drugs through the skin is greatly increased as 
compared to un-entrapped drug
. 
1.10.13.6 Transdermal drug delivery systems utilizing niosomes 
(26)
It is difficult to achieve excellent bioavailability of drug from ocular dosage 
form like ophthalmic solution, suspension and ointment due to the tear 
production, impermeability of corneal epithelium, non-productive absorption 
and transient residence time. But to achieve good bioavailability of drug 
various vesicular systems are proposed to be use, in experimental level, like 
niosomes, liposomes. Bioadhesive-coated niosomal formulation of 
acetazolamide prepared from span 60, cholesterol stearylamine or dicetyl 
phosphate exhibits more tendencies for reduction of intraocular pressure as 
compared to marketed formulation (Dorzolamide). The chitosan-coated 
. 
Recently, transdermal vaccines utilizing niosomal technology is also being 
researched. A study conducted by P. N. Gupta et al has shown that niosomes 
(along with liposomes and transfersomes) can be utilized for topical 
immunization using tetanus toxoid. However, the current technology in 
niosomes allows only a weak immune response, and thus more research 
needs to be done in this field. 
1.10.13.7 Ophthalmic drug delivery 
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niosomal formulation timolol maleate (0.25%) exhibits more effect for 
reduction intraocular pressure as compared to a marketed formulation with 
less chance of cardiovascular side effects(48)
Niosomal system can be used as diagnostic agents. Conjugated niosomal 
formulation of gadobenate dimeglcemine with [N-palmitoyl-glucosamine 
(NPG)], PEG 4400, and both PEG and NPG exhibit significantly improved 
tumor targeting of an encapsulated paramagnetic agent assessed with MR 
imaging
. 
1.10.13.8 Other applications 
Diagnostic imaging with niosomes 
(68)
Radiolabelled (I
. 
Niosome formulation as a brain targeted delivery system for the 
vasoactive intestinal peptide (VIP) 
125) VIP-loaded glucose-bearing niosomes were injected 
intravenously to mice. Encapsulated VIP within glucose-bearing niosomes 
exhibits higher VIP brain uptake as compared to control(69)
Marketed products 
. 
Niosomes can also be utilized for sustained drug release and localized drug 
action to greatly increase the safety and efficacy of many drugs. Toxic drugs 
which need higher doses can possibly be delivered safely using niosomal 
encapsulation. 
It is obvious that niosome appears to be a well preferred drug delivery system 
over liposome as niosome being stable and economic. Also niosomes have 
great drug delivery potential for targeted delivery of anti-cancer, antiinfective 
agents. Drug delivery potential of niosome can enhance by using novel 
concepts like proniosomes, discomes and aspasome. Niosomes also serve 
better aid in diagnostic imaging and as a vaccine adjuvant.  
Lancome has come out with a variety of anti-ageing products with niosomes. 
L’Oreal is also conducting research on anti-ageing cosmetic products. 
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2. LITERATURE REVIEW 
2.1 Ocular inserts 
Sasaki Hitoshi et al., (1993)(1) developed disc type ophthalmic inserts of 
beta-blockers with various polymers and drug release from the inserts were 
investigated. Release of tilisolol from ten different types of polymer inserts 
showed a variety patterns. In the inserts prepared with poly(2-hydroxypropyl 
methacrylate)HPM and poly(2-hydroxyethyl methacrylate), the release data 
were fitted to a simple power equation and it was found that the release 
characteristics of tilisolol from these systems followed behavior conforming to 
a non-Fickian mechanism. Medium pH and medium temperature influenced 
the release of tilisolol from the HPM insert.
John H. Draize et al., (1944)
 Various beta-blockers also showed 
controlled release from their HPM inserts. Macromolecular dye and insulin 
showed a slow release with an initial burst effect. Release data for an HPM 
insert under various conditions were also fitted to a simple power equation. 
The in vivo release pattern of tilisolol from an HPM insert in rabbit conjunctival 
sac reflected the in vitro release pattern.  
(2)
Kauffmann et al., (1971)
 modified the interpretation of Friedinwald 
procedure for the objective measurement of injuries to rabbit eyes and 
extended the same principle to the evaluation of other physiological effects. In 
the “Modified Draize Technique”, they have transformed quantitative 
observations of physiological effects to reasonably quantitative objective 
measurements and also they have applied the principal of assigning 
numerical values to physiological phenimena in order to obtain data easily 
subject to arithmatical interpretation. It has been considered as the official 
method in the Federal Hazardous Substance Act, USA.  
(3)
Loucas S.P. and Hadded H.M., (1972)
 studied the various medical properties of soft 
contact lens indicating their ability to take up and release medications. Both 
humans and animals were used for the study. 
(4)
Grass et al., (1984)
 concluded that solid state dosage 
forms of pilocarpine in the cul-de-sac gave more uniform release. 
(5) carried out in vitro dissolution and mitosis studies in 
rabbits to evaluate the sustained action properties of pilocarpine nitrate in 
polymeric films and gels. Significant prolongation of drug release was 
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demonstrated when the polymer systems were compared to simple aqueous 
or viscous solutions.  
M. F. Saettone et al., (1984)(6)
K.P. Rao et al., (1988)
 formulated polymeric ophthalmic inserts 
containing pilocarpine with four different types of polyvinyl alcohol, PVA, and 
two types of hydroxypropylcellulose. Pilocarpine was present as the nitrate, or 
as the salt with polyacrylic acid, PAA. In-vivo miosis vs time experiments on 
albino rabbits, showed that all inserts increased significantly the bioavailability 
of pilocarpine, with respect to a standard solution of pilocarpine nitrate. Two 
PVA inserts, containing the PAA-salt of pilocarpine, were particularly effective. 
The preparations were also submitted to in-vitro release tests and to 
differential scanning calorimetry, to ascertain the release mechanism, and to 
verify, via the thermal behaviour, possible interactions between drug and 
polymers. The chemical and physicochemical factors, most likely to influence 
the ophthalmic bioavailability of pilocarpine from the present preparations, are 
briefly reviewed. 
(7) used pepsin-treated telopeptide-poor foetal calf skin 
collagen as a carrier for a controlled release of pilocarpine nitrate. Three types 
of collagen-pilocarpinenitrate drug delivery systems were developed. In vitro 
release of pilocarpinenitrate from these systems was studied. The release 
studies indicated that after an initial boost release, pilocarpine was released at 
a constant rate following zero-order kinetics. The release of the drug can be 
manipulated based on the type of modification made on the collagen carrier. 
The release rate of pilocarpinenitrate could be regulated from 5 to 15 days 
depending on the modification made on the collagen carrier. Collagen film
Attia et al., (1988)
, 
because of its biological inertness, structural stability and good 
biocompatibility, proved to be the most promising carrier for ophthalmic drug 
delivery systems. 
(8)
Dumortier et al., (1994)
 evaluated  in vivo (in rabbits) performance of 
dexamethasone ophthalmic film and concluded that ophthalmic film delivery 
system may target the drug to the eye tissue in which the drug is otherwise 
poorly available.  
(9) compared the lachrymal and plasmatic kinetic of 
morphine from a thermosensitive gel, an insert and a simple solution and 
evaluated the lacrimation in rabbits. It was observed that the inserts prolonged 
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the lachrymal and plasmatic kinetics of morphine. In lachrymal fluid, the 
maximum concentration was delayed from 2.9 to 51.4 min. 
Marco fabrizio saettone et al., (1995)(10)
Gautler and Gurny, (1995)
 discussed the advantages, 
disadvantages and requirement for the success of ocular inserts. They 
examined few inserts which are available in the market or are being 
developed by pharmaceutical companies for drug delivery. They discussed 
S.O.D.I., Ocusert, Collagen Shields, Ocufit, Minidisc and NODS with special 
attention to biological / clinical performances and potential for future 
applications and development.   
(11)
N. Udupa et al., (1996)
 reviewed the technologies involved in the 
development of various types of ophthalmic inserts. The design, conception, 
release mechanism, in vivo-in vitro assays, limitations and therapeutic 
rationale for the use of ophthalmic inserts were discussed. 
(12)
Manvi et al., (1997)
 incorporated norfloxacin and its betacyclodextrin 
complex into polymeric matrices and showed sustained drug release. The in 
vitro and in vivo release of complex was found to be better than the plain 
drug. 
(13)
R. Gurny et al., (1998)
 developed timolol maleate circular ophthalmic insert by 
solvent casting technique using cellulose acetate as polymer with PEG 600 
and diethyl phthalate as plasticizer in two different concentration. Plasticizer 
system influences their effect on drug release. The correlation was obtained in 
both in-vivo and in-vitro method.  
(14)
Patrizia chetoni et al., (1998)
 developed a soluble ocusert having gentamicin 
sulphate and dexamethasone phosphate and demonstrated the concomitant 
release of both drugs during the first 10 hr treatment, followed by an adequate 
concentration of gentamicin sulphate above the MIC of 4 μg/mL during 50 hr 
by using CAP solid dispersion. 
(15) developed rod-shaped mucoadhesive 
ophthalmic inserts fitting the upper or lower conjuctival fornix using silicone 
elastomer and polyacrylic acid(PAA) or polymethacrylic acid (PMA) 
interpenetrating polymer network grafted on surface. They showed 90% 
release of oxytetracyclin HCL after 12 days from this inserts. 
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R. Vijaya muthu manikander et al., (1998)(16)
Samual H. Yalkowsky et al., (1999)
 reported that diclofenac 
sodium ocular inserts using 4% HPMC released the drug over an extended 
period of 11 hr. 
(17)
Saisivam et al., (1999)
 formulated a gelfoam based ocular 
device containing 1.7 mg of Phenylephrine and 0.6 mg of Tropicamide. The in 
vivo results showed that the mydriatic response produced by the proposed 
device is larger and longer lasting than that produced by eye drops with an 
equivalent amount of Phenylephrine and Tropicamide. 
(18)
Karatas et al., (2000)
 proved zero order release of ciprofloxacin 
hydrochloride from ocuserts made up of  HPMC(2%)  as drug reservoir and 
EC (6%) as a rate controlling membrane. 
(19)
S. Jayaprakash et al., (2000)
 prepared ophthalmic inserts containing Indomethacin 
using water soluble polymers such as hydroxypropl cellulose (HPC), 
methlycellulose (MC), hydroxypropyl methlycellulose (HPMC) and polyvinyl 
alcohol (PVA), according to the film casting (FC) and compression molding 
(CM) methods and studied the effects of different polymers and methods on in 
vitro drug release. The hydrophilicity of inserts was tested by measuring their 
water vapor absorption. In vitro insert hydration was also determined by 
measuring their water absorption.  Drug release was reduced by the use of 
high viscosity and less soluble polymers. Inserts prepared by the compression 
molding technique exhibited higher release rates than those prepared by film 
casting method. 
(20)
G. Di Colo et al., (2001) prepared and evaluated ocular inserts of ofloxacin 
using poly(ethylene oxide) alone and with neutralized eudragit L100 by 
powder compression technique. These inserts were able to form insitu 
mucoadhesive gels which eroded slowly to release the drug. The inserts 
based on the PEO – EUD Na17 compound yielded a profile typical of a zero 
order controlled delivery system
 investigated different polymers (HPMC, 
PVP, MC, EC) for ocuserts and proved zero order release of ketorolac 
tromethamine from ocuserts consisted of 3% HPMC and 4% EC as a rate 
controlling membrane. 
(21)
They also studied correlation between PEO molecular weight and insert 
properties potentially related to its therapeutic efficacy and showed that low 
.  
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molecular weight PEO were suitable for ocuserts while high molecular weight 
PEO were not suitable(22)
They also evaluated PEO based inserts, containing Chitosan microparticles, 
which produced microstructural changes and hence accelerated both insert 
erosion and ofloxacin release. Chitosan increased the diffusive contribution to 
the release mechanism with respect to the inserts based on plain PEO. Thus 
they suggested ability of chitosan-hydrochloride to enhance corneal 
permeability
.  
(23)
Ging-Ho Hsiue et al., (2001)
. 
(24)
Margit Hornof et al., (2003)
 investigated pilocarpine trapped in a matrix 
diffusion-controlled drug delivery system using hydrophilic inserts of Poly(2-
hydroxyethyl methacrylate) (pHEMA) to ensure an increased bioavailability of 
pilocarpine and prolong the length of time in which the medication remains in 
the eyes of the test subjects. The physical and chemical properties of 
pilocarpine were investigated to elucidate the mechanism of drug–polymer 
interaction and the effect on drug release behavior of controlled release 
polymeric devices. In vitro release studies indicated that pilocarpine continued 
to be released from the inserts for a 24 h period. The results of intraocular 
pressure tests performed on albino rabbits were consistent with the observed 
in vitro behavior. The pressure decrease was significant for a period longer 
than 48 h. It confirms that the inserts, as sustainable releasing devices, are 
promising carriers for ophthalmic drug delivery systems 
(25)  developed a mucoadhesive ocular insert for 
the controlled delivery of ophthalmic drugs. The inserts tested were based 
either on unmodified or thiolated poly(acrylic acid).Water uptake and swelling 
behavior of the inserts as well as the drug release rates of the model drugs 
fluorescein and two diclofenac salts with different solubility properties were 
evaluated in vitro. Fluorescein was used as fluorescent tracer to study the 
drug release from the insert in humans. The mean fluorescein concentration 
in the cornea/tearfilm compartment as a function of time was determined after 
application of aqueous eye drops and inserts composed of unmodified and of 
thiolated poly(acrylic acid). The acceptability of the inserts by the volunteers 
was also evaluated. Inserts based on thiolated poly(acrylic acid) were not 
soluble and had good cohesive properties. A controlled release was achieved 
for the incorporated model drugs. The in vivo study showed that inserts based 
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on thiolated poly(acrylic acid) provide a fluorescein concentration on the eye 
surface for more than 8 hr, whereas the fluorescein concentration rapidly 
decreased after application of aqueous eye drops or inserts based on 
unmodified poly(acrylic acid). Moreover, these inserts were well accepted by 
the volunteers. The present study indicates that ocular inserts based on 
thiolated poly(acrylic acid) are promising new solid devices for ocular drug 
delivery.  
Hitoshi Sasaki et al., (2003)(26)
Naseem A. Charoo et al., (2003)
 prepared a unique one-side-coated insert that 
releases from only uncoated side. It was prepared by attaching a 
polypropylene tape on the one side of the polymer disc of poly(2-
hydroxypropylmethacrylate) containing Tilisolol as a model drug. Ocular 
application of the one-side-coated insert produced the constant 
concentrations of tilisolol in the tear fluid over 180 min. A release of Tilisolol 
from the one-side-coated insert was twice slower than from the uncoated 
insert. 
(27)
P. M. Dandagi et al., (2003)
 prepared ocuserts using sodium alginate 
and ciprofloxacin hydrochloride as a drug reservoir, Eudragit and PVA films as 
a rate controlling membrane and demonstrated zero order release of the drug 
over  an extended period of 12 hr. 
(28)
F. V. Manvi et al., (2004)
 prepared ketorolac tromethamine ocular films 
using PVP and Sod. CMC. In vitro drug release studies were carried out by 
using bichambered donor receptor compartment model designed with open 
end cylinder using transparent cellulose type semi permeable membrane. 
Formulations were also subjected to in vivo drug release study after 
sterilization by U.V. radiation followed by sterility test as per I.P. method. 
(29)
Samanta et al., (2004)
 prepared diclofenac sodium circular ocular 
inserts using gelatin(18% w/v and 20% w/v) as a polymer and glycerin as a 
plasticizer in two different concentration (70 % w/v and 50 % w/v) on dry 
weight of gelatin. in vitro and in vivo release of the inserts were determined. It 
was confirmed by strong positive correlation between the two results 
indicating that inserts could control drug release and might improve ocular 
bioavailability and reduce toxicity of diclofenac sodium.  
(30) developed ciprofloxacin hydrochloride ocuserts and 
evaluated their potential for prolonged ocular delivery. Inserts were fabricated 
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with sodium alginate films loaded with drug and then treated with calcium 
chloride. In vitro release of the drug from the inserts followed Higuchi’s and 
first order kinetic models. The in vivo studies were carried out in rabbit eyes 
by measuring tear fluid concentration against time. 
P. M. Dandagi et al., (2004)(31)
Venkateshwara Rao et al., (2004)
 formulated ocular films with cromolyn sodium 
using PVA and sodium alginate. Films showed extended release of drug for 
12 hr following zero order kinetics and non-fickian mechanism. They also 
demonstrated strong in vitro-in vivo correlation. 
(32)
D. Dhachinamorthi et al., (2005)
 prepared norfloxacin ocular inserts 
using PVP, EVA, HPMC. They have developed new technique of in vitro 
evaluation in a fabricated flow through cell. All the films prepared were found 
to be uniform in thickness, and the partition coefficient of norfloxacin and its 
betacyclodextrin complex was 0.048 and 0.853, respectively. I.R. spectra 
revealed complexation of norfloxacin with b-cyclodextrin. In vitro results 
revealed that 2 patch/insert formulations, V1 and V2, followed perfect zero 
order kinetics release (n = 1), and 3 formulations, V3, V4 and V5, released the 
drug by super case II kinetics (n > 1). The study confirmed the improved 
solubility of norfloxacin when complexed with b-cyclodextrin and that it can be 
delivered through films made of HPMC matrix cast with EC alone or with a 
combination of PVP K30. 
(33)
V. Sankar et al., (2005)
 prepared ofloxacin ocuserts using 
different polymers such as HPMC, MC and EC at different concentrations. 
The Physicochemical parameters and in vitro release of the drug from the 
formulations were studied using commercial semipermeable membrane. A 
zero-order release formulation with 3% HPMC, 4% EC was subjected to in 
vivo after sterilization. The expected zero order release for one day was 
observed in formulation mentioned as above. 
(34) used MC and Sodium CMC as polymers for 
ocuserts and showed sustained release of diclofenac sodium. Ocuserts were 
evaluated for uniformity of drug content, in vitro drug release and stability 
studies. It was concluded that ocuserts prepared with 4% SCMC and 1% MC 
showed sustained release of drug and it was found to be stable at 30 and 40 
oC for 2 month. 
 Chapter 2        Literature review 
 Hitesh B. Gevariya                                                 55                                                         Ph.D. Thesis 
Yasmin sultana et al., (2005)(35)
S. Jayaprakash et al., (2005)
  worked on pefloxacin mesylate ocular 
inserts using Eudragit RS 100, Eudragit RL 100 and PVP K-30 and 
demonstrated drug release for 5 days with good long term stability of 
formulations. 
(36)
Hiratani H. et al., (2005)
 prepared timolol maleate ocuserts using 
different polymers such as HPMC, EC, and Eudragit RL 100 at various 
concentrations. The zero order release was observed in the formulation 
containing 1.25% HPMC and 1.25% EC as a drug reservoir and 2% HPMC as 
rate controlling membrane which was subjected for in vivo studies. The 
expected zero order release for one day was observed in the formulation 
mentioned as above. 
(37)
J. K. Pandit et al., (2006)
 evaluated the ocular in vivo release of timolol 
maleate from molecularly imprinted soft contact lenses on male Nippon albino 
rabbit. They concluded that imprinted soft contact lenses are promising drug 
devices able to provide greater and more sustained drug concentration in tear 
fluid with lower dosage than conventional eye drops.  
(38)
Aysegul Karatas and Tamer Baykara, (2006)
 prepared soluble ocular inserts of ciprofloxacin 
using high and low molecular weight PVA and performed microbiological 
evaluation. Inserts showed matrix diffusion kinetic release showing an 
anomalous release mechanism (erosion controlled release). 
(39) prepared inserts of water-
soluble ketorolac tromethamin (KT) and water-insoluble indomethacin (IND) 
using hydrogels such as Poly (butyl methacrylate) (pBMA), Poly (2-
hydroxyethyl methacrylate) (pHEMA), and poly (2-hydroxypropyl 
methacrylate) (pHPMA), and a plasticizer such as Polyethylene glycol 300 
(PEG) by film casting method. Swelling properties of these inserts was 
determined and they were irradiated with an absorbed dose of 1.2 Mrad by 
means of a Co- 60 source. The effects of these parameters on the drug 
release were examined. The mechanism of drug release was identified by 
means of the semi-empirical equation developed by Korsmeyer and Peppas. 
Swelling of the hydrogels and release of drugs from the hydrogels increased 
with size of side chain, hydroxyl groups on the side chain of the acrylate and 
using PEG 300 in the formulation, which increase hydrophilicity. Water–
soluble KT showed higher release than water–insoluble IND. It was also 
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observed no effect of irradiation dose on the release of drugs from the inserts. 
Release of KT mainly fit to the Fickian diffusion mechanism, whereas drug 
release of IND mainly showed the non-Fickian release mechanism according 
to their n exponent values. 
A. S. Mundada and B. K. Shrikhande, (2006)(40)
Leo H. Koole et al., (2007)
 prepared reservoir using 
natural hydrophilic polymer viz. gelatin while rate-controlling membrane was 
prepared using hydrophobic ethyl cellulose. Since targeted prolong release 
was observed in formulation CF2 and CF5, these formulations were further 
subjected to in vivo drug release study using rabbits as an animal model. In 
vitro drug release kinetic data was treated according to Zero, First, and 
Higuchi kinetics to access the mechanism of drug release. Correlation 
between in vitro and in vivo drug release was found to be strong revealing the 
efficacy of the formulation.  
(41)
Tanwar Y.S. et al., (2007)
 prepared the ophthacoil, a flexible and tubular 
device for delivery of drugs to the tear film of the eye. Poly(2-hydroxyethyl 
methacrylate)- and poly(2-hydroxyethyl methacrylate-co-1-vinyl-2-
pyrrolidone)-microspheres were prepared by suspension polymerization. The 
resultant particles were swollen in a highly concentrated solution of either the 
dye fluorescein sodium or the antibiotic chloramphenicol. The loaded particles 
were placed in the central cavity of the ocular device. In vitro release profiles 
showed a six-fold increase of the capacity for the dye fluorescein sodium, but 
not for the antibiotic chloramphenicol. Flexibility measurements revealed that 
by introducing microspheres in the central cavity of the device, flexibility did 
not decrease. Finally, a preliminary in vivo evaluation of the device (n = 5) 
was done for a 2 hr-period to assess the tolerance of the device in the human 
eye. Ophthalmologic examinations and photographs of the eye indicated no 
signs of irritation. Volunteers reported that the presence of the device in the 
eye could be noticed, but no irritation was reported. 
(42) prepared polyvinyl alcohol (PVA) ofloxacin films 
by mercury substrate method. The weight and thickness of the inserts were in 
the range of 57.3-126.0 mg and 55.6-99.3 microns. Tensile strength and 
percent elongation at break varied with the nature of rate-controlling 
membrane and film thickness. Moisture vapour transmission through films 
followed zero-order kinetics and decreased with increase in film thickness. 
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The drug content varied from 99.53-99.86%. The method of exposure to UV 
radiation was used for sterilization of ocular inserts and no microbial growth 
was observed in any formulation during sterility testing by direct inoculation 
method. Ocular insert F3 with rate-controlling membrane of Eudragit RS100, 
when inserted into the eye of rabbit showed controlled release up to 24 hr. 
There was a good correlation between in vitro and in vivo release data. The 
developed formulation was effective against selected microorganism during in 
vitro antimicrobial efficacy studies.  
S.Ramkanth et al., (2009)(43)
Baillie a. J. et al., (1985)
 prepared diclofenac sodium ocuserts by using 
different polymers such as hydroxy propyl methyl cellulose (HPMC), hydroxy 
propyl cellulose (HPC), methyl cellulose (MC) and ethyl cellulose (EC) at 
various concentrations and combinations using dibutyl phthalate (DBP) as 
plasticizer. The invitro drug release was studied using commercial semi 
permeable membrane. A zero order release formulation F3 were sterilized by 
ethylene oxide and subjected to in vivo studies. IR spectral observation show 
there is no interaction of drug with polymer which indicates the intactness of 
drug in formulation. Ocular toxicity test and accelerated stability studies were 
also carried out for the formulation F3. 
 
2.2 Niosomes 
(44)
Rogerson
 prepared vesicles on hydration of a mixture of a 
single or double alkyl-chain, non-ionic surfactant with cholesterol. These 
vesicles, or ‘niosomes’, are capable of entrapping and retaining water soluble 
solutes such as carboxyfluorescein, are osmotically active and can be 
formulated to release entrapped solute slowly. The physical characteristics of 
the vesicles were found to be dependent on the method of production and 
three such methods, based on liposome technology, are described. The 
vesicles have been characterized by photon correlation spectroscopy, freeze 
fracture electron micrography, measurement of solute entrapment efficiency, 
and solute release rates. Vesicular forms of the single chain surfactant which 
could be formed under certain conditions in the absence of cholesterol are 
also described. 
 et al., (1987)(45) studied the effect of encapsulation of adriamycin 
into niosomes, and its resultant chemical purity  by means of HPLC and high-
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speed scanning spectrophotometry (the simultaneous use of which allowed 
investigation of potential non-fluorescent drug degradation products), and the 
process shown not to adversely affect the drug. Efficiency of entrapment of 
aqueous solutions of the drug was apparently dependant on neither vesicle 
composition nor method of production, and evidence of a degree of 
surfactant-adriamycin association was provided by the high entrapment 
values. Light-induced drug degradation was reduced by niosome 
encapsulation, and efflux of entrapped adriamycin was decreased by inclusion 
of cholesterol into the vesicles, in a manner similar to that reported for 
liposome preparations. Thus only chemically pure adriamycin was entrapped 
in, and released from, niosomes. 
Florence et al., (1988)(46)  prepared multilamellar niosomes from a c16
Alexander et al., (1994)
 
triglyceryl ether with and without cholesterol and containing doxorubicin 
(adriamycin) were administered to s180 tumour-bearing mice by bolus 
injection. Although in-vitro drug release from cholesterol-containing niosomes 
is delayed, in-vivo there was little difference between the two preparations 
when plasma levels were compared. As previously observed, half-lives of the 
drug were prolonged compared with free solution profiles. Liver uptake was 
not significantly affected by niosome encapsulation of doxorubicin. Tumour 
levels of drug were higher following administration of cholesterol-containing 
niosomes and this was reflected in the more effective reduction in tumour 
growth.  
(47) formulated multilamellar vesicles (niosomes) of a 
series of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan 
trioleate (Span 85) using a mechanical shaking technique without sonication. 
5(6)-Carboxyfluorescein (CF) was used as a model solute to investigate 
entrapment efficiency and release. For Span 80, cholesterol and dicetyl 
phosphate (DCP) in the molar ratio 47.5:47.5:5.0, entrapment efficiency 
increased linearly with increasing concentration of lipid. Entrapment efficiency 
per mmol lipid, however, was constant at about 34%, independent of the lipid 
concentration. Entrapment efficiency increased with increasing cholesterol 
content when vesicles were prepared by changing the molar ratio of non-ionic 
surfactant to cholesterol. Most efficient entrapment of CF occurred with Span 
60 (HLB 4.7). Mean size of the un-sonicated niosomes showed a regular 
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increase with increasing HLB from Span 85 (HLB 1.8) to Span (HLB 8.6). The 
release rate of CF from vesicles depended on the surfactant used in the 
preparation of the vesicles. 
Yoshioka et al., (1995)(48)
Uchegbu and S. P. Vyas, (1998)
 developed the niosomes-in-water-in-oil (v/w/o) 
system. The properties of the surfactant used to form the vesicles, the 
surfactant or surfactant mixture used to stabilize the emulsion and the nature 
of the oil phase can be changed to provide systems of different capacities for 
drug or antigen and different release characteristics. The same nonionic 
surfactant is used as the principle amphipile to form the niosomes and to 
stabilize the w/o emulsion, thus promoting stability by decreasing transfer of 
surfactant between the stabilizing monolayers and the vesicle bilayers. The in 
vitro release of carboxyfluoroscein and 5-fluorouracil encapsulated within the 
niosomes of the v/w/o system has been investigated, the nature of the oil 
phase and surfactant-oil interactions being important in determining the rate of 
solute release. Initial studies of the system in vivo, as an adjuvant for tetanus 
toxoid, using cottonseed oil as the external oil phase, showed enhanced 
immunological activity over the free antigen or vesicles. 
(49)
Alhaique et al., (1998)
 gave summary of the achievements in 
the field of niosome research to date. They suggested that the self assembly 
of surfactants into niosomes is governed not only by the nature of the 
surfactant but by the presence of membrane additives, the nature of the drug 
encapsulated and the actual method of preparation. Methods of niosome 
preparation and the number of different morphologies that have been 
identified are detailed. The influence of formulation factors on niosome 
stability is also examined as are methods to optimise drug loading. In vivo 
these systems have been evaluated as immunological adjuvants, anti-
cancer:anti-infective drug targeting agents and carriers of anti-inflammatory 
drugs. Niosomes have also been used in diagnostic imaging. Efforts to 
achieve transdermal and ophthalmic drug delivery with some formulations are 
also discussed. 
(50) prepared niosomes from polysorbate 20 and 
cholesterol by means of two different methods: by direct sonication of an 
aqueous dispersion of the various components (bulk) or by solubilization of 
the components, evaporation of the organic solvent to form a film inside the 
 Chapter 2        Literature review 
 Hitesh B. Gevariya                                                 60                                                         Ph.D. Thesis 
vessel used for the preparation and then by sonication (film). The influence of 
the preparation technique on the properties of the obtained structures was 
studied. Vesicles with bigger dimensions and higher entrapment efficiency 
were obtained when sonication was carried out after the film formation. 
Vesicle formation in the presence of ionic surfactants was investigated in 
order to evaluate the effect of charged components on vesicle dimensions, 
entrapment efficiency and stability. Dimethyldioctadecylammonium bromide 
(DDOA) and cetylpyridinium chloride (CPy) were used to introduce a positive 
charge in the vesicle structure, while dicetylphosphate (DCP) was used for a 
negative charge. Better resistance to osmotic stress and higher entrapment 
efficiency values were obtained with vesicles containing DCP and CPy.  
Uchegbu et al., (2000)(51)
Blazek-Welsh and David G., (2001)
 prepared polymeric vesicles and niosomes bearing 
glucose or transferrin ligands for drug targeting. A glucose-palmitoyl glycol 
chitosan (PGC) conjugate was synthesised and glucose-PGC polymeric 
vesicles prepared by sonication of glucose-PGC/ cholesterol. N-
palmitoylglucosamine (NPG) was synthesised and NPG niosomes also 
prepared by sonication of NPG/ sorbitan monostearate/ cholesterol/ 
cholesteryl poly-24- oxyethylene ether. TEM imaging confirmed the presence 
of glucose units on the surface of PGC polymeric vesicles and NPG 
niosomes. Transferrin was coupled to PGC vesicles at a level of 0.60 ± 0.18 g 
of transferring per g polymer. The proportion of FITC-dextran positive A431 
cells was 42% (FITC-dextran solution), 74% (plain vesicles) and 90% 
(transferrin vesicles).  
(52) developed proniosomes, a dry 
formulation using a sorbitol carrier coated with nonionic surfactant, which can 
be used to produce niosomes within minutes by the addition of hot water 
followed by agitation. The sorbitol carrier in the original proniosomes was 
soluble in the solvent used to deposit surfactant, so preparation was tedious 
and the dissolved sorbitol interfered with the encapsulation of one model drug. 
A novel method is reported here for rapid preparation of proniosomes with a 
wide range of surfactant loading. A slurry method has been developed to 
produce proniosomes using maltodextrin as the carrier. The time required to 
produce proniosomes by this simple method is independent of the ratio of 
surfactant solution to carrier material and appears to be scalable.  
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David G. Rhodes et al., (2001)(53)
Joke A. Bouwstra et al., (2001)
 developed a novel method for producing 
proniosomes with a maltodextrin carrier, which provides for rapid 
reconstitution of niosomes with minimal residual carrier. Slurry of maltodextrin 
and surfactant was dried to form a free-flowing powder which could be 
rehydrated by addition of warm water. Successful rehydration of surfactant to 
produce niosomes from dried film requires that the film be as thin as possible 
to avoid the clumping and precipitation that occurs when pure, granular 
surfactant is hydrated directly. The appearance of a coarse, broken surface 
on the proniosomes correlates with inefficient rehydration and occurrence of 
aggregation and precipitate in the final niosome suspension. 
(54)
Rambhau et al., (2004)
 prepared vesicles composed of the single 
chain non-ionic surfactant octaoxyethylenelaurate-ester (PEG-8-L), the 
sucrose laurate-ester L-595 and cholesterol sulfate (CS) to monitor local 
dynamic properties of lipid molecules in vesicle bilayers and to study the 
elasticity of vesicle bilayers. Studies with the spin label probes 5-, 12- and 16-
doxyl stearic acid (DSA) indicated that both the order parameter and the 
rotational correlation times increased when the doxyl group was positioned 
closer to the headgroup region. These findings indicate that the fluidity of 
membranes decreased near the headgroup region. Comparing 16-DSA 
incorporated in vesicle formulations with either 30 or 70 mol% showed no 
difference in alkyl chain mobility as was reflected by the order parameter. The 
rotational correlation times, however, showed a slowdown from 0.38 to 0.71 
and 1.13 ns when the PEG-8-L molar content was decreased from 100 to 70 
and 30 mol% for PEG-8-L:L-595:CS vesicles, respectively. Extrusion 
measurements indicated an increase in elasticity of vesicle bilayers as the 
molar content of PEG-8-L was increased from 10 to 90 mol%.  
(55) developed azidothymidine (AZT) Aspasomes 
(Ascorbyl palmitate (ASP) vesicles) containing 18–72 mol% cholesterol and a 
negatively charged lipid (dicetyl phosphate) by film hydration method followed 
by sonication. Differential scanning calorimetric data of aspasome dispersion 
and anhydrous mixtures of ascorbyl palmitate, cholesterol and dicetyl 
phosphate confirm the formation of bilayered vesicles with ascorbyl palmitate. 
Cholesterol content in aspasome did not exhibit any relation with vesicle size, 
zeta potential or percent entrapment. A substantial change in release rate of 
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azidothymidine from aspasome was noticed on varying the proportion of 
cholesterol. A preparation with 45 mol% of cholesterol showed maximum 
retardation in release rate, than other compositions. The antioxidant potency 
of Aspasomes was assessed by measuring the protection offered by this 
preparation against quinolinic acid induced lipoperoxidation of whole human 
blood in vitro, where in the lipoperoxidation was monitored by measuring 
thiobarbituric acid reactive substances (TBARS) levels. Aspasome rendered 
much better antioxidant activity than ascorbic acid. Transdermal permeation 
of aspasomal AZT, ASP-AZT aqueous dispersion and AZT-solution across 
excised rat skin was investigated in vitro using Franz diffusion cell. 
Permeation of aspasomal AZT was much higher than the other two 
preparations. However, ASP-AZT aqueous dispersion has also enhanced 
permeation of AZT significantly over the AZT-solution, indicating skin 
permeation enhancing property of ascorbyl palmitate. 
Behrooz Nasseri, (2005)(56) studied mechanical characteristics of non-ionic 
bilayer membranes composed of sorbitan monostearate, cholesterol and poly-
24-oxyethylene cholesteryl by measuring the modulus of surface elasticity (μ), 
a measure of membrane strength, as a function of cholesterol content and 
temperature. The modulus of surface elasticity increased slowly with 
increasing cholesterol concentration, with a sharp increase around 40 mol% 
cholesterol (on average an increment of 0.43×106 Nm−2 per molar 
percentage), and displayed a maximum of 6.5×106 Nm−2 around 47.5 mol% 
cholesterol. Further cholesterol resulted in a decrease inμ. Generally the 
interaction of cholesterol with the sorbitan monostearate should increase the 
rigidity of the membrane. However, the latter effect may be due to the 
formation of cholesterol clusters at high cholesterol content where excess 
amounts of cholesterol cannot interact with the sorbitan monostearate, and 
deposits on the bilayers compromising their uniformity, strength and 
permeability. This behaviour was evident when measurements were carried 
out above and below 25 o
Aggarwal and I. P. Kaur, (2005)
C.  
(57) prepared chitosan (REVTMbio1) or 
Carbopol (REVTMbio2 and 3) coated niosomal timolol maleate (0.25%) 
formulations by reverse phase evaporation (REV) and compared to timolol 
solution (TMS; 0.25%) in terms of in vitro release and IOP lowering 
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pharmacodynamic effect. The in vitro release phase of timolol (91% release in 
2 h) was extended significantly by its incorporation into niosomes and further 
by the polymer coating (40–43% release upto 10 h). The developed 
formulations were evaluated for their pharmacodynamics in albino rabbits, by 
measuring intraocular pressure (IOP) using a non-contact pneumatonometer, 
and were compared to a marketed in situ gel forming solution of timolol 
(Timolet GFS, 0.5%; Sun Pharma). REVTMbio1 formulation showed a more 
sustained effect of upto 8 h (vis a vis 6 h for carbopol-coated niosomes). TMS 
in comparison showed effect for only 2 h though the peak effect was slightly 
more (14%). Lowering of IOP in the contralateral eye (20–40% as compared 
to 100% in case of TMS), considerably reduces with REV and REVbio 
formulations indicating lesser systemic side effects. Moreover, the results of 
REVTMbio1formulation containing 0.25% of timolol maleate compared well 
with the 0.5% marketed gel formulation, indicating our formulation to be 
significantly better considering that similar effect is obtained at half the 
concentration.  
Ibrahim Alsarra et al., (2005)(58)
Samar Mansour et al., (2005)
 investigated  permeation of a potent 
nonsteroidal anti-inflammatory, ketorolac, across excised rabbit skin from 
various proniosome gel formulations using Franz diffusion cells. Each of the 
prepared proniosomes significantly improved drug permeation and reduced 
the lag time (P<0.05). Proniosomes prepared with Span 60 provided a higher 
ketorolac flux across the skin than did those prepared with Tween 20 (7- and 
4-fold the control, respectively). A change in the cholesterol content did not 
affect the efficiency of the proniosomes, and the reduction in the lecithin 
content did not significantly decrease the flux (P>0.05). Each of the prepared 
niosomes achieved about 99% drug encapsulation. Vesicle size was markedly 
dependent on the composition of the proniosomal formulations.  
(59) formulated niosomes from Span 40 or Span 
60 and cholesterol in the molar ratios of 7:4, 7:6 and 7:7 using reverse-phase 
evaporation and thin film hydration methods. The results showed that the type 
of surfactant, cholesterol content and the method of preparation altered the 
entrapment efficiency and drug release rate from niosomes. Higher 
entrapment efficiency was obtained with multilamellar niosomes prepared 
from Span 60 and cholesterol in a 7:6 molar ratio. Niosomal formulations have 
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shown a fairly high retention of acetazolamide inside the vesicles 
(approximately 75%) at a refrigerated temperature up to a period of 3 months. 
Each of the tested acetazolamide niosomes prepared by either method 
produced a significant decrease in IOP compared to the solution of free drug 
and plain niosomes. Multilamellar acetazolamide niosomes formulated with 
Span 60 and cholesterol in a 7:4 molar ratio were found to be the most 
effective and showed prolonged decrease in IOP. Histological examination of 
corneal tissues after instillation of niosomal formulation for 40 days showed 
slight irritation in the substantia propria of the eye which is reversible and no 
major changes in tissues were observed.  
S.P. Vyas (2005)(60)
Fadda et al., (2007)
 encapsulated DNA encoding hepatitis B surface antigen 
(HBsAg) in niosomes composed of span 85 and cholesterol as constitutive 
lipids using reverse phase evaporation method. Prepared niosomes were 
characterized for their size, shape and entrapment efficiency. The immune 
stimulating activity was studied by measuring serum anti-HBsAg titer and 
cyokines level (IL-2 and IFN-γ) following topical application of niosomes in 
Balb/c mice and results were compared with naked DNA and liposomes 
encapsulated DNA applied topically as well as naked DNA and pure 
recombinant HBsAg administered intramuscularly. The proposed system is 
simple, stable and cost effective compared to liposomes. 
(61) formulated minoxidil loaded liposome and niosome 
formulations to improve skin drug delivery. Multilamellar liposomes were 
prepared using soy phosphatidylcholine at different purity degrees 
(Phospholiponw 90, 90% purity, soy lecithin (SL), 75% purity) and cholesterol 
(Chol), whereas niosomes were made with two different commercial mixtures 
of alkylpolyglucoside (APG) surfactants (Oramixw NS10, Oramixw CG110), 
Chol and dicetylphosphate. Minoxidil skin penetration and permeation 
experiments were performed in vitro using vertical diffusion Franz cells and 
human skin treated with either drug vesicular systems or propylene glycol–
water–ethanol solution (control). Penetration of minoxidil in epidermal and 
dermal layers was greater with liposomes than with niosomal formulations and 
the control solution. These differences might be attributed to the smaller size 
and the greater potential targeting to skin and skin appendages of liposomal 
carriers, which enhanced globally the skin drug delivery.   
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Ajay Solanki et al., (2007)(62)
Indu P. Kaur et al., (2007)
 used 3-factor, 3-level Box-Behnken design to 
optimize niosomes. Contour plots were constructed to show the effects of X1, 
X2 and X3 on the PDE. A model was validated for accurate prediction of the 
PDE by performing checkpoint analysis. The computer optimization process 
and contour plots predicted the levels of independent variables X1, X2, and 
X3 (0, -0.158 and –0.158 respectively), for maximized response of PDE with 
constraints on vesicle size. The Box-Behnken design demonstrated the role of 
the derived equation and contour plots in predicting the values of dependent 
variables for the preparation and optimization of piroxicam proniosomes. 
(63)
Abbas Pardakhty et al., (2007)
 prepared carbopol coated acetazolamide 
niosomes by reverse phase evaporation method. The pharmacodynamic 
studies showed 33% fall in IOP with the developed formulation, and the effect 
was sustained for 6 h after instillation. The effect compared well with a four 
times higher concentration of dorzolamide (Dorzox®), a topical CAI available 
in the market. In the present study, the aqueous humor disposition of the drug 
from the developed bioadhesive coated niosomal formulation (ACZREVbio) is 
compared with the aqueous suspension of the drug (containing 1% (w/v) 
Tween 80 as a dispersing agent) at similar concentrations. The concentration 
of acetazolamide absorbed in the aqueous humor at various times from the 
control suspension and from ACZREVbio was determined by microdialysis in 
male albino rabbits. The peak concentration of drug absorbed in the aqueous 
humor from the ACZREVbio formulation (14.94 µg/mL) was almost two times 
of that obtained with the equivalent amount of acetazolamide control 
suspension (6.93 µg).An important observation was the fact that a high drug 
concentration of 12.02 µg reached immediately, i.e., 20 min after instillation of 
ACZREVbio indicating a high penetration being achieved, while a meagre 
concentration of only 3.53 µg is obtained at 60 min after instillation of the 
control suspension.   
(64) studied niosomes of polyoxyethylene alkyl 
ethers (BrijTM) for encapsulation of insulin prepared by film hydration method. 
Without cholesterol, brij 35 and brij 58 did not form niosomes, apparently 
because of relatively large polar head groups in comparison with their alkyl 
chains. The size of vesicles depended on the cholesterol content, charge 
incorporation or hydrophilicity of surfactants. Entrapment of insulin in bilayer 
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structure of niosomes protected it against proteolytic activity of chymotrypsin, 
trypsin and pepsin in vitro. The maximum protection activity was seen in brij 
92/cholesterol (7:3 molar ratios) in which only 26.3±3.98% of entrapped 
insulin was released during 24 h in simulated intestinal fluid (SIF). The kinetic 
of drug release for most formulations could be best described by Baker and 
Lonsdale equation indicating diffusion based delivery mechanism.  
Attia et al., (2007)(65)
Massimo Fresta et al., (2007)
 prepared acyclovir niosomes by thin film hydration 
method in a trial to improve its poor and variable oral bioavailability. The lipid 
mixture consisted of cholesterol, span 60, and dicetyl phosphate in the molar 
ratio of 65:60:5, respectively. The percentage entrapment was ~11% of 
acyclovir used in the hydration process. The vesicles have an average size of 
0.95 μm, a most probable size of 0.8 μm, and a size range of 0.4 to 2.2 μm. 
Most of the niosomes have unilamellar spherical shape. In vitro drug release 
profile was found to follow Higuchi’s equation for free and niosomal drug. The 
average relative bioavailability of the drug from the niosomal dispersion in 
relation to the free solution was 2.55 indicating more than 2-fold increase in 
drug bioavailability. The niosomal dispersion showed significant increase in 
the mean residence time (MRT) of acyclovir reflecting sustained release 
characteristics.  
(66) prepared a novel niosomes of ammonium 
glycyrrhizinate, a natural compound, using a new non ionic surfactant, α,ω-
hexadecyl-bis-(1-aza-18-crown-6)(Bolasurfactant)-Span80-cholesterol (2:3:1 
molar ratio). The tolerability of Bola-surfactant both as free molecules or 
assembled ion niosome vesicles was evaluated in vitro on cultured of human 
keratinocyte cells (NCTC2544). Human tolerability was evaluated on 
volunteers. The ability of Bola-niosomes to promote intracellular delivery was 
evaluated by confocal laser scanning microscopy (CLSM) studies. Human 
stratum corneum and epidermis (SCE) membranes were used in vitro to 
investigate the percutaneous permeation. The anti-inflammatory activity of 
ammonium glycyrrhizinate was evaluated in vivo on human volunteers with a 
chemically induced erythema. Experimental data show that Bola-niosomes 
are characterized by a mean size of 400 nm and are able to provide an 
encapsulation efficiency of 40% with respect to the drug amount used during 
preparation. Bolaniosomes were also able to significantly improve (p <0.001) 
 Chapter 2        Literature review 
 Hitesh B. Gevariya                                                 67                                                         Ph.D. Thesis 
the percutaneous permeation of ammonium glycyrrhizinate. Bola-niosomes 
showed a suitable tolerability both in vitro and in vivo. Ammonium 
glycyrrhizinateloaded Bola-niosomes determined a significant (p <0.001) and 
noticeable improvement of the in vivo anti-inflammatory activity of the drug.  
Ibrahim et al., (2008)(67)
Jim Jiao, (2008)
 formulated and evaluated proniosomal transdermal 
carrier systems for flurbiprofen using span 20 (Sp 20), span 40 (Sp 40), span 
60 (Sp 60) and span 80 (Sp 80) without and with cholesterol at percentages 
ranging from 0% to 50%. The effect of surfactant type and cholesterol content 
on drug release was investigated. Drug release was tested by diffusion 
through cellophane membrane and rabbit skin. Drug release from the 
prepared systems was compared to that from flurbiprofen suspensions in 
distilled water and HPMC (hydroxypropylmethylcellulose) gels. In case of Sp 
20 and Sp 80, the added amount of cholesterol affected the preparation type 
to be either proniosomal alcoholic solutions or liquid crystalline gel systems. 
On the other hand, both Sp 40 and Sp 60 produced gel systems in presence 
or absence of cholesterol. Due to the skin permeation barrier, rabbit skin 
showed lower drug diffusion rates compared to cellophane membrane. 
(68)
Ghada Abdelbary  and Nashwa El-gendy, (2008)
 summarized the surface and thermodynamic properties of 
polyoxyethylated nonionic surfactants (Polysorbates, Tyloxapol, Poloxamers, 
Cremophor EL, Brij, and alpha-Tocopherol TPGS), evaluated the recent 
advancement of these surface active agents in ophthalmic topical drug 
delivery, and analyzed advantages and potential pitfalls of using them as 
ocular formulation ingredients to address solubility, compatibility, and 
bioavailability issues. The effects of these surfactants on biopharmaceutics of 
the ocular drugs are assessed and information on their safety to the eye 
tissues over chronic exposure is provided.  
(69) prepared niosomal 
formulations using various surfactants (Tween 60, Tween 80 or Brij 35), in the 
presence of cholesterol and a negative charge inducer dicetyl phosphate 
(DCP) in different molar ratios and by employing a thin film hydration 
technique. Results showed a substantial change in the release rate and an 
alteration in the %EE of gentamicin sulphate from niosomal formulations upon 
varying type of surfactant, cholesterol content and presence or absence of 
DCP. In-vitro drug release results confirmed that niosomal formulations have 
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exhibited a high retention of gentamicin sulphate inside the vesicles such that 
their in vitro release was slower compared to the drug solution. A preparation 
with 1:1:0.1 molar ratio of Tween 60, cholesterol and DCP gave the most 
advantageous entrapment (92.02%±1.43) and release results 
(Q8h=66.29%±1.33) as compared to other compositions. Ocular irritancy test 
performed on albino rabbits, showed no sign of irritation for all tested 
niosomal formulations. 
Junyaprasert V B et al., (2008)(70)
Adnan Azeem et al., (2009)
 studied an influence of different types of 
membrane additives including negative charge (dicetylphosphate, DCP), 
positive charge (stearylamine, STR) and non-ionic molecule (cholesteryl poly-
24-oxyethylene ether, SC24) on the physicochemical properties of drug-free 
and drug-loaded span 60, unilamellar niosomes. The results show that 
incorporation of salicylic acid to the niosomes did not affect zeta potential 
values; however, addition of the membrane additives changed the zeta 
potential depending on the type of the additives.  The particle sizes of all 
developed niosomes were between 217 to 360 nm. The entrapment efficiency 
(%E.E.) of all salicylic acid niosomes at pH 3 was higher than that of 
niosomes at pH 5, indicating that salicylic acid in unionized form was 
preferably incorporated in niosomes. Furthermore, the positively charged 
niosomes showed the highest %E.E. of salicylic acid owing to electrostatic 
attraction between STR and salicylic acid. In addition, all niosomes showed 
no leakage of the salicylic acid after 3 months of storage indicating the good 
stability. 
(71)
Pratap S. Jadon et al., (2009)
 offered some recent advances on niosomes 
as sustained and targeted drug delivery. The review considers the current 
status and explores the potential of niosomes in drug delivery with special 
attention to their role in drug targeting. Their methods of preparation, 
formulation aspects, advantages, limitations, and applications are also 
discussed.  
(72) studied niosomes to improve poor and 
variable oral bioavailability of griseofulvin using span 20, span 40, and span 
60. The lipid mixture consisted of surfactant, cholesterol, and dicetyl 
phosphate in the molar ratio of 125:25:1.5, 100:50:1.5, and 75:75:1.5, 
respectively. The niosomal formulations were prepared by thin film method 
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and ether injection method. Result indicated that the niosomes prepared by 
thin film method with span 60 provided higher entrapment efficiency. The 
niosomal formulation exhibited significantly retarded in vitro release as 
compared with free drug. The in vivo study revealed that the niosomal 
dispersion significantly improved the oral bioavailability of griseofulvin in 
albino rats after a single oral dose. The maximum concentration (Cmax) 
achieved in case of niosomal formulation was approximately double (2.98 
μg/mL) as compared to free drug (1.54 μg/mL). Plasma drug profile also 
suggested that the developed niosomal system also has the potential of 
maintaining therapeutic level of griseofulvin for a longer period of time as 
compared to free griseofulvin. The niosomal formulation showed significant 
increase in area under the curve0-24 (AUC; 41.56 μg/mL h) as compared to 
free griseofulvin (22.36 μg/mL h) reflecting sustained release characteristics. 
D. Cosco et al., (2009)(73)
Kandasamy Ruckmani and Veintramuthu Sankar, (2010)
 proposed innovative of 5-fluorouracil (5-FU) 
niosomes made up of α,ω-hexadecylbis-(1-aza-18-crown-6) (bola), Span 80® 
and cholesterol (2:5:2 molar ratio) as suitable delivery systems for the 
treatment of breast cancer. The bola-niosomes, after sonication procedure, 
showed mean sizes of ~200 nm and a loading capacity of ~40% with respect 
to the amount of 5-FU added during the preparation. Similar findings were 
achieved with PEG-coated bola-niosomes (bola, Span 80®, cholesterol, 
DSPE-mPEG2000, 2:5:2:0.1 molar ratio respectively). In vivo experiments on 
MCF-7 xenograft tumor SCID mice models showed a more effective 
antitumoral activity of the PEGylated niosomal 5-FU at a concentration ten 
times lower (8 mg/kg) than that of the free solution of the drug (80 mg/kg) 
after a treatment of 30 days. 
(74) studied effects 
of process-related variables like hydration and sonication time, rotation speed 
of evaporation flask, and the effects of charge-inducing agent and 
centrifugation on zidovudine entrapment and release from niosomes. 
Formulation of zidovudine niosomes was optimized by altering the proportions 
of Tween, Span and cholesterol. Non-sonicated niosomes were in the size 
range of 2-3.5 μm and sonicated niosomes formulated with Tween 80 and 
dicetylphosphate (DCP) had a mean diameter of 801 nm. Zidovudine 
niosomes formulated with Tween 80 entrapped high amounts of drug and the 
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addition of DCP enhanced drug release for a longer time (88.72% over 12 h). 
The mechanism of release from Tween 80 formulation was the Fickian type 
and obeyed first-order release kinetics. Niosomes can be formulated by 
proper adjustment of process parameters to enhance zidovudine entrapment 
and sustainability of release.  
Ebtessam A Essa et al., (2010)(75)
Ahmed A. Aboelwafa et al., (2010)
 investigated various formulations and 
processing factors on vesicular Z-average particle size. The selected 
variables were membrane additives, [including cholesterol (CHO), 
dicetylphosphate (DCP) and stearylamine (SA)], sonication time as well as 
drug loading factor (using mannitol and estradiol). Sorbitan monopalmitate 
(span 40) niosomes were prepared by the conventional thin film hydration 
method. The results indicated that CHO increased the vesicular size, with 2:1 
and 1:1 (span 40:CHO) ratios showing the same size. Sonication reduced the 
vesicle size by 23, 35 and 42% after 10, 20 and 30 min, respectively. After 30 
min, the effect of sonication was minor. The addition of charge inducing 
agents changed the zeta potential depending on the type of the additives. 
Surface charge increased the size by 24 and 11% when using DCP and SA, 
respectively. Drug incorporation increased the vesicle size to an extent based 
on its aqueous solubility. There were about 35 and 6.2% increase in vesicular 
size for estradiol and mannitol, respectively, supporting the partitioning of 
lipophilic drug within the fatty acyl side chains of the bilayer membrane. 
(76) investigated the effects of formulation 
variables on development of carvedilol (CAR) proniosomal gel. Different 
nonionic surfactants; polyoxyethylene alkyl ethers, namely Brij 78, Brij 92, and 
Brij 72; and sorbitan fatty acid esters (Span 60) were evaluated for their 
applicability in preparation of CAR proniosomal gels. A 23 full factorial design 
was employed to evaluate individual and combined effects of formulation 
variables, namely cholesterol content, weight of proniosomes, and amount of 
CAR added on performance of proniosomes. Proniosomes prepared with Brij 
72 and Span 60 showed better niosome forming ability and higher EE% than 
those prepared with Brij 78 and Brij 92. Higher EE % was obtained by 
increasing both weight of proniosomes and amount of CAR added, and 
decreasing cholesterol content. Release rate through cellulose membrane 
was inversely affected by weight of proniosomes. In Span 60 proniosomes, on 
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increasing percent of cholesterol, a decrease in release rate was observed. 
While in Brij 72 proniosomes, an enhancement in release rate was observed 
on increasing amount of CAR added. Permeation experiments showed that 
skin permeation was mainly affected by weight of proniosomes and Span 60 
proniosomal gels showed higher permeation enhancing effect than Brij 72.  
Mohamed Nasr, (2010)(77) prepared celecoxib proniosomes and evaluated 
the influence of proniosomal formulation on the oral bioavailability of the drug 
in human volunteers. Proniosomes were prepared by sequential spraying 
method, which consisted of cholesterol, span 60, and dicetyl phosphate in a 
molar ratio of 1:1:0.1, respectively. The average entrapment was about 95%. 
The prepared proniosomes showed marked enhancement in the dissolution of 
celecoxib as compared to pure drug powder. The bioavailability of 200 mg 
single dose of both celecoxib proniosomal formulation and a conventional 
marketed celecoxib capsule was studied in human volunteers. The obtained 
results show that the proniosomal formulation significantly improved the 
extent of celecoxib absorption than conventional capsule. The mean relative 
bioavailability of the proniosomal formulation to the conventional capsule was 
172.06±0.14%. The mean Tmax for celecoxib was prolonged when given as 
proniosomal capsule. There was no significant difference between the values 
of Kel and t1/2 
Indu Pal Kaur et al., (2010)
for both celecoxib preparations.  
(78) established the pharmacokinetic and 
pharmacodynamic superiority of the developed ocular formulation of Timolol 
(TM). Aqueous humor concentration of TM in male albino rabbits, after 
instillation of one drop of TM solution (TMS) or TMREVbio was measured 
using the microdialysis method. Peak concentration of drug in aqueous humor 
from TMREVbio (12.46 μg/mL achieved at 60 min) was almost 1.7 times that 
of the control drug solution (TMS, 0.25%; 7.2 μg/mL). An important 
observation was that the high drug concentrations achieved upon TMREVbio 
administration were maintained for up to 2 hr. AUC for TMREVbio formulation 
was 2.34 times that of the TMS. Results confirm a sustained and controlled 
effect of the developed formulation. 
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3. DRUG AND EXCIPIENTS PROFILE 
3.1 Drug profile  
3.1.1 Betaxolol Hydrochloride(1-6)
3.1.1.1 Chemical name
  
(7)
 
Figure 3.1: Chemical structure of Betaxolol HCl 
3.1.1.5 Properties 
State: Solid white powder 
Melting point: 113-117 
: 2-propanol, 1-4-2-(cyclopropylmethoxy) 
ethylphenoxy-3-(1-methylethyl) amino-, 
hydrochloride 
3.1.1.2 Molecular formula: C18H29NO3. HCl 
3.1.1.3 Molecular weight: 343.9 
3.1.1.4 Chemical structure  
o
Betaxolol is a competitive, β1-selective (cardioselective) adrenergic 
antagonist. Betaxolol is used to treat hypertension, arrhythmias, coronary 
heart disease, glaucoma, and is also used to reduce non-fatal cardiac events 
in patients with heart failure. Activation of β1-receptors (located mainly in the 
heart) by epinephrine increases the heart rate and the blood pressure, and 
the heart consumes more oxygen. Drugs such as betaxolol that block these 
receptors therefore have the reverse effect: they lower the heart rate and 
blood pressure and hence are used in conditions when the heart itself is 
deprived of oxygen. They are routinely prescribed in patients with ischemic 
C  
Solubility: 451 mg/L in water. It is freely soluble in chloroform, methylene 
chloride, ethanol and methanol. 
CaCO2 permeability: 4.81 [ADME Research, USCD] 
pKa: 9.4 
3.1.1.6 Pharmacodynamics  
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heart disease. In addition to its effect on the heart, betaxolol reduces the 
pressure within the eye (intraocular pressure). Betaxolol blocks beta-receptors 
that are found on the ciliary body. This action reduces the amount of aqueous 
humour that is secreted into the eyeball by the ciliary body. Betaxolol also 
blocks beta-receptors found on the blood vessels that supply the ciliary body. 
This causes the blood vessels to constrict, and reduces the amount of watery 
fluid that filters out of the blood vessels to form aqueous humour. The 
reduction in intraocular pressure reduces the risk of damage to the optic nerve 
and loss of vision in patients with elevated intraocular pressure due to 
glaucoma. 
3.1.1.7 Absorption 
Absorption of an oral dose is complete. There is a small and consistent first-
pass effect resulting in an absolute bioavailability of 89% ± 5% that is 
unaffected by the concomitant ingestion of food or alcohol. 
3.1.1.8 Metabolism 
Primarily hepatic. Approximately 15% of the dose administered is excreted as 
unchanged drug, the remainder being metabolites whose contribution to the 
clinical effect is negligible. Half life of drug is 12-14 hr and protein binding is 
50%. 
Dosing: The usual dose is 1 to 2 drops into each affected eye twice daily. 
3.1.1.9 Toxicity 
Oral LD50s are 350 to 400 mg betaxolol/kg in mice and 860 to 980 mg/kg in 
rats. Predicted symptoms of overdose include bradycardia, congestive heart 
failure, hypotension, bronchospasm, and hypoglycemia. 
3.1.1.10 Side effects 
Ophthalmic betaxolol can cause side effects which are usually mild and 
transient. The most common side effect is transient ocular (temporary eye) 
discomfort. Rarely, betaxolol eye drops can result in side effects that are seen 
with oral beta-adrenergic blockers. For example, persons can experience 
fatigue, insomnia, nausea, dizziness, lightheadedness, depression, slow heart 
rate, low blood pressure, cold extremities, and shortness of breath or 
wheezing. 
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3.2 Polymer profile 
3.2.1 Polyethylene oxide(8-10)
3.2.1.1 Nonproprietary names: USPNF - Polyethylene oxide. 
  
3.2.1.2 Synonym: Polyox
3.2.1.3 Chemistry: The USPNF 23 describes Polyethylene oxide as a 
nonionic homopolymer of ethylene oxide, represented by the formula 
(CH2CH2O)n, where n represents the average number of oxyethylene groups. 
It may contain up to 3% of silicon dioxide. 
3.2.4 Category: Mucoadhesive; tablet binder; thickening agent. 
3.2.5 Application in pharmaceutical formulation or technology 
Polyethylene oxide can be used as a tablet binder at concentrations of 5–
85%. The higher molecular weight grades provide delayed drug release via 
the hydrophilic matrix approach. 
The relationship between swelling capacity and molecular weight is a good 
guide when selecting products for use in immediate- or sustained-release 
matrix formulations. 
Polyethylene oxide has been shown to be an excellent mucoadhesive 
polymer. Low levels of Polyethylene oxide are effective thickeners, although 
alcohol is usually added to water-based formulations to provide improved 
viscosity stability. Polyethylene oxide films demonstrate good lubricity when 
wet. This property has been utilized in the development of coatings for 
medical devices. Polyethylene oxide can be radiation crosslinked in solution 
to produce a hydrogel that can be used in wound care applications. 
3.2.1.6 Description: White to off-white, free-flowing powder. Slight 
ammoniacal odor. 
3.2.1.7 Typical properties: 
Angle of repose: 34° 
Density (true):  1.3 g/cm
; polyoxirane;  polyoxyethylene.  
3 
Melting point: 65–70 °C  
Moisture content: <1%   
Solubility:  Polyethylene Oxide is soluble in water and a number of common 
organic solvents such as acetonitrile, chloroform, and methylene chloride. It is 
insoluble in aliphatic hydrocarbons, ethylene glycol, and most alcohols. 
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3.2.1.8 Stability and storage conditions: Store in tightly sealed containers in 
a cool, dry place. Avoid exposure to high temperatures since this can result in 
reduction in viscosity. 
3.2.1.9 Incompatibilities: Polyethylene Oxide is incompatible with strong 
oxidizing agents. 
3.2.1.10 Safety: Animal studies suggest that Polyethylene Oxide has a low 
level of toxicity regardless of the route of administration. It is poorly absorbed 
from the gastrointestinal tract but appears to be completely and rapidly 
eliminated. The resins are neither skin irritants nor sensitizers, and they do 
not cause eye irritation. 
3.2.1.11 Regulatory status: It is included in the FDA Inactive Ingredients 
Guide (sustained-release tablets). It is also included in the Canadian List of 
Acceptable Non-medicinal Ingredients. 
 
3.2.2 Polyvinyl pyrollidone(11)
3.2.2.1 Nonproprietary names 
 
• BP: Povidone 
• JP: Povidone 
• PhEur: Povidonum 
• USP: Povidone 
3.2.2.2 Synonyms 
E1201
3.2.2.3 Chemical name  
; Kollidon; Plasdone; poly[1-(2-oxo-1-pyrrolidinyl)ethylene]; polyvidone; 
polyvinylpyrrolidone; PVP; 1-vinyl-2-pyrrolidinone polymer. 
1-Ethenyl-2-pyrrolidinone homopolymer 
3.2.2.4 Empirical formula and molecular weight 
(C6H9NO) n
The USP 28 describes povidone as a synthetic polymer consisting essentially 
of linear 1-vinyl-2-pyrrolidinone groups, the differing degree of polymerization 
of which results in polymers of various molecular weights. It is characterized 
by its viscosity in aqueous solution, relative to that of water, expressed as a K-
value, in the range 10–120. The K-value is calculated using Fikentscher’s 
equation
 2500–3 000 000 
(12)  
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                                    [3.1] 
where z is the relative viscosity of the solution of concentration c (in % w/v), 
and k is the K-value × 10–3
                       [3.2] 
where z is the relative viscosity of the solution of concentration c (in % w/v). 
. 
Alternatively, the K-value may be determined from the following equation: 
3.2.2.5 Structural formula 
 
Figure 3.2: Structure of PVP 
 
3.2.2.6 Functional category 
Disintegrant; dissolution aid; suspending agent; tablet binder. 
3.2.2.7 Applications in pharmaceutical formulation or technology 
Although povidone is used in a variety of pharmaceutical formulations, it is 
primarily used in solid-dosage forms. In tableting, povidone solutions are used 
as binders in wet-granulation processes(13). Povidone is also added to powder 
blends in the dry form and granulated in situ
14
 by the addition of water, alcohol, 
or hydroalcoholic solutions. Povidone is used as a solubilizer in oral and 
parenteral formulations and has been shown to enhance dissolution of poorly 
soluble drugs from solid-dosage forms( ). Povidone solutions may also be 
used as coating agents. 
Povidone is additionally used as a suspending, stabilizing, or viscosity-
increasing agent in a number of topical and oral suspensions and solutions. 
The solubility of a number of poorly soluble active drugs may be increased by 
mixing with povidone. Special grades of pyrogen-free povidone are available 
and have been used in parenteral formulations. 
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3.2.2.8 Description 
Povidone occurs as a fine, white to creamy-white colored, odorless or almost 
odorless, hygroscopic powder. Povidones with K-values equal to or lower than 
30 are manufactured by spray-drying and occur as spheres. Povidone K-90 
and higher K-value povidones are manufactured by drum drying and occur as 
plates. 
3.2.2.9 Typical Properties 
Acidity/alkalinity: pH = 3.0–7.0 (5% w/v aqueous solution). 
Density (bulk): 0.29–0.39 g/cm3 for Plasdone. 
Density (tapped): 0.39–0.54 g/cm3 for Plasdone. 
Density (true): 1.180 g/cm3 
Flowability:  
• 20 g/s for povidone K-15; 
• 16 g/s for povidone K-29/32. 
Melting point: softens at 150°C. 
Moisture content   
povidone is very hygroscopic, significant amounts of moisture being absorbed 
at low relative humidities. 
Particle size distribution 
• Kollidon 25/30: 90% >50 μm, 50% >100 μm, 5% >200 μm; 
• Kollidon 90: 90% >200 μm, 95% >250 μm. 
Solubility 
Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol, and 
water; practically insoluble in ether, hydrocarbons, and mineral oil. In water, 
the concentration of a solution is limited only by the viscosity of the resulting 
solution, which is a function of the K-value. 
Viscosity (dynamic)   
The viscosity of aqueous povidone solutions depends on both the 
concentration and the molecular weight of the polymer employed. Dynamic 
viscosity of 10% w/v aqueous povidone (Kollidon) solutions at 20°C for K-
28/32 is 5.5-8.5 mPa s. 
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3.2.2.10 Stability and storage conditions 
Povidone darkens to some extent on heating at 150 °C, with a reduction in 
aqueous solubility. It is stable to a short cycle of heat exposure around 110–
130 °C; steam sterilization of an aqueous solution does not alter its properties. 
Aqueous solutions are susceptible to mold growth and consequently require 
the addition of suitable preservatives. 
Povidone may be stored under ordinary conditions without undergoing 
decomposition or degradation. However, since the powder is hygroscopic, it 
should be stored in an airtight container in a cool, dry place. 
3.2.2.11 Incompatibilities 
Povidone is compatible in solution with a wide range of inorganic salts, natural 
and synthetic resins, and other chemicals. It forms molecular adducts in 
solution with sulfathiazole, sodium salicylate, salicylic acid, phenobarbital, 
tannin, and other compounds. The efficacy of some preservatives, e.g. 
thimerosal, may be adversely affected by the formation of complexes with 
povidone. 
3.2.2.12 Safety 
Povidone has been used in pharmaceutical formulations for many years, 
being first used in the 1940s as a plasma expander, although it has now been 
superseded for this purpose by dextran(15). 
Povidone is widely used as an excipient, particularly in oral tablets and 
solutions. When consumed orally, povidone may be regarded as essentially 
nontoxic since it is not absorbed from the gastrointestinal tract or mucous 
membranes(15). Povidone additionally has no irritant effect on the skin and 
causes no sensitization. 
Evidence also exists that povidone may accumulate in the organs of the body 
following intramuscular injection(16).  
A temporary acceptable daily intake for povidone has been set by the WHO at 
up to 25 mg/kg body-weight. LD50 (mouse, IP): 12 g/kg 
3.2.2.13 Regulatory status 
Accepted for use in Europe as a food additive. Included in the FDA Inactive 
Ingredients Guide (IM and IV injections; ophthalmic preparations; oral 
capsules, drops, granules, suspensions, and tablets; sublingual tablets; 
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topical and vaginal preparations). Included in nonparenteral medicines 
licensed in the UK. Included in the Canadian List of Acceptable Non-medicinal 
Ingredients. 
 
3.2.4 Poly(methyl methacrylate)(8) 
3.2.4.1 Empirical formula :
3.2.4.2 Synonyms: methyl methacrylate polymer; PMMA. ( C5H8O2) n 
3.2.4.3 Properties   
• Hard, rigid, transparent (very clear to see through)  
• softening point is 125 o C  
• Absorbs very little visible light but there is a 4% reflection at each polymer-
air interface for normal incident light.  
• PMMA is a polar material and has a rather high dielectric constant 
• Solubility 
    PMMA prepared by free radical polymerization is amorphous and is 
therefore soluble in solvents with similar solubility parameters such as 
benzene, toluene, chloroform, methylene chloride, esters, ethyl acetate, 
and amyl acetate. 
3.2.4.4 Stability 
PMMA has good resistance to alkalis (sodium hydroxide, etc.), aqueous 
inorganic salts (the Pacific Ocean) and dilute acids. PMMA has a better 
resistance to hydrolysis than PMA probably by virtue of the shielding of the 
methyl group.  
3.2.4.5 Use 
 Poly(methyl methacrylate) has been used as a material for intraocular lenses, 
for denture bases, and as a cement for dental prostheses. 
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3.3 Other excipients and materials  
3.3.1 Cholesterol(8) 
3.3.1.1 Synonyms - Cholesterin; cholesterolum. 
3.3.1.2 Chemical name - Cholest-5-en-3β-ol  
3.3.1.3 Empirical formula - 
3.3.1.5 Structural formula 
C27H46O 
3.3.1.4 Molecular weight- 386.67 
 
Figure 3.3: Structure of cholesterol 
 
3.3.1.6 Functional category - Emollient; emulsifying agent. 
3.3.1.7 Applications in pharmaceutical formulation or technology 
Cholesterol is used in cosmetics and topical pharmaceutical formulations at 
concentrations of 0.3–5.0% w/w as an emulsifying agent. It imparts water-
absorbing power to an ointment and has emollient activity. 
Cholesterol also has a physiological role. It is the major sterol of the higher 
animals, and it is found in all body tissues, especially in the brain and spinal 
cord. It is also the main constituent of gallstones. 
3.3.1.8 Description 
Cholesterol occurs as white or faintly yellow, almost odorless, pearly leaflets, 
needles, powder, or granules. On prolonged exposure to light and air, 
cholesterol acquires a yellow to tan color. 
3.3.1.9 Typical Properties 
Boiling point: 360 °C 
Density: 1.052 g/cm3 for anhydrous form. 
Dielectric constant D20: 5.41 
Melting point: 147–150 °C 
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Solubility(17): Freely soluble in acetone, benzene, chloroform, ether and 
vegetable oils. It is practically insoluble in water. 
Specific rotation [α]20D: −39.5° (2% w/v solution in chloroform); −31.5° (2% w/v 
solution in ether). 
3.3.1.10 Stability and storage conditions 
Cholesterol is stable and should be stored in a well-closed container, 
protected from light. 
3.3.1.11 Incompatibilities 
Cholesterol is precipitated by digitonin. 
3.3.1.12 Method of manufacture 
The commercial material is normally obtained from the spinal cord of cattle by 
extraction with petroleum ethers, but it may also be obtained from wool fat. 
Purification is normally accomplished by repeated bromination. Cholesterol 
may also be produced by entirely synthetic means. 
Cholesterol produced from animal organs will always contain cholestanol and 
other saturated sterols. 
3.3.1.13 Safety 
Cholesterol is generally regarded as an essentially nontoxic and nonirritant 
material at the levels employed as an excipient(18). It has, however, exhibited 
experimental teratogenic and reproductive effects, and mutation data have 
been reported(19). 
Cholesterol is often derived from animal sources and this must be done in 
accordance with the regulations for human consumption. The risk of bovine 
spongiform encephalopathy (BSE) contamination has caused some concern 
over the use of animal-derived cholesterol in pharmaceutical products. 
However, synthetic methods of cholesterol manufacture have been 
developed. 
3.3.1.14 Regulatory status 
It is included in the FDA Inactive Ingredients Guide (injections, ophthalmic, 
topical, and vaginal preparations). 
It is included in nonparenteral medicines licensed in the UK and in the 
Canadian List of Acceptable Non-medicinal Ingredients. 
 
Chapter 3 Drug and excipients profile 
 
 Hitesh B. Gevariya 90                                                    Ph. D. Thesis 
 
 
3.3.2 Span 60(8) 
3.3.2.1 Synonym: Sorbitan monostearate 
3.3.2.2 Chemical Name: Sorbitan mono-octadecanoate 
3.3.2.3 Chemical Formula: C24H46O6 
3.3.2.4 Molecular Weight: 431 
3.3.2.5 Structural formula 
 
R1 = R2 = OH, R3 = R (see below) for sorbitan monoesters 
R1 = OH, R2 = R3 = R for sorbitan diesters 
R1 = R2 = R3 = R for sorbitan triesters 
where R = (C17H35)COO for isostearate 
                 (C11H23)COO for laurate 
(C17H33)COO for oleate 
(C15H31)COO for palmitate 
(C17H35)COO for stearate 
The sesquiesters are equimolar mixtures of monoesters and diesters. 
Figure 3.4: Structure of span 
 
3.3.2.6 Functional category 
Emulsifying agent; nonionic surfactant; solubilizing agent; wetting and 
dispersing/suspending agent. 
3.3.2.7 Applications in pharmaceutical formulation or technology 
Sorbitan monoesters are a series of mixtures of partial esters of sorbitol and 
its mono- and dianhydrides with fatty acids. Sorbitan diesters are a series of 
mixtures of partial esters of sorbitol and its monoanhydride with fatty acids. 
Sorbitan esters are widely used in cosmetics, food products, and 
pharmaceutical formulations as lipophilic nonionic surfactants. They are 
mainly used in pharmaceutical formulations as emulsifying agents in the 
preparation of creams, emulsions, and ointments for topical application. When 
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used alone, sorbitan esters produce stable water-in-oil emulsions and 
microemulsions but are frequently used in combination with varying 
proportions of a polysorbate to produce water-in-oil or oil-in-water emulsions 
or creams of varying consistencies. 
Sorbitan monolaurate, sorbitan monopalmitate and sorbitan trioleate have 
also been used at concentrations of 0.01–0.05% w/v in the preparation of an 
emulsion for intramuscular administration.  
3.3.2.8 Description: Cream Solid 
3.3.2.9 Typical properties 
Acid value: 5-10 
Flash point:>149 °C 
HLB value: 4.7 
Hydroxyl value: 235-260 
Iodine number: ≤1 
Melting point: 53-57 
Moisture content: ≤1 
Saponification value: 147-157 
Solubility: sorbitan esters are generally soluble or dispersible in oils; they are 
also soluble in most organic solvents. In water, although insoluble, they are 
generally dispersible. 
Surface tension of 1% aqueous solution: 46 mN/m 
3.3.2.10 Stability and storage conditions 
Gradual soap formation occurs with strong acids or bases; sorbitan esters are 
stable in weak acids or bases. Sorbitan esters should be stored in a well-
closed container in a cool, dry place. 
3.3.2.11 Safety 
Sorbitan esters are widely used in cosmetics, food products, and oral and 
topical pharmaceutical formulations and are generally regarded as nontoxic 
and nonirritant materials. However, there have been occasional reports of 
hypersensitive skin reactions following the topical application of products 
containing sorbitan esters(20). When heated to decomposition, the sorbitan 
esters emit acrid smoke and irritating fumes. 
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The WHO(21) has set an estimated acceptable daily intake of sorbitan 
monopalmitate, monostearate, and tristearate, and of sorbitan monolaurate 
and monooleate at up to 25 mg/kg body-weight calculated as total sorbitan 
esters. 
LD50 (rat, oral )(19): 31 g/kg. Very mildly toxic by ingestion.  
3.3.2.12 Handling precautions 
Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Eye protection and gloves are recommended. 
3.3.2.13 Regulatory status 
Certain sorbitan esters are accepted as food additives in the UK. Sorbitan 
esters are included in the FDA Inactive Ingredients Guide (inhalations; IM 
injections; ophthalmic, oral, topical, and vaginal preparations). Sorbitan esters 
are used in nonparenteral medicines licensed in the UK. Sorbitan esters are 
included in the Canadian List of Acceptable Non-medicinal Ingredients. 
 
3.3.3 Tween 60(8) 
3.3.3.1 Synonym: Polysorbate 60 
3.3.3.2 Chemical name : Polyoxyethylene 20 sorbitan monostearate 
3.3.3.3 Empirical formula: C64H126O26 
3.3.3.4 Molecular weight.: 1312 
3.3.3.5 Structural formula 
 
Figure 3.5: Structure of polysorbates 
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w + x + y + z = 20 (Polysorbates 20, 40, 60, 65, 80, and 85) 
w + x + y + z = 5 (Polysorbates 81) 
w + x + y + z = 4 (Polysorbates 21 and 61) 
R = fatty acid 
 
3.3.3.6 Functional category 
Emulsifying agent; nonionic surfactant; solubilizing agent; wetting, 
dispersing/suspending agent. 
3.3.3.7 Applications in pharmaceutical formulation or technology 
Polyoxyethylene sorbitan fatty acid esters (polysorbates) are a series of 
partial fatty acid esters of sorbitol and its anhydrides copolymerized with 
approximately 20, 5, or 4 moles of ethylene oxide for each mole of sorbitol 
and its anhydrides. The resulting product is therefore a mixture of molecules 
of varying sizes rather than a single uniform compound. 
Polysorbates containing 20 units of oxyethylene are hydrophilic nonionic 
surfactants that are used widely as emulsifying agents in the preparation of 
stable oil-in-water pharmaceutical emulsions. They may also be used as 
solubilizing agents for a variety of substances including essential oils and oil-
soluble vitamins, and as wetting agents in the formulation of oral and 
parenteral suspensions. They have been found to be useful in improving the 
oral bioavailability of drug molecules that are substrates for p-glycoprotein.(22) 
Polysorbates are also widely used in cosmetics and food products. 
3.3.3.8 Description 
Cream Solid. Polysorbates have a characteristic odor and a warm, somewhat 
bitter taste. Their colors and physical forms at 25°C is yellow oily liquid, 
although it should be noted that the absolute color intensity of the products 
may vary from batch to batch and from manufacturer to manufacturer. 
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3.3.3.9 Typical properties 
Acid value: 2% 
Acidity/alkalinity: pH = 6.0–8.0 for a 5% w/v aqueous solution. 
Flash point: 149 °C 
HLB value: 14.9 
Hydroxyl value: 81-96 
Specific gravity at 25 oC : 1.1 
Viscosity (dynamic) : 600 mPa s 
Iodine number: ≤1 
Melting point: 53-57 oC 
Moisture content: 3 
Saponification value: 45-55 
Solubility: Tween is generally insoluble in oils; they are also soluble in 
methanol and water.  
Surface tension of 0.1% w/v aqueous solution: 42.5 mN/m 
3.3.3.10 Stability and storage conditions 
Polysorbates are stable to electrolytes and weak acids and bases; gradual 
saponification occurs with strong acids and bases. The oleic acid esters are 
sensitive to oxidation. Polysorbates are hygroscopic and should be examined 
for water content prior to use and dried if necessary. Also, in common with 
other polyoxyethylene surfactants, prolonged storage can lead to the 
formation of peroxides. 
Polysorbates should be stored in a well-closed container, protected from light, 
in a cool, dry place. 
3.3.3.11 Incompatibilities 
Discoloration and/or precipitation occur with various substances, especially 
phenols, tannins, tars, and tarlike materials. The antimicrobial activity of 
paraben preservatives is reduced in the presence of polysorbates(23). 
3.3.3.12 Safety 
Polysorbates are widely used in cosmetics, food products, and oral, 
parenteral, and topical pharmaceutical formulations and are generally 
regarded as nontoxic and nonirritant materials. There have, however, been 
occasional reports of hypersensitivity to polysorbates following their topical 
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and intramuscular use(24). The WHO has set an estimated acceptable daily 
intake for polysorbates 20, 40, 60, 65, and 80, calculated as total polysorbate 
esters, at up to 25 mg/kg body-weight(21). 
Polysorbate 60: LD50 (rat, IV): 1.22 g/kg(19). Moderately toxic by IV route. 
3.3.3.13 Regulatory status 
Polysorbates 60, 65, and 80 are GRAS listed. Polysorbates 20, 40, 60, 65, 
and 80 are accepted as food additives in Europe. Polysorbates 20, 40, 60, 
and 80 are included in the FDA Inactive Ingredients Guide (IM, IV, oral, rectal, 
topical, and vaginal preparations). Polysorbates are included in parenteral and 
nonparenteral medicines licensed in the UK. Polysorbates 20, 21, 40, 60, 61, 
65, 80, 81, 85, and 120 are included in the Canadian List of Acceptable Non-
medicinal Ingredients. 
 
3.3.4  Polyethylene Glycol 400(8, 25)  
3.3.4.1 Synonym: Polyoxyethylene glycol, Lutrol E, Macrogol 400, Carbowax 
3.3.4.2 Description: Polyethylene glycol is an addition polymer of ethylene 
oxide and water. Liquid grades occur as a clear, colorless as slightly yellow-
colored viscous liquids. 
3.3.4.3 Molecular weight: 380-420 
3.3.4.4 Typical properties 
Flash point               : 238 oC 
Density    : 1.11-1.14 g/cm3 at 25 °C 
Glass Transition Temperature : 120 °C 
Refractive index    : 1.467 
Viscosity    : 131 at 25 oC 
3.3.4.5 Incompatibilities: Polyethylene glycol due to the two terminal 
hydroxyl groups can exhibit some oxidizing activity.  
3.3.4.6 Health and safety: Polyethylene glycols are widely used in a variety 
of pharmaceutical formulations. Generally, they are regarded as nontoxic and 
nonirritant materials(26). 
However the most serious effects associated with polyethylene glycols are 
hyperosmolarity metabolic acidosis following the topical use of polyethylene 
glycols in burn patients. 
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3.3.4.7 Stability and storage conditions: Polyethylene glycols are 
chemically stable in air and in solution. Polyethylene glycols should be stored 
in well closed container in a cool, dry place. 
3.3.4.8 Applications in pharmaceutical formulation or technology 
Polyethylene glycols (PEGs) are widely used in a variety of pharmaceutical 
formulations including parenteral, topical, ophthalmic, oral, and rectal 
preparations. It has been used experimentally in biodegradable polymeric 
matrices used in controlled-release systems(27). 
Polyethylene glycols liquids are useful as plasticizer in transdermal films to 
avoid ruptures to provide strength to the formulation. 
 
3.3.5  Dibutyl Phthalate(8)  
3.3.5.1 Synonyms: benzenedicarboxylic acid; butyl phthalate; Celluflex DBP; 
DBP; dibutyl-o-phthalate; di-n-butyl phthalate; Elaol; Ergoplast FDB; 
Genoplast B; Hatcol DBP; Hexaplast M/B; Kodaflex DBP; Monocizer DBP; 
Palatinol C; phthalic acid dibutyl ester; Polycizer DBP; PX 104; RC Plasticizer 
DBP; Staflex DBP; Unimoll DB; Vestimol C; Witcizer 300. 
3.3.5.2 Description: Dibutyl phthalate occurs as an odorless, oily, colorless, 
or very slightly yellow-colored, viscous liquid.  
3.3.5.3 Molecular weight: 278.34 
3.3.5.4 Typical properties: 
Boiling point : 340 °C 
Density : 1.0465 g/cm3 at 20 °C 
Flash point : 171 °C  
Melting point : -35 °C 
Partition coefficient: Octanol : water log kow = 4.50 
Refractive index: nD20 = 1.491–1.495 
Solubility: very soluble in acetone, benzene, ethanol (95%), and ether; soluble 
1 in 2500 of water at 20 °C. 
Viscosity (dynamic): 20 mPa s at 20 °C. 
3.3.5.5 Incompatibilities 
Dibutyl phthalate reacts violently with chlorine. It also reacts with oxidizing 
agents, acids, bases, and nitrates. 
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3.3.5.6 Health and safety 
Dibutyl phthalate is generally regarded as a relatively nontoxic material, 
although it has occasionally been reported to cause hypersensitivity reactions. 
It is widely used in topical cosmetic and some oral pharmaceutical 
formulations(19). 
3.3.5.7 Stability and storage conditions 
Dibutyl phthalate should be stored in a well-closed container in a cool, dry, 
location. Containers may be hazardous when empty since they can contain 
product residues such as vapors and liquids. 
3.3.5.8 Applications in pharmaceutical formulation or technology 
Dibutyl phthalate is used in pharmaceutical formulations as a plasticizer in 
film-coatings. It is also used extensively as a solvent particularly in cosmetic 
formulations such as antiperspirants, hair shampoos and hair sprays.  
 
3.4 Preparation of Buffer Solutions 
3.4.1 Saline pH 7.4, Phosphate-buffered(7) 
Dissolve 2.38 g of disodiumhydrogen phosphate, 0.19 g of potassium 
dihydrogen phosphate and 8.0 g of sodium chloride in sufficient water to 
produce 1000 mL. Adjust the pH if necessary. 
3.4.2 Simulated Tear Fluid (pH 7.4)(28) 
Dissolve KCL (1.7893 gm), NaCl (6.3118 gm), NaHCO3 (2.1842 gm), CaCl2 
(44.4 mg) and MgCl2 (47.6 mg) in 1 liter of distilled water and adjust the pH 
7.4 by adding required amount of 0.1 N HCl. 
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4. EXPERIMENTAL SETUP 
Table 4.1: Materials used in present investigation 
Sr. No. Material Sources 
1 
2 
3 
4 
5 
7 
8 
 
9 
10 
11 
12 
13 
14 
15 
16 
17 
19 
Betaxolol HCl 
PVP 
Sodium alginate 
Poly ethylene oxide 
EC 
PMMA 
Potassium dihydrogen 
orthophosphate 
Sodium hydroxide 
PEG 400 
Dibutyl phthalate 
Chloroform 
Dichloromethane 
Acetone 
Span 20,40,60,80 
Tween 20,60,80 
Cholesterol 
ATGM, SBCDM 
Ciron Drugs Ltd., Mumbai 
Loba Chemie, Mumbai 
Loba Chemie, Mumbai 
Alfa Aesar, USA 
SD Fine Chemicals, Mumbai 
Himedia , Mumbai 
Qualigens Fine Chemical, Mumbai 
 
SD Fine Chemicals, Mumbai 
Qualigens Fine Chemical, Mumbai 
Qualigens Fine Chemical, Mumbai 
SD Fine Chemicals, Mumbai 
SD Fine Chemicals, Mumbai 
SD Fine Chemicals, Mumbai 
SD Fine Chemicals, Mumbai 
SD Fine Chemicals, Mumbai 
Loba Chemie, Mumbai 
Himedia, Mumbai 
 
Table 4.2: Softwares used in present investigation 
Software Make/Developer 
Design-Expert® Stat-Ease, Inc., Minneapolis MN, 
USA. 
 version 8.0.7 trial 
SpectraTreats 3.11.01Rel1 Elico Limited, India. 
Microsoft Office 2007 
EndNote X5 
Microsoft Corporation, USA. 
Thomson Reuters, USA 
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Table 4.3: Instruments used in present investigation 
Sr. No. Material Sources 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
 
13 
14 
15 
16 
17 
18 
 
19 
20 
 
21 
22 
 
23 
Electronic balance 
Digital pH meter  
USP XXIII dissolution apparatus  
Hot air oven  
UV-Visible spectrophotometer 1700 
FT/IR-4100 type A  
Orbital shaking incubator  
Sonica ultrasonic cleaner 
HPLC (Model- LC 20 AT) 
BOD incubator 
Magnatic stirrer – KMS 400 
Rotary flash evaporator 
 
Freeze dryer-Alpha 1-4 LD plus 
DSC 1/700 
XRD – D8 Advance 
TEM (H 7500) 
SEM 
Zetasizer 
 
Laminar flow hood  
Filter paper 
 
Tonometer 
Viscometer (DV-II+Pro) 
 
Theta optical tensiometer 
Shimadzu, Japan. 
Elico, India. 
Campbell, Mumbai. 
Technico, Chennai. 
Shimadzu, Japan. 
Jasco, Japan. 
Remi, Mumbai 
Spincotech , India 
Shimadzu, Japan. 
Technico, Chennai. 
Jasco, Japan. 
EIE instruments Pvt. Ltd, 
Ahmedabad, India 
Martin Christ, Germany 
Mettler Toledo, Germany 
Bruker, Germany 
Hitachi Ltd., Japan 
Jeol Ltd., Japan 
Malvern Instruments Ltd., 
UK 
Esco, Singapore 
Whatman Inc., Clifton, 
NJ, USA 
Schiotz, Germany 
Brookfield, Middleboro, 
USA 
Biolin scientific, Sweden 
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5. LONG ACTING BETAXOLOL OCULAR INSERTS BASED ON 
POLYMER COMPOSITE 
5.1 Aim of present investigation 
Ocular drug delivery is a challenge for the formulator. A drop of an aqueous 
solution, irrespective of instilled volume is eliminated completely from the eye 
within 5 to 6 min of its application and only a small amount (1-3%) actually 
penetrates the cornea and reaches the intraocular tissue(1)
Recent trend in ocular research is to formulate a dosage form which not only 
prolongs the residence of system in eye but also helps to reduce the 
elimination of the drug. In the same area many drug delivery systems 
including insitu gel
. 
(2), microemulsions(3), nanoparticles(4), liposome(5), 
niosomes(6), ocular inserts(7)
Ophthalmic inserts offer many advantages over conventional dosages forms, 
like increased ocular residence, possibility of releasing drug at a slow and 
constant rate, accurate dosing, exclusion of preservatives and increased shelf 
life. Design, construction and technology of ocular insert in a controlled and 
sustained ocular delivery device are gaining rapid improvement to overcome 
these constraints
 etc. are being investigated worldwide by many 
researchers. The developmental technology of new ocular dosage forms has 
witnessed tremendous improvement during last few decades and its use is 
expected to increase in near future. 
(7, 8)
Betaxolol is selective beta-1-adrenegic receptor blocker and used in the 
treatment of ocular hypertension and chronic open angle glaucoma
.  
(9). There 
are only a few ocular inserts available on the market, made of EVA as a rate 
controlling membrane(10, 11). Likewise, poly (methylmethacrylate) (PMMA) is 
also an excellent film-forming polymer but the films of PMMA alone are 
brittle(12)
Release of drug through polymer films is dependent on properties of polymers 
and plasticizers. In the present investigation polymers have been blended on 
varying ratios to combine the advantages of the individual polymers. 
. It offers more resistance to the diffusion of drug molecules, and is 
less explored as a polymer for ocular delivery of drugs. The current literatures 
indicate that no inserts are made of hydrophobic monolithic systems using 
betaxolol.  
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Advantages of polymer blends include easy fabrication of devices, controlling 
drug release, manipulation of drug loading and other devices properties such 
as hydration, degradation rate and mechanical strength. 
There are two major ocular therapeutic systems existing. Those are matrix 
and reservoir type ocular therapeutic systems. The present work aimed to 
develop a matrix-dispersion-type ocular drug delivery system of Betaxolol HCl 
using blend of polymers. Matrix type of ocular systems have been 
investigated and found to be effective in drug delivery. There are reports 
describing the use of polymers like HPMC(13), HPC, EC and Carbopol(14), 
PVP(15), Eudragit and PVA(16)
Hence this investigation has been designed to study the drug release kinetics 
of betaxolol from a hydrophobic matrix system of PMMA cast with 
incorporating different proportions of PEO. With the addition of hydrophilic 
polymer to PMMA, the films become resilient and do not break easily and it 
was ascertained that the diffusion might improve. Matrix type Inserts of 
betaxolol HCl was formulated using polymer blend of Polyethylene oxide and 
PMMA with a plasticizer, dibutyl phthalate. Formulation was designed for 24 
hr therapy.  
 for ocular delivery systems. These ocular 
delivery systems are neither extremely hydrophobic nor extremely hydrophilic. 
Therefore, varying the ratio of these polymers in the composition of the films 
provides better control of drug release characteristics. Ocular administration 
of Betaxolol has the disadvantage of low bioavailability due to extensive and 
highly variable defense mechanisms of the eye. In addition, Betaxolol has a 
half-life of 12 to 14 hr and requires bid dosing. Owing to these disadvantages, 
an ocular insert of Betaxolol was designed and developed.  
It was our prime objective to develop ocular inserts that 
1. Release the drug for prolonged period of time preferably 24 hr. 
2. Provide an increased ocular residence time resulting in prolonged drug         
    delivery in eye. 
3. Deliver a drug at a controlled rate over a period of time.   
4. Show better in-vivo performance than conventional dosage forms. 
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5.2 Estimation of betaxolol hydrochloride 
5.2.1 Method of estimation 
UV visible spectroscopic method for analysis of Betaxolol HCl was adopted in 
present work. An accurately weighed quantity of Betaxolol HCl (100mg) was 
dissolved in 100 mL of simulated tear fluid (STF, pH 7.4) to generate a stock 
solution having concentration of 1mg/mL. Stock solution (10 mL) was further 
diluted to 100 mL to produce standard solution having concentration of 
100µg/mL. The standard solution was serially diluted with STF pH 7.4 to get 
working standard solutions having concentration of 2, 4, 6, 8, 10, 12, 14, 16, 
18 and 20 µg/mL. The absorbance of the solutions was measured at 274.0 
nm using double beam UV visible spectrophotometer against STF pH 7.4 as a 
blank. The plot of absorbance v/s concentration (µg/mL) was plotted (Figure 
5.1) and data was subjected to linear regression analysis in Microsoft 
Excel®(17)
 
. 
 
Figure 5.1: Standard curve of betaxolol HCl in STF pH 7.4 
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5.2.2 Validation of method of estimation(17)
5.2.2.1 Linearity and range 
 
The prepared aliquots (2-20 μg/mL) were scanned for absorbance at λmax 
5.2.2.2 Accuracy and precision 
value 274 nm. The absorbance range was found to be 0.105-1.024. These 
solutions obeyed Beer-Lambert’s law in above concentration range with 
correlation coefficient value 0.999. 
Accuracy and precision were investigated by analyzing three concentrations 
of Betaxolol HCl (i.e. 3, 6 and 9 mg) in three independent replicates on the 
same day (Intra-day accuracy and precision) and on three consecutive days 
(Inter-day accuracy and precision). The data evaluated was summarized in 
Table 5.1. 
 
Table 5.1: Results of recovery and precision of betaxolol HCl 
Sr. 
No. 
Amount of 
drug 
(mg) 
Amount found 
(mg) 
% Recovery 
%RSD 
(n=3)  
intra-day 
%RSD 
(n=3) 
inter-day 
1 3 2.99 99.83 0.144 0.138 
2 6 5.98 99.72 0.096 0.166 
3 9 9.03 100.42 0.190 0.071 
 
Intra-day and Inter-day relative standard deviation (%RSD) values and also 
the low RSD values obtained indicated good intermediate precision of 
method.  
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5.3 Experimental 
5.3.1 Determination of solubility and partition coefficient of betaxolol 
5.3.1.1 Solubility  
The solubility of Betaxolol was determined in different solvents. An excess 
quantity of the drug was added in 5 mL of each solvent in screw capped glass 
test tubes and shaken for 12 hr at room temperature. The solution was 
filtered, diluted and the solubility was determined by UV visible 
spectrophotometer(18, 19)
5.3.1.2 Partition coefficient
. 
(19) 
The partition coefficient of Betaxolol HCl was determined in n-octanol: 
phosphate buffer pH 7.4 system. An accurately weighed (500 mg) amount of 
Betaxolol HCl was added into 10 mL each of n-octanol and aqueous phase in 
a screw capped tube. The mixture was shaken for 24 hr until equilibrium was 
reached. Phases were separated; the aqueous phase was filtered, diluted and 
the amount of Betaxolol HCl solubilised in aqueous phase was determined by 
measuring the absorbance at 274 nm spectrophotometrically. 
  
The partition coefficient of Betaxolol HCl was calculated from the ratio 
between the concentration of Betaxolol HCl in organic and aqueous phase 
using following equation: 
                    𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝐶𝐶𝑃𝑃𝐶𝐶𝐶𝐶𝐶𝐶𝑃𝑃𝐶𝐶𝑃𝑃𝐶𝐶𝑃𝑃𝑃𝑃 = Concentration   in  Organic  PhaseConcentration  in  Aquous  Phase                   [5.1] 
5.3.2 Preliminary screening  
Preliminary study was carried out for screening of various polymers and their 
concentrations. 
5.3.2.1 Selection of polymers 
Polymers were selected from among PVP, PEO, HPMC, EC and PMMA 
based on the type of films formed at different concentrations, the strength of 
the films formed and appearance of the films. Bearing in mind all these 
factors, it was concluded that PVP and PEO with PMMA form very good films 
(Table 5.2). In order to idealize a film for ocular inserts, even combinations of 
hydrophilic-hydrophobic polymers at different concentrations were tried. 
Finally, it was deduced that PMMA and PEO can be a better combination to 
give a sustained release for a prolonged period and also fulfill the other 
requirements at various concentration. 
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Table 5.2: Formulation compositions for preliminary screening of 
polymers for films of Betaxolol 
Ingredients A1 A2 A3 A4 A5 A6 A7 
Betaxolol HCl 10 10 10 10 10 10 10 
PEO 167 --- --- 167 --- --- 150 
PVP --- 240 --- --- 240 --- 150 
HPMC --- --- 167 --- --- 167 --- 
Ethyl Cellulose 333 360 333 --- --- --- --- 
PMMA --- --- --- 333 360 333 --- 
PEG 400 --- --- --- --- --- --- 100 
Dibutyl Phthalate 150 180 150 150 180 150 --- 
Solvent  S1 S1 S2 S2 S1 S2 Water 
Note:  All values are in mg. 
Solvent: S1: Dichloromethane: Acetone (1:1) and S2: Chloroform: DCM (6:4) 
 
This investigation was aimed to use composite polymer in matrix type ocular 
formulation. For screening the polymers and polymer blend a formulation 
study was carried out. Above Table 5.2 shows some of the important 
formulations screened for actual study. Formulation A1, A2 and A3 were 
prepared using EC and hydrophilic polymers combination. It was found that 
good film was not obtained in case of A3 whereas A1 and A2 gave the film but 
film obtained was not good in appearance and contents were not distributed 
uniformly. Formulation A4 to A6 were prepared using PMMA and hydrophilic 
polymers combination. All the films were good in appearance and uniformity. 
Considering above result it was decided to prepare the ocular films by using 
the PEO in combination with PMMA. Formulation A7 prepared with PEO and 
PVP was better as compared to films of HPMC with PEO and PVP. It was 
found that alone PMMA was not able to form good film whereas EC alone was 
able to form good uniform film but it was brittle.  
5.3.2.2 Water absorption test for polymers(20)
Water uptake measurement was performed by using an apparatus consisting 
of G15 Buchner sintered glass filter of 3.8 cm diameter with one end 
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connected to a graduated 1 mL pipette via silicone rubber tube. The lower 
part of the filter and pipette were filled with distilled water at room temperature 
just before the experiment. The evaporation of water was minimized with 
aluminum foil wrapped around the filter. 
Polymer discs of PEO were prepared by directly compressing 200 mg of the 
dried polymer in a hydraulic press. The prepared discs were placed at the 
center of the filter and the uptake of water for 24 hr was determined by 
obtaining the change in volume of water in the graduated pipette. The mean 
of 5 determinations were taken to represent the water uptake for the polymer. 
5.3.3 Design of experiment 
A 2-factor 3-level full factorial design was used for the formulation and 
optimization of inserts. This design is suitable for exploring quadratic 
response surface and constructing second order polynomial models. The non 
linear quadratic model generated by the design in the form:(21)
           Y = X
 
0 + X1A + X2B + X3A2 + X4B2 + X5
Where, Y is the measured response associated with each factor level 
combination: X
AB + E                         [5.2] 
0 is an intercept: X1 - X5 are the regression coefficients: A and 
B are the factors studied and E is the associated error term. Independent 
factors used in the design are listed in Tables 5.3 and 5.4 show applied 32
 
 full 
factorial design. 
Table 5.3: Independent factors for formulations of betaxolol ocular 
inserts 
Independent 
variable 
Factor A 
Drug to polymer ratio 
(Drug : Total polymer) 
Factor B 
Polymer to polymer ratio 
(PMMA : PEO) 
Low Medium   High Low Medium High 
Coded levels -1 0 1 -1 0 1 
Actual levels 1:2 1:4 1:6 9:1 8:2 7:3 
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Table 5.4: A 32 Full factorial design layout of betaxolol ocular inserts 
Run 
Factor A 
Drug to polymer ratio 
Factor B 
Polymer to polymer ratio 
(PMMA:PEO) 
Coded Actual Coded Actual 
1 -1 1:2 -1 9:1 
2 -1 1:2 0 8:2 
3 -1 1:2 1 7:3 
4 0 1:4 -1 9:1 
5 0 1:4 0 8:2 
6 0 1:4 1 7:3 
7 1 1:6 -1 9:1 
8 1 1:6 0 8:2 
9 1 1:6 1 7:3 
 
5.3.4 Formulation of ocular inserts 
The monolithic films of Betaxolol HCl with PMMA and PEO were prepared by 
solvent evaporation technique(22)
 
. Chloroform was used as solvent. The 
composition of ocular films of Betaxolol HCl is shown in Table 5.5. 
Table 5.5: Formulation compositions for ocular inserts of betaxolol 
Inserts Drug (mg) Total polymer (% w/v) 
PMMA:PEO 
(Ratio) 
F1 0.5 1 9:1 
F2 0.5 1 8:2 
F3 0.5 1 7:3 
F4 0.5 2 9:1 
F5 0.5 2 8:2 
F6 0.5 2 7:3 
F7 0.5 3 9:1 
F8 0.5 3 8:2 
F9 0.5 3 7:3 
 All formulations contain dibutyl phthalate as plasticizer 30 % 
w/w of polymer weight 
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The weighed quantities of polymers were dissolved in 13 mL solvent and 
plasticizers (30% w/w of polymers) were incorporated. To this solution 
Betaxolol HCl (65 mg) was added and mixed thoroughly with the help of 
magnetic stirrer for 10 min at 25 rpm. Polymeric solution was sonicated for 30 
sec to remove the air. Polymeric solution was then poured into a petridish (6.8 
cm diameter) placed on a flat even surface. The rate of evaporation was 
controlled by inverting the funnel over the petridish. After drying at room 
temperature for 24 hr, circular ocular inserts of diameter 6 mm were cut using 
fabricated mould, sterilized under UV for 10 min and 60 min and packed in 
aluminum foil and stored in desiccators until further use. 
  
5.4 Evaluation and statistical optimization 
5.4.1 Physicochemical evaluation/characterization of ocular inserts 
5.4.1.1 Physical appearance  
All the ocular films were visually inspected for color, clarity and smoothness. 
5.4.1.2 Surface pH(23)
Surface pH of the inserts was determined by allowing them to swell in a 
closed petri dish at room temperature for 30 min in 0.1 mL of distilled water. 
The swollen devices were removed and placed on pH paper to determine the 
surface pH. After 1 min the color developed was compared with the standard 
color scale. 
 
5.4.1.3 Thickness(23)
Thickness of the film is an important factor while considering its drug release 
from ocular delivery systems. If thickness varies from one film to another, the 
drug release from the film also varies. So it is must to keep the thickness of 
the film uniform to get reproducible results. In the present study, the thickness 
of the formulated films was measured using digital micro meter of sensitivity of 
0.01mm (mitutoyo, Japan). Average of 3 readings was taken and standard 
deviation values were calculated. 
 
5.4.1.4 Weight uniformity(23)
As weight variation between the formulated films can lead to difference in 
drug content and in vitro behavior, evaluation was carried out by weighing 10 
films by an electronic balance (least count – 0.1 mg). The average weight and 
standard deviation were then calculated and reported. 
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5.4.1.5 Tensile strength and percentage elongation at break(24)
The tensile strength of ocuserts refers to tension or force required to tear off 
the insert apart into two pieces. This was determined with an instrument 
assembled in the laboratory. 
 
Instrument: A small strip of ocular film measuring 5 cm×1 cm was cut with a 
sharp blade. One end of the film was fixed by placing in the film holder. 
Another end of the film was fixed with the help of forceps having triangular 
ends to keep the strip straight while stretching and a hook was inserted. A 
thread was tied to the hook, passed over the pulley and a small pan attached 
to the other end to hold weights. A small pointer was attached to the thread 
that travels over the graph paper affixed on the base plate. 
Procedure: To determine elongation and tensile strength, the film was pulled 
by means of a pulley system. Weights were gradually added (5g/min) to the 
pan to increase the pulling force till the film was broken. Elongation was 
determined simultaneously by noting the distance traveled by the pointer on 
the graph paper before the film was broken. The weight necessary to break 
the film was noted as break force. Percentage elongation at break and tensile 
strength was calculated using the following formula. % 𝐶𝐶𝑒𝑒𝑃𝑃𝑃𝑃𝑒𝑒𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑃𝑃𝑃𝑃 𝑏𝑏𝑃𝑃𝐶𝐶𝑃𝑃𝑏𝑏 =  IB − Io × 100                          [5.3] 
Where Io is the original length of the film and IB 
 
is the length of the film at break when stress was applied. 
Tensile strength =   Break  forceab (1+∆L/L)                                      [5.4] 
                   Where a, b and L are width, thickness and length of the strip 
respectively and ∆L is the elongation at break. 
                           Break force = weight required to break the film (Kg). 
5.4.1.6 Folding endurance(25)
The flexibility of polymeric films can be measured quantitatively in terms of 
folding endurance. Folding endurance was determined by repeatedly folding a 
small strip of ocular film (2×2 cm) at the same place till it breaks. The number 
of times film could be folded at the same place, without breaking gives the 
value of folding endurance. 
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5.4.1.7 Moisture uptake(22, 25)
The percentage moisture uptake test was carried out to check the physical 
stability or integrity of the film. Ocular films were weighed individually and 
placed in a desiccator containing 100 mL of saturated solution of sodium 
chloride (~ 75 % humidity). After three days, films were taken out and 
reweighed; the percentage moisture uptake was calculated by using following 
formula. 
 
Percentage moisture uptake =  Final  weight  – Initial  Weight Initial  weight  × 100                 [5.5] 
5.4.1.8 Percentage moisture content(22, 25)
The percentage moisture loss test was carried out to check the integrity of the 
film at dry condition. Ocular films were weighed individually and placed in a 
desiccator containing anhydrous calcium chloride. After three days, films were 
taken out and reweighed; the percentage moisture loss was calculated by 
using following formula. 
 
Percentage moisture content =   Initial  weight  – Final  Weight Initial  weight × 100            [5.6] 
5.4.1.9 Water vapor transmission studies(26)
The glass vials of 5 mL capacity were washed thoroughly and dried to 
constant weight in an oven. One gram of fused calcium chloride was taken in 
vials and the polymer films were fixed over the brim with the help of an 
adhesive. These pre-weighed vials were stored in humidity chamber at RH 
80% with temperature of 25 
  
o
5.4.1.10 Determination of drug content
C for a period of 24 hr. The weight gain was 
determined every hour up to a period of 24 hr to note the weight gain. Water 
vapor transmission (WVT) was calculated by taking the difference in weight of 
film before and after the study for a total period of 24 hr.  
(23)
The films were dissolved in 5 mL chloroform. The drug was extracted from 
chloroform using phosphate buffer. The volume was adjusted to 100 mL with 
phosphate buffer pH 7.4 and the solutions were filtered through filter. 
Chloroform was evaporated at 60 
 
oC. The drug content in each formulation 
was determined spectrophotometrically at 274 nm. Similarly, a blank solution 
was prepared using dummy film. Average drug content of three films was 
determined. 
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5.4.1.11 Surface morphology 
Surface characteristics of polymer blend were studies by scanning electron 
microscopy. Films were mounted on an aluminum stub using double-sided 
adhesive carbon tape and coated with gold palladium using JEOL JFC 1600 
auto fine coater for 90 sec. Samples were examined using scanning electron 
microscope JSM-6380 LV (Jeol Ltd., Tokyo, Japan) at 20 kv accelerating 
voltage. 
5.4.1.12 Hydrophilicity 
Contact angle was measured at R.T. by optical tensiometry using contact-
angle meter (Theta optical tensiometer, Biolin scientific AB, Sweden) 
equipped with T200 60 fps digital camera. Drops of STF (pH 7.4) were 
prepared with a precision syringe (1 mL, Hamilton 1001TPLT) and were 
dropped onto the surface of the polymer. The static contact angle was 
measured at contact time t=10 
5.4.1.13 Differential scanning calorimetry (DSC) 
s. 
Differential scanning calorimetry (DSC) scans of pure drug and drug loaded 
ocular insert were performed using DSC 1/700 (Mettler Toledo, Germany). 
The analysis was performed with a heating range of -25 o
5.4.1.14 X-Ray diffraction 
C to 250 °C and at a 
rate of 10 °C/min in nitrogen atmosphere. The sample weight was 
approximately 6 mg. 
X-Ray diffraction (XRD) patterns of pure betaxolol and ocular film were 
recorded using a powder X-Ray diffractometer (XRD-D8 Advance, Bruker, 
Germany) over the interval 10-80° 2θ-1. The experimental condition was: 
generator tension (voltage) of 38 kV, generator current of 34 mA, scan step 
time of 30.6 sec-1 and scan step size of 0.049° 2θ-1
5.4.2 In vitro drug release study
. 
(27)
Since there was no specific official method prescribed for in vitro studies of 
ocular inserts, we fabricated an open flow through assembly, simulating the 
condition of the ocular cavity, by using the classical standard cylindrical tube 
which has the diameter of 15 mm. Dialysis membrane (Dialysis membrane 
110, mw cut-off 12000-14000, Hi Media, India), immersed in water for one 
hour to remove the preservatives followed by rinsing in phosphate buffered 
saline (PBS) solution, acted as corneal epithelium, was tied to one end of 
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open cylinder which acted as donor compartment. An ocular insert was placed 
inside this compartment with 0.7 mL of simulated tear fluid (STF pH 7.4). 
Then, the glass tube was suspended in the dissolution flask of a USP 
dissolution apparatus such that entire surface of the membrane was in contact 
with the receptor compartment containing 250 mL of STF (pH 7.4). The 
content of the receptor compartment was stirred continuously at 25 rpm. 
Samples of 1 mL were withdrawn from the receptor compartment at periodic 
intervals and replaced by equal volume of fresh solution. The samples were 
analyzed spectrophotometrically at 274 nm against reference standard using 
STF as blank. 
5.4.3 Data treatment and analysis 
The following parameters were determined from the in vitro data obtained for 
the diffusion of Betaxolol hydrochloride through the membrane. 
5.4.3.1 Diffusion rate 
Diffusion rate is the milligrams of Betaxolol HCl diffused through membrane 
per unit time. It can be determined by dividing the milligrams of Betaxolol HCl 
diffused by time in hour(28) Dr = 𝑄𝑄𝑇𝑇                                                           [5.7] .  
5.4.3.2 The steady-state flux(29)
Absorption is a passive diffusion process and can be described by Fick’s 
second law equation 
 
JS = 𝑑𝑑𝑄𝑄𝑑𝑑𝑃𝑃 × 1𝐴𝐴                                                       [5.8] 
Where JS
The steady-state flux values of the Betaxolol HCl through the membrane were 
calculated from the slope of the linear portion of the cumulative amount 
permeated through the membrane per unit area versus time plot. 
 is the steady-state flux in micrograms/square centimeter per hour, 
dQ is the change in quantity of material passing through the membrane into 
the receptor compartment expressed in micrograms, A is the active diffusion 
area in square centimeters, and dt is the change in time in hr.  
5.4.3.3 Permeability coefficient(29)
To determine the permeability coefficient, the following equation was used: 
  
KP = 𝐽𝐽𝑆𝑆𝐶𝐶𝑑𝑑                                                           [5.9] 
Chapter 5 Long acting betaxolol ocular inserts based on polymer composite 
 
Hitesh B. Gevariya      116                                                     Ph. D. Thesis 
 
Where KP is the permeability coefficient, JS is the flux calculated at the steady 
time, and Cd
5.4.3.4 Kinetics of permeation 
 is the donor concentration. 
For finding out the mechanism of drug release from ocular system, the 
diffusion data obtained from the above experiments was treated with the 
different release kinetic equations(30)
Zero order release equation: 
.  
Q = K0
Higuchi’s square root of time equation:
 t                                                      [5.10] 
(25)
Q = K
  
H t1/2
Where, Q is amount of drug release at time t, K
                                                   [5.11] 
0 is zero order release rate 
constant, KH
5.4.3.5 Mechanism of release 
 is Higuchi’s square root of time release rate constant. 
Korsmeyer and Peppas equation is used to determine the mechanism of drug 
release(31, 32)
F = (M
.  
t/M) = Km tn                                                                
Where, M
[5.12] 
t is drug release at time t, M is total Amount of drug in dosage form, 
F is fraction of drug release at time t, Km
5.4.4 Statistical analysis 
 is constant which depends on 
geometry of dosage form and n is diffusion exponent indicating the 
mechanism of drug release, where for cylinder value of n is 0.45 indicate 
fickian diffusion, between 0.45 and 0.89 indicate anomalous transport and 
0.89 indicate case-II transport. 
The selected responses obtained from the various systems were tested for 
significant differences. Statistical analysis of data was carried out using 
analysis of variance (ANOVA). The individual response was evaluated using 
F-test and F value and P value were generated. The statistical analysis was 
conducted using Design-Expert® version 8.0.2 trial (Stat-Ease, Inc., 
Minneapolis MN). 
The following responses were selected for statistical analysis: 
 Diffusion rate 
 Flux 
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5.4.5 Drug-excipients compatibility studies(33)
The FTIR spectra of the pure drug and physical mixture (betaxolol, PEO and 
PMMA) were taken as KBr pellets in the range of 4000–650 cm
  
–1
5.4.6 Sterility testing 
 (FT/IR-4100 
type A spectrophotometer, Jasco, Japan). The infrared analysis of optimized 
insert was carried out in the same range by ATR-IR spectroscopy (Perkin 
Elmer Model 1600 FT-IR spectrophotometer with ATR mode Perkin Elmer, 
USA). 
(34)
Sterility is one of the most vital requirements for an ophthalmic preparation. 
The tests for sterility are intended for detecting the presence of viable forms of 
microorganisms in ophthalmic preparations. The principle governing these 
tests is that if the microorganisms are placed in a medium which provides 
nutritive material and water, kept at a favourable temperature, the organisms 
will grow and their presence can be indicated by turbidity in the originally clear 
medium. In the present study, two media namely, alternate thioglycolate 
medium (ATGM) and soyabean-casein digest medium (SBCD) were used to 
investigate the presence/absence of aerobic, anaerobic bacteria and fungi, in 
the formulated sterilized ocular inserts. 
 
5.4.6.1 Preparation of culture medium 
a) ATGM was used to detect the growth of aerobic and anaerobic bacteria. 
7.25 g of readymade ATGM was dissolved in 250 mL of purified water and 
the pH was adjusted to 7.1±0.2 with 1M NaOH. This was sterilized in an 
autoclave at 115 o
b) SBCD medium was used to detect the growth of aerobic bacteria and 
fungi. 7.25 g of readymade SBCD was dissolved in 250 mL of purified water 
and the pH was adjusted to 7.1±0.2 with 1M NaOH. This was sterilized in an 
autoclave at 115 
C for 30 min. The medium was freshly prepared and 
allowed to cool just prior to use.  
o
5.4.6.2 Test procedure 
C for 30 min. The medium was freshly prepared and 
allowed to cool just prior to use. 
Sterilized inserts were directly inoculated in above medium aseptically as 
described in IP 2007 and labeled as ‘Test’. Simultaneously, positive and 
negative controls were also prepared and all the three tubes were incubated 
at specified temperatures. 
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5.4.7 In vivo studies 
Approval for the use of animals in the study was obtained from the 
Institutional Animal Ethics Committee (1338/c/CPCSEA). New Zealand rabbits 
of either sex weighing 2.5 to 3.1 kg were used for in vivo studies. The rabbits 
were housed singly in restraining cages during the experiment and allowed 
food and water ad libitum. Free lag and eye movement was allowed. No 
ocular abnormalities were found on external and slit-lamp examination prior to 
beginning of the study. 
 5.4.7.1 In vivo release study(24)
On the day of experiment the sterilized ocuserts were placed into the lower 
cul-de-sac of rabbits. The inserts were inserted into one eye of seven rabbits 
at same time and another eye served as control. After 1, 2, 4, 6, 10, 22 and 
24 hr, the inserts were carefully removed and analyzed for remaining drug 
content by UV analysis. The amount of drug remaining was subtracted from 
initial drug content of inserts to find the amount of drug released in the rabbit 
eye. Observations for any fall out of insert were also recorded throughout the 
experiment.  
 
5.4.7.2 Corneal residence time evaluation 
Precorneal residence time of ocular drugs has been assessed by certain 
invasive techniques(35) and non-invasive techniques(36, 37). 
i) Tear sampling and analysis 
These approaches 
however, require isolation of ocular tissues or the use of radioisotopes. In the 
present study, an effort was therefore made to develop a non-invasive method 
to assess the precorneal residence of the drug from the formulated delivery 
system based on HPLC technique. 
Tear samples equivalent to 1 µL were collected from the left eye after 
application of test delivery system at 0, 0.10, 1, 2, 4, 6, 10, 22, 24 hr post 
dosing. Glass capillary tubes having 320 µm internal diameter and 1 µL 
premark were placed near the canthus of the eye without applying pressure. 
Tear fluid was drained into the tubes due to capillary action. Samples 
equivalent to 1 µL were mixed with 50 µL of mobile phase and injected into 
HPLC chamber. Data were collected and interpreted and results were 
tabulated. 
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ii) HPLC Condition(38)
Mobile phase: methanol:acetonitrile:0.1% diethylamine (pH adjusted to 3 with   
orthophosphoric acid) (30:60:10, %v/v) 
 
Flow Rate: 1.0 mL/min 
Column: Phenomenex C18 Column. (Luna C-250, 34.6 mm, 5 mm) 
Detector:  SPD-M20A Prominence diode array detector 
Retention Time: 4.08 min 
Injection Volume: 20 µl by Rheodyne 7725i injector 
Standard solution:  2 μg/mL of Betaxolol in HPLC grade water. 
5.4.7.3 Ocular safety study(39, 40)
The ocular safety of administered delivery system is based on the Draize 
Irritancy Test (Table 5.6). The observations based on scoring approach (Table 
5.7) established the safety of the developed ocular inserts in rabbit eye. 
 
 
Table 5.6: Draize irritancy test for ocular safety 
Ocular tissue 
Scoring 
scale 
Calculations Total 
Cornea: Opacity (O) 
              Area involved (A) 
0,1,2,3,4 
0,1,2,3,4 
O×A×5 80 
Iris: Values for congestion and   
hemorrhage (I) 
0, 1, 2 I×5 10 
Conjunctiva : Redness (R) 
                     Chemosis (C) 
                     Discharge (D) 
0, 1, 2, 3 
0, 1, 2 , 3, 4 
0, 1, 2, 3 
(R+C+D)×2 20 
                                                     Total Maximum                               110 
Note: Score of 0 is normal, 3 and 4 is severe in case of O, R, C and D. 
          Score of 0 is none, 1,2,3,4 is the extent of cornea covered for A. 
          Score of 0 is normal and 2 are severe in case of I. 
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Table 5.7: Safety evaluation chart 
Score Rating 
0.0– 0.5 
0.5 – 2.5 
2.5 – 15 
15.0 – 25.0 
25.0 – 50.0 
50.0 – 80.0 
80.0 – 110.0 
Non irritating 
Practically non irritating 
Minimally irritating 
Mildly irritating 
Moderately irritating 
Severely irritating 
Extremely irritating 
 
5.4.7.4 In vivo anti-glaucoma activity evaluation(41, 42)
i) Animal care and handling 
 
The animals were acclimatized to the standard laboratory conditions in cross 
ventilated animal house at temperature 25±2 °C relative humidity 44–56% and 
light and dark cycles of 12:12 hr, fed with standard pallet diet and water ad 
libitum during experiment. The experiment was approved by the institutional 
ethics committee and as per CPCSEA guidelines (approval no. 
1338/c/CPCSEA). 
ii) Steroid induced model(43)
Eyes of the 12 rabbits were treated 3 times daily by 0.5% dexamethasone eye 
drops for 2 weeks. Dexamethasone sodium phosphate (Taj Pharmaceuticals 
Ltd., Mumbai) was dissolved in phosphate buffer saline to a final 
concentration of 0.5 % at pH 7.4. The intraocular pressure was measured at 
noon twice a week by Schiotz tonometer.  
 
iii) Antiglaucoma activity evaluation 
For evaluation, the rabbits with induced glaucoma were randomly divided in 
three groups (n=4). First group was treated with marketed preparation of 
betaxolol HCl eye drop equivalent to 0.50 mg. In second group placebo film 
and in third group medicated film (F8) of betaxolol HCL was inserted in to 
lower cul de sac of rabbits. The intraocular pressure (IOP) changes were 
recorded up to 26 hr at specified time intervals. The ocular hypotensive 
activity is expressed as the average difference in IOP according to the 
equation ΔIOP = IOP’0’time – IOP’t’time(42, 44). 
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5.4.8 Ageing study(27)
The optimized inserts (F8) were stored in amber colored glass bottles at 3 
different temperatures 4 
 
oC, Room temperature and 40±0.5 o
 
C for a period of 
6 months. The samples were withdrawn after 60, 120 and 180 days and 
analyzed for physical appearance, drug content, folding endurance and 
sterility.  
5.5 Results and discussion 
In the present study ocular films of betaxolol HCl were prepared using 
combination of polymers (PMMA and PEO). A 32
5.5.1 Preliminary screening 
 full factorial design was 
employed and so nine formulations were obtained. Films were evaluated for 
their use as ocular delivery system with a view to obtain sustained release. 
Solubility of Betaxolol HCl was determined in different solvents and the 
observations are shown in Table 5.8. The maximum solubility was found in 
water and ethanol and least in ethyl acetate.  
Partition coefficient of Betaxolol HCl in n-octanol and phosphate buffer pH 7.4 
was found to be 1.07. PEO was found to take up 1.6 folds of its own weight of 
water over a period of 24 hr. 
 
Table 5.8: Solubility profile of betaxolol HCl in different solvents 
SR. No. Solvents Solubility 
1. Ethyl acetate + 
2. Chloroform ++++ 
3. Methylene chloride +++ 
4. Methanol ++++ 
5. Ethanol ++++ 
6. Distilled water  ++++ 
7.    0.1N NAOH      ++ 
8.    0.1N HCl      +++ 
+        Practically insoluble              ++  Slightly soluble  
+++   Soluble                 ++++   Freely soluble 
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5.5.2 Physicochemical evaluation 
In the present investigation solvent evaporation technique is adopted and it 
was found to be giving thin uniform films. All prepared ocular films have good 
appearance with smooth surface. Films prepared were semitransparent. 
Surface texture was smooth and uniform. 
Weight and thickness measurements of films were carried out and low 
standard deviation values in film weight and thickness measurements ensure 
the uniformity of weight and thickness in each film. A good weight uniformity 
of all formulation indicates an even distribution of drug and the polymers in the 
matrix film prepared by solvent evaporation technique. It was also accounted 
that weight and thickness of films were increasing with increasing polymer 
concentration. However there was no significant effect of PMMA:PEO ratio on 
weight and thickness of the film. Weight variation and thickness data of ocular 
films is shown in Table 5.9.  Formulations were not thick enough to produce 
any irritation while placing and being in cul-de-sac as inferred from ocular 
irritancy test. 
 
Table 5.9: Physical properties of prepared ocular films of betaxolol 
RUN 
Weight of 
films(mg)*  
Thickness 
(mm)#  
Tensile 
strength
Kg/cm
# 
2 
%Elongation 
at break
(EB)  
# 
Folding 
endurance#     
F1 4.09± 0.069 0.118± 0.016 0.75 ± 0.03  3.26± 0.21 69±2       
F2 4.2± 0.046     0.13±0.0063 0.68 ± 0.01  8.13± 0.23 90.3±2.08  
F3 4.11± 0.052 0.148±0.007 0.57 ± 0.01  12.63± 0.4 99.3±2.51  
F4 6.43± 0.094 0.19 ± 0.015 0.84 ± 0.02  2.95± 0.32 65.3±3.51                            
F5 6.49± 0.082 0.20± 0.0072    0.72 ± 0.01  7.18± 0.43 81±2.61                     
F6 6.44± 0.044 0.21± 0.0054     0.65 ± 0.01 12.17± 0.21 94.6±2.08         
F7 8.89± 0.057 0.24± 0.0032     1.34 ± 0.05  2.28± 0.32 61.3±2.08  
F8 9.09± 0.04 0.248± 0.004      0.92 ± 0.02  7.89± 0.46 73.3±2.52  
F9 8.91± 0.052 0.25± 0.0154 0.80 ± 0.02  11.93± 0.54 89.6±3.78 
All readings are in the form of Mean±SD,   # Average of 3 runs,   *Average of 
10 determinations 
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The surface pH of the prepared inserts were found in between 6.5 to 7.5, 
indicating that the inserts did not have an irritation potential as the pH is within 
the accepted ocular range(45)
Tensile strength for all inserts is shown in Table 5.9. It shows that 
formulation F7 shows highest tensile strength among all batches i.e. 1.34 ± 
0.05 kg/cm
. 
2
Folding endurance values revealed that maximum folding endurance was 
found at low concentration of polymer. Formulation F3 shows highest folding 
endurance. Decrease in folding endurance at higher concentration of polymer, 
may be due to increase in thickness of films. At Low amount of polymer 
addition of PEO in PMMA films, increase folding endurance significantly but at 
high amount of polymer, the effect was less.   
. It was also found that inserts containing more amount of PMMA 
shows higher tensile strength whereas increasing amount of PEO in insert 
lower the tensile strength. Increasing values of EB with increase in PEO 
amount suggests that PEO increases elasticity of the films. 
Ocular inserts were also evaluated for % moisture content, % moisture uptake 
and water vapour transmission (WVT) rate. Results were tabulated in Table 
5.10.  
Moisture content values of inserts were found in range of 2.50 ± 0.07 to 6.05 
± 0.17 %. It also shows that moisture content of inserts increase with 
increasing amount of PEO. This is due to hydrophilic properties of PEO. PEO 
content was more in formulation F9 and so more moisture content was found. 
It was also noticed that moisture uptake properties of formulation also depend 
on PEO content. Moisture uptake value was more for formulation F9 as it 
contains more amount of PEO. Same observation was also found in water 
vapour transmission rate of inserts. Water vapour transmission rate was found 
in range of 0.81 × 10-3 to 4.20 × 10-3 gm/cm2
Films containing more amount of PMMA show less WVT rate. These could be 
due to the hydrophilicity of the films was changed towards higher hydrophobic 
property when the higher amount of PMMA was present as compared to PEO.  
h.  
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Table 5.10: Evaluation of prepared ocular films of betaxolol 
Inserts % Moisture content (%MC ± SD)a 
% Moisture uptake 
(%MU ± SD)a 
Water vapour 
transmission rate 
  (gm/cm2h)a× 10-3 
F1 2.50 ± 0.07  04.17 ± 0.14  0.85±0.01  
F2 2.78 ± 0.05 05.00 ± 0.09 1.21±0.03  
F3 4.17 ± 0.12 09.37 ± 0.16 1.84±0.02  
F4 2.94 ± 0.04  05.15 ± 0.12   0.96±0.05  
F5 4.17 ± 0.10 08.33 ± 0.08 1.36±0.03  
F6 5.47 ± 0.15 10.94 ± 0.12 3.06±0.02  
F7 3.85 ± 0.09  07.69 ± 0.07  1.14±0.03  
F8 4.81 ± 0.08 09.62 ± 0.09 2.21±0.02  
F9 6.05 ± 0.17 11.08 ± 0.11 4.20±0.05  
a Average ± SD of three determination has been reported 
 
The water uptake or absorption behavior of the polymeric film plays an 
important role at the beginning stage of drug release from dosage form(46)
 
. 
Thus, the film with higher moisture uptake supposed to give higher drug 
release rate initially. 
Figure 5.2: Comparative WVT rate of ocular formulation of betaxolol 
 
Good uniformity in the drug content among the batches was observed for all 
the formulations. Drug content was found in the range of 99.07% to 102.13%.  
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Table 5.11: Drug content of prepared ocular films of betaxolol HCl 
Inserts Drug content* (mg ± SD) 
Drug content* 
(% ± SD) 
F1 0.511±0.0076  102.13±1.51 
F2     0.501±0.010 100.2±2.03 
F3     0.502±0.006 100.5±1.21 
F4 0.506±0.0031    101.27±0.61 
F5 0.497±0.0045 99.46±0.90 
F6 0.495±0.0021 99.07±0.42 
F7 0.499±0.0042 99.87±0.83 
F8 0.501±0.0023 100.13±0.46 
F9 0.503±0.0042 100.53±0.83 
* Average of five readings±SD 
 
The drug content analysis of the prepared formulations have shown that the 
process employed to prepare films in this study was capable of giving films 
with uniform drug content and minimum batch variability. 
5.5.3 Surface morphology (SEM) 
SEM study (Figure 5.3) revealed that surface of the ocular films are smooth 
indicating the complete miscibility of PEO with PMMA. This finding is similar to 
that of J.baldrian (47)
            
 who suggested that when the concentration of PEO is 
less than or equal to 20wt. %, the polymers are completely miscible and the 
blend is amorphous. This result is also supported by DSC and XRD studies.     
  
Figure 5.3: Scanning electron microscopy (SEM) images of inserts F7 
and F8. Experimental   condition: magnification= ×1000, Acc. V 20 kV, 
signal SEI, ___ 10 µm 
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5.5.4 Hydrophilicity 
Static STF Contact angles (θs) of films were below 50 indicating increasing 
hydrophilicity of the surface as the concentration of PEO increased in the 
matrix. As θs is only related to the outermost 10Å of each sample, the surface 
composition of blend is greatly correlated with θs (48)
5.5.5 Drug-excipients compatibility study 
. This result also reveals 
that PEO was uniformly distributed throughout the bulk of PMMA and 
concentration of PEO at surface increases with bulk concentration, making 
the insert hydrophilic enough to be wetted by tear fluid and adhere to corneal 
surface for longer duration. 
Interpretation of IR spectrum (49)  of Betaxolol (Figure 5.4A) shows characteristic 
peaks at 3237 cm-1 (hydroxyl group O-H stretching), 2928 cm-1 (methyl C-H 
stretching), 2858 cm-1 (methylene C-H stretching), 1612 cm-1 (aromatic ring C=C-C 
stretching), 1557 cm-1 and 1513 cm-1 (secondary amine N-H bending), 1474 cm-1 
(methylene C-H bending ), 1376 cm-1 (methyl C-H sym. bending ), 1246 cm-1 (alkyl 
aryl ether c-o-c stretching), 1179 cm-1 (aromatic in plane C-H bending), 1087 cm-1 
(aliphatic ether c-o-c stretching) and 1050 cm-1
 
 (amine C-N stretching). 
Figure 5.4: IR spectra of (A) Betaxolol HCL (B) Mixture of PMMA/ PEO/BX (C) 
Ocular insert F8 
FTIR spectra of mixture (Figure 5.4B) and insert F8 (Figure 5.4C), in 
comparison to IR spectra of pure drug, show no substantial shifting of the 
position of the functional groups, indicating no major interaction between drug 
and polymers. However, broadening and reduced intensity of peaks in IR 
spectra of insert indicates encapsulation of betaxolol in polymeric matrix.  
Although shifting and broadening of drug peak at 3237 cm-1 in the IR spectra 
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of insert F8 indicate that hydrogen bonding has occurred between the lone 
electron pairs of the oxygen atom of polymers and the hydrogen atom of the 
hydroxyl group of the drug. 
5.5.6 Differential scanning calorimetry  
From the overlay of the DSC thermograms, it has been observed that 
Betaxolol is crystalline in nature (Figure 5.5).  
 
Figure 5.5: DSC spectra of pure drug and ocular film 
Thermogram exhibited a sharp melting endotherm at an onset temperature of 
112.82 oC, a peak temperature of 119.76 oC and a heat of fusion of 6.97 J/g. 
While the thermogram of film shows crystallization of betaxolol from glass at 
67.18 oC followed by fusion at 116.89 o
5.5.7 X-ray diffraction (XRD) study 
C. The thermal behavior of film 
suggested that the drug is present in the film as semicrystalline form as the 
fusion peak in the film is very weak compared to the pure drug. 
XRD spectrum of Betaxolol (Figure 5.6) revealed that the drug is crystalline in 
nature. 
 
Figure 5.6: XRD patterns of Betaxolol (black line) and Insert F8 (red line) 
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XRD pattern of film showed that characteristic peaks of betaxolol were 
reduced in number and intensity indicating that the drug crystallinity was 
decreased in the inserts. 
5.5.8 In vitro drug diffusion studies 
In this study, Matrix-type inserts of Betaxolol HCl was prepared with polymer 
blend (PMMA and PEO). All formulations prepared were subjected to in vitro 
diffusion study to ensure the effect of polymer concentration and polymer 
blend. The data obtained for in- vitro study were tabulated and represented 
graphically. 
Table 5.12 shows percentage cumulative drug release profile (average of 3 
runs) for all formulations F1 to F9. The Maximum drug release was found at 
lower polymer concentration and as the polymer amount was increased from 
1% to 3% w/v, the release was found to be decreased. Ocusert F7 shows 
minimum drug release i.e. 79.26% in 24 hr. 
Order of cumulative drug permeated was found as follows: 
Eye drops>F3> F6 > F2 > F5 > F1 > F9 > F4 > F8 > F7 
From in vitro release results, insert F8 was selected as optimized formulation 
and subjected to further studies. 
 
Table 5.12: Percent cumulative amount of betaxolol permeated through 
membrane 
Time 
(hr) 
F 1 F 2 F 3 F 4 F 5 F 6 F 7 F 8 F 9 
% 
CP 
% 
CP % CP 
% 
CP % CP 
% 
CP 
% 
CP % CP 
% 
CP 
1 5.43 7.21 9.43 3.14 4.78 7.31 2.16 5.46 6.74 
2 9.45 13.41 16.2 8.25 7.98 14.65 5.92 9.27 12.45 
4 17.72 22.84 26.36 15.76 16.84 23.76 9.25 17.45 21.35 
6 28.43 33.24 41.28 24.33 30.65 38.54 15.24 23.34 32.18 
8 39.44 44.34 52.34 35.98 41.54 48.87 22.67 32.65 41.82 
10 50.15 58.45 65.87 48.73 56.87 62.87 31.24 41.79 51.84 
12 62.12 67.42 76.89 59.16 65.8 71.25 37.14 50.08 62.14 
22 98.78 99.87 100.21 99.65 100.25 99.74 67.24 87.88 98.87 
24 98.87 99.79 100.22 99.45 100.73 99.65 79.26 100.45 99.15 
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Diffusion profiles of all formulation were subjected to data treatment. Diffusion 
data were treated with zero order, Higuchi and Peppas equation. Diffusion 
parameters like Diffusion rate, Flux and Permeability coefficient were also 
determined.  
Drug permeation profile of all formulations is shown in Figure 5.7. It shows 
that formulation F8 shows almost 100 percent drug release. Lowest drug 
release was found in case of F7 as it contained more amount of hydrophobic 
polymer compare to all others. 
5.5.8.1 Effect of polymer concentration 
In vitro permeation profile shows that concentration of polymer in the film 
plays a very important role on drug permeation. ANOVA study shows that 
factor A (drug to polymer ratio) has significant effect on maximum drug 
permeated i.e. Cmax
The Maximum average diffusion rate found was 0.0306 mg/h in case of 
formulation F3 whereas F7 shows minimum drug release with diffusion rate of 
0.017 mg/h. Flux values attained for all formulation are shown in Table 5.13.  
. Figure 5.7 shows that as concentration of polymer 
increases there was decrease in drug permeation.   
 
Table 5.13: Permeation parameters of betaxolol through membrane 
Inserts 
Diffusion rate 
Dr 
Flux 
JS 
Permeability 
coefficient 
KP 
mg/h mg/cm2h cm/h 
F1 0.0247 0.013958 2.79×10-2 
F2 0.0273 0.015459 3.09×10-2 
F3 0.0306 0.017299 3.46×10-2 
F4 0.0236 0.013364 2.67×10-2 
F5 0.0252 0.014275 2.86×10-2 
F6 0.0286 0.016195 3.24×10-2 
F7 0.0170 0.009609 1.92×10-2 
F8 0.0221 0.012514 2.50×10-2 
F9 0.0256 0.014499 2.90×10-2 
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Result of flux also favors that drug release was inversely proportional to 
polymer concentration. Among all inserts, maximum flux was found in case F3 
i.e. 0.01730 mg/cm2
Diffusion of molecules through polymer matrix was rate limiting step for 
permeation of molecule. The process of drug release in most controlled 
release devices is governed by diffusion, and the polymer matrix has a strong 
influence on the diffusivity as the motion of a small molecule is restricted by 
the three-dimensional network of polymer chains. It has been reported that 
diffusion rate of molecule is inversely proportional to diffusion path
h.  
(50)
Thickness of inserts increases with increasing the amount of polymer. This 
lead to an increase in diffusion path of molecules and so less release was 
observed in case of formulation containing high concentration of polymer. 
. 
 
 
Figure 5.7: In vitro drug release profiles of betaxolol inserts and eye 
drops 
 
5.5.8.2 Effect of polymer composition 
The effect of polymer blend on drug permeation profile was also studied and 
results are shown in Table 5.13 and Figure 5.7. In vitro permeation study 
shows that change in polymer blend will alter the drug permeation profile. 
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ANOVA study shows that factor B (HPMC to EC ratio) has significant effect on 
drug permeation profile. 
Average diffusion rate of formulation F1 to F3 was found 0.0247, 0.0273 and 
0.0306 mg/h respectively. This shows that diffusion rate was increased with 
increase in PEO concentration. Similar observations were also found in case 
of batches F4 to F6 and F7 to F9. Result of flux also indicates that drug 
release was directly proportional to PEO concentration.  
Drug permeation data represented in Table 5.13 shows that increasing 
concentration of PMMA will retard the drug release and so drug permeation. 
Release rates were increased when the concentration of PEO increased in 
the formulations. This is because as the proportion of this polymer in the 
matrix increased, there was an increase in the amount of water uptake and 
hydration of the polymeric matrix and thus more drugs was released(51)
The drug release was found to increase on increasing the concentration of 
hydrophilic polymer in the polymer matrix. The polyether chains of PEO can 
form strong hydrogen bonds with water, therefore, when inserts are brought 
into contact with an aqueous medium, the polymer tends to hydrate, forming a 
superficial gel which eventually erodes as the polymer dissolves
. 
(52)
The kinetic treatment of diffusion data of different batches is shown in Table 
5.14. It can be concluded that Korsemeyer and Peppas model fit the best for 
all the inserts as correlation coefficient value for all the inserts were more than 
0.9867. This is followed by Higuchi and zero order equation. From the n value 
it can be seen that all the formulations follow non fickian diffusion of drug 
release
.  This is 
due to the fact that dissolution of aqueous soluble fraction of the polymer 
matrix leads to the formation of gelaneous pores. The formation of such pores 
leads to decrease in the mean diffusion path length of drug molecules to 
release into the diffusion medium and hence, to cause higher release rate. 
(30). This can be supported by the good fit of Higuchi equation. The 
drug was released by diffusion from the polymer matrix. Results also indicated 
that inserts show zero order drug release at high amount of polymer. Drug 
release from such matrices may be controlled by polymer swelling or erosion, 
or drug diffusion in the hydrated gel, or by these processes altogether(52)
 
. 
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Table 5.14: Kinetics modeling of permeation profile of ocular inserts 
containing betaxolol 
Inserts Zero order   Higuchi     Korsmeyer-Peppas            Release 
        mechanism         R         R2   R2       N 2 
F1 0.9869 0.9789 0.995 0.9573 Anomalous transport 
F2 0.9714 0.9869 0.9944 0.8522 Anomalous transport 
F3    0.933 0.9836 0.9867 0.7785 Anomalous transport 
F4 0.9904 0.9721 0.9937    1.095 Super case-II transport 
F5 0.9752 0.9826 0.9871    1.024 Super case-II transport 
F6 0.9517 0.9891 0.9881 0.8423 Anomalous transport 
F7 0.9951 0.9445 0.9935    1.107 Super case-II transport 
F8 0.9986 0.9552 0.9963 0.9215 Anomalous transport 
F9 0.9859 0.9847 0.9979 0.8661 Anomalous transport 
 
5.5.9 Statistical analysis 
5.5.9.1 ANOVA for diffusion rate (DR) 
ANOVA for response surface quadratic model was generated by software. 
Below is the ANOVA table for diffusion rate. 
 
Table 5.15: Result of analysis of variance for measured response 
diffusion rate 
Source Sum of squares df 
Mean 
square 
F 
Value 
p-value 
Prob > 
F 
Model 1.218E-04 5 2.435E-05 27.15 0.0106 
A-Drug: Polymer 5.340E-05 1 5.340E-05 59.54 0.0045 
B-PMMA:PEO 6.337E-05 1 6.337E-05 70.66 0.0035 
AB 1.823E-06 1 1.823E-06 2.03 0.2493 
A2 3.125E-06 1 3.125E-06 3.48 0.1588 
B2 4.500E-08 1 4.500E-08 0.050 0.8372 
Residual 2.691E-06 3 8.969E-07   
C or Total 1.245E-04 8    
 
Chapter 5 Long acting betaxolol ocular inserts based on polymer composite 
 
Hitesh B. Gevariya      133                                                     Ph. D. Thesis 
 
The Model F-value of 27.15 implies the model is significant.  There is only a 
1.06% chance that a "Model F-Value" this large could occur due to noise. 
Values of "Prob > F" less than 0.05 indicate model terms are significant.  In 
this case A and B are significant model terms. The polynomial equation 
derived from the coefficients of estimate in term of coded factor is  
DR = 0.026-2.983E-03A+3.250E-03B+6.750E-04AB-1.250E-03A2+1.500E-04B2 
[5.13] 
R2
Prob > F less than 0.05 indicate that drug : Polymer ratio and PMMA : PEO 
ratio has significant effect on diffusion  rate of Betaxolol HCl. Following Figure 
(Figure 5.8) shows the effect of significant interaction terms on diffusion rate.  
 = 0.9784 
The relationship between the dependent and independent variables was 
further elucidated using contour and response surface plots. Response 
surface 3D plot shows that as amount of polymer increased, DR was reduced 
due to increased diffusion path at high amount of polymer whereas increase 
in PEO amount in insert resulted in increase in DR because PMMA retards 
water penetration and so diffusion of molecules through the film.   
                                 
    
Figure 5.8: (a) Response surface plot (3D) and (b) contour plot showing 
the effect of drug to polymer ratio and PMMA to PEO ratio on the 
diffusion rate (DR) 
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Same observations were also indicated by counter plot. Contour plot shows 
that at high level of Polymer amount, PMMA:PEO has more significant effect 
compared to low level of polymer amount. It also shows that increasing 
amount of PEO has significant effect on DR at high amount of polymer.  
It is well known that the addition of hydrophilic component to an insoluble film 
former leads to enhanced release rate constant. This may be due to 
dissolution of the aqueous soluble fraction of the film, which leads to creation 
of pores and decrease of mean diffusion path length of the drug molecule to 
be released(53)
5.5.9.2 ANOVA for flux (J) 
. 
ANOVA for response surface quadratic model was generated by software. 
Below is the ANOVA table for Flux. 
 
Table 5.16: Result of analysis of variance for measured response flux 
Source Sum of squares df 
Mean 
square 
F 
Value 
p-value 
Prob > F 
Model 3.903E-005 5 7.806E-00 26.92 0.0107 
   A-Drug:Polymer  1.698E-005 1 1.698E-005 58.58 0.0046 
B-PMMA:PEO 2.039E-005 1 2.039E-005 70.35 0.0036 
AB 5.999E-007 1 5.999E-007 2.07 0.2459 
A2 1.042E-006 1 1.042E-006 3.59 0.1543 
B2 1.018E-008 1 1.018E-008 0.035 0.8633 
Residual 8.697E-007 3 2.899E-007   
C or Total 3.990E-005   8    
  
The Model F-value of 26.92 implies the model is significant.  There is only a 
1.07% chance that a "Model F-Value" this large could occur due to noise. 
Values of "Prob > F" less than 0.05 indicate model terms are significant.  In 
this case A and B are significant model terms. The polynomial equation 
derived from the coefficients of estimate in term of coded factor is:  
Flux=0.015-1.682E-03A+1.844E-03B+3.872E-04AB-7.217E-04A2+7.133E-05B2  
[5.14] 
R2 = 0.9782 
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From the value of Prob>F, it has found that amount of polymer and polymer 
ratio had significant effect on steady state flux. It was also noticed that 
PMMA:PEO had more significant effect than drug:polymer ratio.  Figure 5.9 
shows the effect of significant interaction terms on flux (J).  
 
 
Figure 5.9: (a) Response surface plot (3D) and (b) contour plot showing 
the effect of drug to polymer ratio and PMMA to PEO ratio on the flux 
 
  
Figure 5.10: (a) Effect of drug to polymer ratio and (b) Effect of PMMA to 
PEO ratio on the measured response flux 
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The relationship between the dependent and independent variables was 
further elucidated using contour and response surface plots. Response 
surface 3D plot shows the interaction effect of independent variable on flux. It 
shows that increasing polymer concentration retards drug permeation so flux 
value was decreased. Increasing concentration of PEO enhances the drug 
diffusion and so flux value was increased. Contour plot shows that retarding 
effect of PMMA was less significant at low level of drug:polymer ratio compare 
to high level. It shows that increasing amount of PEO has significant effect on 
flux at high amount of polymer. Amount of polymer had significant effect on 
flux when both polymers (PMMA:PEO) used in 9:1 combination.          
5.5.9.3 ANOVA for Q12h (%) 
ANOVA for response surface quadratic model and reduced model was 
generated by software. Below is the ANOVA table for percent amount 
released at 12 hr (Q12h). 
 
Table 5.17: Result of analysis of variance for measured response Q12h 
Source 
Sum of 
squares 
df 
Mean 
square 
F 
Value 
p-value 
Prob > F 
Full Model 1092.02 5 218.40 28.15 0.0100 
   A-Drug:Polymer  542.83 1 542.83 69.98 0.0036 
B-PMMA:PEO 448.24 1 448.24 57.78 0.0047 
AB 26.16 1 26.16 3.37 0.1636 
A2 74.54 1 74.54 9.61 0.0533 
B2 0.25 1 0.25 0.032 0.8703 
Residual 23.27 3 7.76   
C or Total 1115.30  8    
Reduced Model 991.07 2 495.54 23.93 0.0014 
   A-Drug:Polymer  542.83 1 542.83 26.22 0.0022 
B- PMMA:PEO 448.24 1 448.24 21.65 0.0035 
Residual 124.22 6 20.70   
C or Total 1115.30  8    
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The Model F-value of 28.15 implies the model is significant.  There is only a 
1.00% chance that a "Model F-Value" this large could occur due to noise. 
Values of "Prob > F" less than 0.05 indicate model terms are significant.  In 
this case A and B are significant model terms. The polynomial equation 
derived from the coefficients of estimate in term of coded factor is 
Q12h = 65.17-9.51 A+8.64B+2.56 AB-6.10A2+0.35B2           [5.14] 
R2
For reduced model, polynomial equation is 
 = 0.9791 
Q12h  = 61.33-9.51A+8.64B                               [5.15] 
R2
Response surface 3D plot (Figure 5.11a) shows the interaction effect of 
independent variable on Q12h. It shows that increasing polymer concentration 
retards drug permeation so Q12h value was decreased. Increasing 
concentration of PEO enhances the drug diffusion and so Q12h value was 
increased. The relationship between the dependent and independent 
variables was further elucidated using contour plots (Figure 5.11b). It shows 
that retarding effect of PMMA was less significant at low level of drug:polymer 
ratio compare to high level. It shows that increasing amount of PEO has 
significant effect on Q12h at high amount of polymer. 
 = 0.8886 
    
    
Figure 5.11: (a) Response surface plot (3D) and (b) contour plot showing 
the effect of drug to polymer ratio and PMMA to PEO ratio on the Q12h 
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5.5.9.4 Checkpoint analysis 
To validate the evolved mathematical models, two checkpoints were selected. 
From the contour plot, two sets of A and B were selected and two batches 
were prepared using the same procedure keeping the other process variables 
constant with the amounts of A and B at the selected checkpoint. The 
experiment was repeated three times and experimentally obtained mean flux, 
DR and Q12h values were compared with predetermined (predicted) values 
(Table 5.18). Good correlation was found between observed and predicted 
values. Hence, it might be concluded that the evolved model might be used 
for theoretical prediction of responses within the factor space. 
 
Table 5.18: Observed and predicted results of check point batches of 
inserts 
Batch A B 
Diffusion rate Flux Q12h (%) 
Observed Predicted Observed Predicted Observed Predicted 
CF1 0.5 -1 0.02019 0.02036 0.01138 0.01152 46.54 47.94 
CF2 -0.5 1 0.02965 0.02983 0.01653 0.01688 77.81 76.14 
 
5.5.10 Sterility testing 
The sterility testing of ocusert F8 was performed for aerobic, anaerobic 
bacteria and fungi by using alternate thioglycollate medium and soyabean 
casein digest medium as per the IP’07 procedure.  
Test for aerobic bacteria: Here, Bacillus subtilis was used as a test 
organism. As shown in Table 5.19 and Figure 5.12A, there was no evidence 
of growth found in the ‘test’ and ‘negative control’  tubes and there was 
macroscopic evidence of microbial growth in ‘positive control’  tube. The 
results suggest that the ocusert F8 tested for aerobic bacteria were passed 
the test for sterility. 
Test for anaerobic bacteria: Here, Bacterioides vulgatus was used as test 
organism. As shown in Table 5.19 and Figure 5.12B, there was no evidence 
of growth found in the ‘test’ and ‘negative control’  tubes and there was 
macroscopic  evidence of microbial growth in ‘positive control’  tube. The 
results suggest that the ocusert F8 tested for anaerobic bacteria were passed 
the test for sterility. 
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Table 5.19: Sterility test observations in ATGM 
Sr. no. Samples 
Days 
1 2 3 5 7 14 
1         Negative Control - - - - - - 
2         Positive control √ √ √ √ √ √ 
3 Surface Sterilized 
10 min 
60 min 
 
- 
- 
 
- 
- 
 
√ 
- 
 
√ 
- 
 
√ 
- 
 
√ 
- 
(-) Absence of microbial growth,  (√) Presence of microbial growth. 
 
Test for fungi: Here, Candida albicans was used as test organisms. As 
shown in Table 5.20 and Figure 5.12C, there was no evidence of growth 
found in the ‘test’ and ‘negative control’ tubes and there was macroscopic 
evidence of microbial growth in ‘positive control’ test tube. The results suggest 
that the ocusert F8 tested for fungi were passed the test for sterility. 
The overall results of the sterility test showed that the surface sterilized 
ocusert F8 passed the sterility test and hence they were sterile preparations. 
 
Table 5.20: Sterility test observations in SBCD medium 
Sr. no. Samples 
Days 
1 2 3 5 7 14 
1 Negative Control - - - - - - 
2          Positive control √ √ √ √ √ √ 
3 Surface Sterilized 
10 min 
60 min 
 
- 
- 
 
- 
- 
 
√ 
- 
 
√ 
- 
 
√ 
- 
 
√ 
- 
(-) Absence of microbial growth, (√) Presence of microbial growth 
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Figure 5.12: Sterility testing for ocusert F8 
A–Aerobic bacteria(ATGM), B-Anaerobic bacteria (ATGM), C- Fungi (SBCDM) 
 
5.5.11 In vivo studies 
5.5.11.1 In vivo release study  
The results of in vivo release study of the ocusert F8 is shown in Table 5.21. 
The ocusert showed 99.87% of drug release after 24 hr which was 
comparable to in vitro drug release (Table 5.21). Thus there was good in vitro 
– in vivo correlation for the ocusert F8 (Figure 5.13) indicating the 
effectiveness of the formulation to be used in vivo. 
 
Table 5.21: Comparison of in vivo-in vitro drug release data 
Time(h) 
In vivo 
% DR 
In vitro 
% DR 
1 2.88 5.46 
2 7.03 9.27 
4 13.67 17.45 
6 21.39 23.34 
10 40.31 41.79 
12 48.78 50.08 
22 89.29 87.88 
24 99.87 100.45 
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Figure 5.13: In vitro – in vivo correlation for formulation F8 
 
Difference factor of 0.0004 and similarity factor of 80.29 for the in vitro-in vivo 
release data of formulation F8 indicates no significant difference between in 
vitro release and in vivo performance of the inserts. 
5.5.11.2 Corneal residence evaluation 
The precorneal residence of betaxolol after application of ocuserts and eye 
drops in rabbit eyes is shown in Table 5.22 and Figure 5.14.  
Table 5.22: Tear fluid concentration of betaxolol 
Time (h) 
Tear fluid concentration (µg/mL) 
Insert F8 Eye drop 
0.1 0.75 50.14 
1 3.16 12.35 
2 4.38 6.85 
4 5.81 2.14 
6 5.18 1.24 
8 4.89 0.08 
10 5.12 N.D. 
12 4.74 N.D. 
22 3.11 N.D. 
24 2.12 N.D. 
N.D.- Not detectable 
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There was a significant improvement in precorneal residence of betaxolol 
after application of the formulated insert as compared to eye drops. In case of 
ocuserts, the levels of drug concentration in tear fluid were maintained for 24 
hr while for eye drops concentration was very less after 6 hr. The increase in 
corneal residence may be attributed to the controlled release of drug from the 
ocuserts as proved by in vivo-in vitro release studies.  
 
 
Figure 5.14:  Tear fluid concentration of betaxolol 
 
5.5.11.3 Ocular safety studies  
The ocular safety study observations were recorded as per Annexure I. The 
ocular safety score of the formulation F8 was found to be 3 at the end of 24 hr 
and therefore, considered as minimally irritating(40)
5.5.11.4 In vivo antiglaucoma efficacy evaluation 
. This mild irritation might 
be due to the organic solvent used in the preparation of the ocular inserts. 
Thus, it can be concluded that they were safe for ocular administration. 
In vivo antiglaucoma activity was carried out on rabbits using steroid induced 
glaucoma model. The data obtained was represented graphically as shown in 
Figure 5.15. In vivo IOP lowering study results revealed that in comparison to 
eye drops, formulation F8 showed better control of IOP up to 24 hr (P< 0.001). 
A single instillation of one drop of 0.5% betaxolol eye drops controlled IOP 
well to the base level up to the period of 8 hr and then after IOP was 
increased, while same dose of betaxolol from insert F8 controlled IOP up to 
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24 hr.  Peak effect was observed at 4 hr and 6 hr in case of eye drops and F8 
respectively. The interesting finding of the study was that IOP was also 
lowered effectively in control eyes of eye drop treated group, which was not 
the case for inserts treated group. This can be an indirect measure of 
systemic absorption of the drug following eye drops treatment, indicating that 
ocusert provides better control over systemic side effects.  
 
 
Figure 5.15: IOP lowering activity of ocusert F8 and eye drops 
 
5.5.12 Ageing study 
Ageing study of the ocusert F8 was performed at R.T., 4 oC and 40 o
Table 5.23: Ageing study results of ocular insert F8 
C for the 
period of 6 months. The results (Table 5.23) showed that there was no 
change in physical appearance of ocuserts. The drug content showed no 
marked change after six months.  
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Control ED Eye drops Ocusert F8 Control F8
Time 
(days) 
            4  o R.T.                              40 C  oC 
RDC FE RDC FE RDC FE 
0 0.504±0.016 93±2 0.505±0.016 92±3 0.503±0.016 91±2 
60 0.0503±0.036 94±3.5 0.496±0.029 89±2.5 0.501±0.063 87±2.5 
120 0.495±0.028 90±1.5 0.502±0.042 91±2 0.498±0.058 84±2.6 
180 0.501±0.032 91±3 0.501±0.038 93±2.5 0.497±0.045 84±2.5 
RDC-Remaining drug content, FE-Folding endurance 
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Folding endurance values were also comparable to initial values indicating 
good physical integrity after six months of storage even at 40 o
 
C. All the 
inserts were found sterile. These results concluded that ocusert F8 was 
chemically, physically and microbiologically stable at RT for six months. 
However, further studies at different temperatures and humidity conditions are 
needed to establish their shelf life. 
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5.6 Conclusion 
Attempt has been made to use blend of polymers in design of sustained 
ocular delivery system of Betaxolol HCl. Study was mainly focused on 
investigating influence of Hydrophilic (PEO) and hydrophobic (PMMA) 
polymers and their concentration on ocular delivery using factorial design 
statistically. Inserts of all batches had desired ocular physicochemical 
properties. Both polymers amount and their ratio had significant influence on 
dependent variables studied. The ratio of hydrophilic and hydrophobic 
polymeric film formers affected the mechanical properties, percentage 
moisture uptake, WVT rate, rate of drug release and consequently the 
permeation of the Betaxolol HCl. Due to addition of hydrophilic polymer, the 
surface of inserts was hydrophilic enough to be easily wetted by tear film. The 
blend of PEO in PMMA matrix was found to be homogenous and blend was 
amorphous in nature. No phase separation was observed in polymer 
composite as revealed from SEM, DSC and XRD studies.  It was found that 
drug permeation was decreased with increasing polymer concentration. It was 
also concluded that presence of PEO in films favors the drug release and so 
permeation whereas PMMA retards drug release. Analysis of variance study 
shows that both the studied factors had significant effect on drug permeation 
profile. The results indicate that the polymeric film composed of PMMA and 
PEO at the ratio of 8:2 and dibutyl phthalate as a plasticizer was suitable for 
developing an ocular drug delivery system for Betaxolol HCl.  
Thus the present work showed that incorporation of hydrophilic polymer into 
hydrophobic matrix system can be successfully done in order to model ocular 
inserts providing promising controlled release delivery system.  The control of 
IOP, systemic absorption and hence possible side effects using inserts was 
found to be better than conventional eye drops. Thus, on the basis of In vivo 
antiglaucoma activity, ocular safety test and stability studies, it can be 
concluded that this betaxolol ocular insert can be a promising once-a-day 
controlled release formulation after due considerations of human in vivo 
studies. 
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6. PREPARATION AND CHARACTERIZATION OF BETAXOLOL 
NIOSOMES 
6.1 Aim of present investigation 
Technological innovations in drug delivery systems in recent years promise 
radical change in the field of pharmacotherapy. Many predict that, by the next 
ten years, drugs will be more specific in pharmacodynamic action, more site 
selective and will be administered less often and in lower quantities(1, 2)
Ocular drug delivery is a challenge for the formulator. A drop of an aqueous 
solution, irrespective of instilled volume is eliminated completely from the eye 
within 5 to 6 minutes of its application and only a small amount (1-3%) 
actually penetrates the cornea and reaches the intraocular tissue
. There 
are many potentially effective drug delivery systems and vehicles. They differ 
in their drug capacities, structure, in vivo and storage stability, modes of 
administration and possible applications. Each of them has favorable 
attributes and limitations. Major technical challenges include drug loading, 
size, cost and stability. Major biological challenges include immunity, drug 
denaturation, targeting and toxicity.   
During the last 25 years intensive investigations have been undertaken on the 
use of delivery systems to carry pharmaceuticals to target sites. The purpose 
of using these delivery systems is to convey active materials to target site. In 
this way the tissue is protected against the side effects of the drug and at the 
same time the stability of the drug can be maintained. In this regard, many 
micromolecular carriers such as liposomes, niosomes, pharmacosomes etc. 
have been designed and studied extensively to modulate biodistribution 
characteristic of the drug. 
(3). Recent 
trend in ocular research is to formulate a dosage form which not only prolongs 
the residence of system in eye but also helps to reduce the elimination of the 
drug. In the same area many drug delivery systems including insitu gel 4( ), 
microemulsions 5( ), nanoparticles 6( ), liposome 7( ), niosomes 8( ), ocular inserts 9( ) 
etc. are being investigated worldwide by many researchers. The 
developmental technology of new ocular dosage forms has witnessed 
tremendous improvement during last few decades and its use is expected to 
increase in near future. 
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Since excessive loss of drug (betaxolol) through nasolacrimal drainage can 
cause respiratory and cardiovascular side effects(10), it is important to 
minimize the systemic absorption and enhance ocular bioavailability of drug. 
This problem can be addressed by use of suitable carrier systems. Niosomal 
vesicular system is one of the potential approaches, which can be suitably 
used 8( )
These structures are analogous to phospholipid vesicles (liposomes) and are 
able to encapsulate hydrophilic and lipophilic solutes and serve as drug 
carriers. The low cost, higher stability, entrapping of more substances, ease of 
handling and storage and availability of prepared materials in pure form have 
led to the exploitation of these compounds as alternative to liposomes
. 
(11-14)
Niosomes in topical ocular delivery are preferred over other vesicular systems 
because of the following reasons: (1) chemical stability; (2) low toxicity 
because of their non-ionic nature; (3) handling surfactants with no special 
precautions or conditions; (4) the ability to improve the performance of the 
drug via better availability and controlled delivery at a particular site; (5) being 
biodegradable, biocompatible and non-immunogenic
. 
Niosomes, therefore, are promising drug carrier and have the potential to 
reduce the side effects of drugs and increased therapeutic effectiveness in 
various diseases. As of today more than 50 drugs are tried in niosome 
formulations by intravenous, per oral, transdermal, inhalation, ocular and 
nasal routes of administration. 
(15)
Until now, a great deal of attention has been paid on incorporation of a great 
number of drugs in niosomes such as anticancer, anti-tubercular, anti-
leishmanial, anti-inflammatory, hormonal drugs and oral vaccine
. 
(16)
The advantage of vesicular systems does not only reside in providing 
prolonged and controlled action at the corneal surface but also involves 
providing controlled ocular delivery by preventing the metabolism of the drug 
from the enzymes present at the tear/corneal epithelial surface. Moreover, 
vesicles offer a promising avenue to fulfill the need for an ophthalmic drug 
delivery system that has the convenience of a drop, but will localize and 
maintain drug activity at its site of action. The penetration of drug molecules 
into the eye from a topically applied preparation is a complex phenomenon. In 
vesicular dosage forms, the drug is encapsulated in lipid vesicles, which can 
. 
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cross cell membrane. Vesicles, therefore, can be viewed as drug carriers 
which can change the rate and extent of absorption as well as the disposition 
of the drug(17)
 
. 
Aim of the present study was to develop a suitable niosomal preparation of 
betaxolol with an optimal ocular pharmacodynamics extended over a 
prolonged period, and a limited systemic absorption and side effects. Hence 
this investigation has been designed to study the drug release kinetics of 
betaxolol from niosomal formulations.  
It was our objective to develop niosomes that: 
1.  Release the drug for prolonged period of time.  
2. Provide an increased ocular residence time resulting in prolonged drug 
delivery. 
3. Delivers a drug at a controlled rate over a period of time. 
4. shows better in-vivo performances than conventional dosage forms. 
 
In context to above intention, following criteria were aimed to achieve: 
1. Niosomes should be discrete and spherical. 
3. Drug entrapment should be more than 50 %. 
3. More than 90 % of drug should be released within 24 hr. 
 
Based on the aforementioned reasons, the purpose of the current study was 
to prepare betaxolol encapsulated niosomes possessing a high drug loading 
capacity in order to be used as ophthalmic carriers for topical ocular glaucoma 
treatment. 
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6.2 Experimental 
6.2.1 Preliminary screening  
Preliminary study was carried out for screening of various nonionic 
surfactants. 
6.2.1.1 Selection of surfactants 
Surfactants were selected from among Span 20, 40, 60, 80 and Tween 60, 80 
based on the size of niosomes, shape of niosomes and appearance of the 
niosomal suspension.  
 
Table 6.1: Formulation compositions for preliminary screening of 
surfactants for niosomes of betaxolol  
Trial Cholesterol Span Tween 
PEO 
(mg) 
20 40 60 80 60 80  
1 1 2      - 
2 1 2      10 
3 1  2     - 
4 1  2     10 
5 1   2    - 
6 1   2    10 
7 1    2   - 
8 1    2   10 
9 1     2  - 
10 1     2  10 
11 1      2 - 
12 1      2 10 
          
Table 6.2: Physical evaluation of test batches of niosomes 
Trial                                      Appearance Shape of niosomes Size of niosomes 
1 Transparent Not formed properly NA 
2 Transparent gel Not formed properly NA 
3 White creamy Sus Spherical Medium 
4 Translucent gel Spherical Medium to Large 
5 White creamy Sus Spherical Medium 
6 Translucent gel Spherical Medium to Large 
7 White creamy gel Spherical Large 
8 Translucent gel Spherical Large 
9 White creamy Sus Spherical Medium 
10 Translucent gel Spherical Medium to Large 
11 Transparent Not formed properly NA 
12 Transparent gel Not formed properly NA 
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For screening the surfactants, a formulation study was carried out. Above 
Table 6.2 shows some of the important formulations screened for actual 
study. Formulations were prepared using surfactant and cholesterol with or 
without PEO. It was found that niosomes were not obtained in case of span 
20 and tween 80 whereas span 60 and tween 60 gave the niosomes that 
were good in appearance, shape and size. Considering above result it was 
decided to prepared the ocular niosomes by using the span 60 and tween 60.  
6.2.1.2 Drug-excipients compatibility study 
Infrared spectra matching approach was used for detection of any possible 
chemical interaction between the drug and excipients. The drug, 1:1 physical 
mixture of cholesterol/drug/span/tween (each 10 mg) was mixed with 400 mg 
of potassium bromide. About 100 mg of this mixture was compressed to form 
a pellet using a hydraulic press at 10 tones pressure. Pellets were scanned in 
the range of 4000-400 cm-1
A 2-factor 3-level full factorial design (3
 in FTIR spectrophotometer (FT/IR-4100 type A 
spectrophotometer, Jasco, Japan). The IR spectrum of physical mixtures was 
compared with that of pure drug to detect any appearance or disappearance 
of peaks.  
6.2.2 Design of experiment 
2) was used for the formulation and 
optimization of niosomes by studying the influence of the two independent 
variables on the responses (Y1 and Y2) percentage drug entrapment (PDE) 
and vesicle size (Mean volume diameter - MVD). This design is suitable for 
exploring quadratic response surface and constructing second order 
polynomial models. Values of selected variables at different levels, after 
measuring the responses either simple linear (Y= X0 + X1A + X2B) or 
interactive (Y= X0 + X1A + X2B + X5AB) or quadratic (Y = X0 + X1A + X2B + 
X3A2 + X4B2 + X5AB + E) models can be evolved by carrying out multiple 
regression analysis of the data and F statistics to identify statistically 
significant terms. The reduced equation, an equation containing only 
statistically significant terms is then used for drawing contour plots to see the 
influence of selected variables when changing from low to high level. The non 
linear quadratic model generated by the design in the form(18) 
Y = X0 + X1A + X2B + X3A2 + X4B2 + X5AB + E                        [6.1] 
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Where, Y is the measured response associated with each factor level 
combination: X0 is an intercept: X1 - X5 are the regression coefficient: A, B are 
the factor studied and E is the associated error term. The independent factors 
used in the design are listed in Table 6.3 and Table 6.4 shows applied 32
Independent variables 
 full 
factorial design. 
 
Table 6.3: Variables and their levels in full factorial design 
Levels 
Low Medium High 
A=molar ratio of 
Span 40/60:cholesterol 
2:1 1:1 1:2 
B=amount of PEO 0 5 10 
Transformed values -1 0 1 
   Dependent variables 
         Y1 = Percentage drug entrapment (PDE) 
         Y2 = Vesicle size (MVD) 
 
Table 6.4: A 32 Full factorial design layout of betaxolol niosomes 
Run 
Factor A 
molar ratio of 
Surfactant:cholesterol  
Factor B 
Amount of PEO (mg) 
Coded Actual Coded    Actual 
1 -1 2:1 -1 0 
2 -1 2:1 0 5 
3 -1 2:1 1 10 
4 0 1:1 -1 0 
5 0 1:1 0 5 
6 0 1:1 1 10 
7 1 1:2 -1 0 
8 1 1:2 0 5 
9 1 1:2 1 10 
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6.2.3 Preparation of niosomes by thin film hydration method 
Niosomes were prepared by thin film hydration method as reported earlier.(19)
Sedimentation, flocculation and turbidity were visually observed and reported 
as degrees of sedimentation using the criteria used by junyapraset
 
Span 60/tween 60 and cholesterol in different molar ratios of 1:2, 1:1, and 2:1 
were dissolved in 10 mL of chloroform in a round bottom flask to get 1.5 mmol 
of lipid concentration. The flask was then attached to a rotary flash evaporator 
(EIE-R, Ahmedabad, India) and the temperature of water bath was maintained 
at 60 °C. The flask was rotated at 150 rpm for 2 h. The combination of heat 
and vacuum evaporated chloroform and resulted in the formation of a thin 
film. The film was kept overnight in vacuum desiccator for the removal of 
traces of chloroform. Accurately weighed, 100 mg of betaxolol hydrochloride 
was dissolved in 10 mL of phosphate-buffered saline solution (PBS, pH 7.4) 
and sterilized through 0.22 μm membrane filter. The drug solution was added 
to the flask containing the film and was rotated at 150 rpm for another 1 h to 
peel off the surfactant/cholesterol film. The hydration of film led to the 
formation of vesicles.  
The niosomal suspension was left to mature overnight at 4 °C. For sterility, all 
the above mentioned steps were done under aseptic conditions. All 
glasswares were sterilized by autoclaving (121 °C for 15 min), phosphate 
buffered saline was passed through a 0.22 μm membrane filter, and the entire 
procedure was carried out in a laminar flow hood (Esco, Singapore). 
Formulations were sonicated three times in a bath-sonicator (Spincotech, 
India) for 2 min with 5-min interval between successive times.  
The formulation was lyophilized at a surfactant:cryoprotectant (sucrose) ratio 
of 1:2.5 after standard pre-freezing at −20 °C. 
 
6.3 Evaluation and statistical analysis 
6.3.1 Appearance and morphology 
6.3.1.1 Visual observation 
(20). The 
experiment was performed in triplicate. 
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6.3.1.2 Optical microscopy 
The size and shape of vesicles in nonsonicated formulations were observed 
by optical microscopy(19)
Morphology analysis of niosomes was carried out using transmission electron 
microscopy. A drop of the niosome colloidal suspension was placed onto a 
carbon-coated copper grid and left for 1 min thus allowing niosomes to adhere 
to the grid. The excess of the niosome suspension was then drawn off by a 
piece of filter paper. A drop of negative stain solution, 1% (w/v) 
phosphotungstic acid solution, was placed on the carbon grid thus staining the 
niosomes. After 3 min, the excess staining agent was removed by adsorbing 
the drop with the tip of a filter paper and the sample was then air-dried. The 
grid was allowed to air dry thoroughly and then examined using a 
transmission electron microscope
 using a calibrated eyepiece micrometer, and 
photographs were taken at ×400 magnification with a digital camera 
(Olympus, 8.1 megapixel, Tokyo, Japan). A small droplet of the vesicle 
suspension was placed on a glass microscope slide, diluted with a few drops 
of distilled water and covered with a glass cover slip. The samples were 
examined for vesicle formation, crystal formation and vesicular size and 
shape. 
6.3.1.3 Characterization of sonicated vesicles by transmission electron 
microscopy (TEM) 
(11)
Betaxolol niosomal formulations were centrifuged at 15,700 rpm for 90 min at 
4 °C using centrifuge (Remi Cooling Centrifuge, Mumbai, India). 
Concentration of the free drug in the supernatant was determined by 
measuring absorbance at 274 nm with a UV spectrophotometer (Shimadzu, 
UV 1800 PC, Kyoto, Japan). The percentage of drug entrapment in niosomes 
was calculated
. 
6.3.2 Determination of un-entrapped and entrapped drug 
(21)
Percent drug entrapment was confirmed by lysing the niosomes. The vesicles 
were separated from the supernatant, washed with PBS solution (2×5 mL), 
and centrifuged for another hour. The drug entrapment efficiency of isolated 
. This process was repeated thrice to ensure that free drug 
was completely removed. %𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑒𝑒𝑒𝑒𝑒𝑒𝑑𝑑𝑒𝑒𝑝𝑝𝑝𝑝𝑒𝑒𝑒𝑒𝑒𝑒 = 𝑒𝑒𝑡𝑡𝑒𝑒𝑒𝑒𝑡𝑡 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 − 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑖𝑖𝑒𝑒 𝑠𝑠𝑑𝑑𝑝𝑝𝑒𝑒𝑑𝑑𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
𝑒𝑒𝑡𝑡𝑒𝑒𝑒𝑒𝑡𝑡 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 × 100                [6.2]  
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vesicles was determined by a slight modification of the technique reported 
earlier(19)
The viscosity of all formulations was determined by Brookfield viscometer 
(Model DV-II+Pro, Middleboro, USA) at 25 °C
. The amount of entrapped drug was estimated by lysis of the 
vesicles. Few drops of chloroform were added to the centrifuge tube to disrupt 
the isolated vesicles. Certain volume of PBS solution was added to extract the 
entrapped drug. Simultaneously, the tube was maintained at a temperature of 
60 °C to evaporate the organic solvent. The PBS solution containing 
entrapped drug was filtered and analyzed for drug content with a 
spectrophotometer. The drug entrapment efficiency was calculated by the 
following equation:  Entrapment efficiency (%) = amount of drug entrapped(mg)amount of drug added(mg) × 100             [6.3] 
6.3.3 pH measurement 
The pH of niosomes was measured by a pH meter (Accumet® basic model 
AB15, Fisher Scientific, Pennsylvania, USA). The pH measurement was 
performed at 25 °C. 
6.3.4 Viscosity measurement  
(22)
The z-average diameter of sonicated vesicles was determined by dynamic 
light scattering
. The spindle CPE 41 was 
rotated at different angular velocity of 2 rpm. Each determination was carried 
out in triplicate. 
6.3.5 Zeta potential measurement 
Zeta potential of suitably diluted niosome dispersion was determined using 
zeta potential analyzer based on electrophoretic light scattering and laser 
Doppler velocimetry method using Zetasizer (Malvern instruments). The 
temperature was set at 25 °C. Charge on vesicles and their mean zeta 
potential values with standard deviation of 5 measurements were obtained 
directly from the measurement. 
6.3.6 Particle size measurement 
(23)
 
 using a Zetasizer. For the measurement, 100 μl of the 
formulation was diluted with an appropriate volume of PBS, pH 7.4 and the 
vesicle diameter and polydispersity index were determined. The measurement 
was taken repeated 3 times for each sample. 
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6.3.7 In vitro drug release study (24)
Results were the mean values of three runs. The mechanism of drug release 
from niosomal formulations was determined using the following mathematical 
models: zero-order kinetics, first-order kinetics, Higuchi kinetics, and the 
Korsmeyer-Peppas model
 
We fabricated an open flow through assembly, simulating the condition of the 
ocular cavity, by using the classical standard cylindrical tube which has the 
diameter of 15 mm. Dialysis membrane (Dialysis membrane 110, mw cut-off 
12000-14000, Hi Media, India), immersed in water for 1 h to remove the 
preservatives followed by rinsing in phosphate buffered saline (PBS) solution, 
acted as corneal epithelium, was tied to one end of open cylinder which acted 
as donor compartment. Niosomes containing entrapped betaxolol obtained 
after centrifugation of 2 mL of the formulation were resuspended in 1 mL of 
PBS (pH 7.4), and used for the release study.  The niosome preparation or 
free betaxolol solution was placed inside this compartment. Then, the glass 
tube was suspended in the dissolution flask of a USP dissolution apparatus 
such that entire surface of the membrane was in contact with the receptor 
compartment containing 250 mL of STF (pH 7.4). The content of the receptor 
compartment was stirred continuously at 25 rpm. Samples of 1 mL were 
withdrawn from the receptor compartment at periodic intervals and replaced 
by equal volume of fresh solution. The samples were analyzed 
spectrophotometrically at 274 nm against reference standard using STF as 
blank. 
(25-27)
 Entrapment efficiency (PDE) 
.  
6.3.8 Statistical analysis 
The selected responses obtained from the various systems were tested for 
significant differences. Statistical analysis of data was carried out using 
analysis of variance (ANOVA). The individual response was evaluated using 
F-test and F value and P value were generated. The statistical analysis was 
conducted using Design-Expert® version 8.0.2 trial (Stat-Ease, Inc., 
Minneapolis MN). 
The following responses were selected for statistical analysis 
 Vesicle Size (MVD) 
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6.3.9 Physical state of drug 
6.3.9.1 Differential scanning calorimetry (DSC) analysis 
DSC thermograms of pure drug and drug loaded niosomes were recorded 
using DSC 1/700 (Mettler Toledo, Germany) in an inert atmosphere of 
nitrogen (150 mL/min). The analysis was performed with a heating range of -
25 oC to 250 °C and at a rate of 10°C per minute. The sample weight was 
approximately 6 mg. 
6.3.9.2 X-Ray diffraction analysis 
X-Ray diffraction (XRD) patterns of pure betaxolol and ocular film were 
recorded using a powder X-Ray diffractometer (XRD-D8 Advance, Bruker, 
Germany) over the interval 0-40° 2θ-1. The experimental conditions were: 
generator tension (voltage) of 38 kV, generator current of 34 mA, scan step 
time of 30.6 sec-1 and scan step size of 0.049° 2θ-1
6.3.10 Sterility testing 
. 
(28)
a) ATGM was used to detect the growth of aerobic and anaerobic bacteria. 
7.25 gms of readymade ATGM was dissolved in 250 mL of purified water 
and the pH was adjusted to 7.1±0.2 with 1M NaOH. This was sterilized in 
an autoclave at 115 
 
Sterility is one of the most vital requirements for an ophthalmic preparation. 
The tests for sterility are intended for detecting the presence of viable forms of 
microorganisms in ophthalmic preparations. The principle governing these 
tests is that if the microorganisms are placed in a medium which provides 
nutritive material and water, kept at a favourable temperature, the organisms 
will grow and their presence can be indicated by turbidity in the originally clear 
medium. In the present study, two media namely, alternate thioglycolate 
medium (ATGM) and soyabean-casein digest medium (SBCD) were used to 
investigate the presence/absence of aerobic, anaerobic bacteria and fungi, in 
the formulated sterilized ocular inserts. 
6.3.10.1 Preparation of culture medium 
o
b) SBCD medium was used to detect the growth of aerobic bacteria and fungi. 
7.25 gms of readymade SBCD was dissolved in 250 mL of purified water 
and the pH was adjusted to 7.1±0.2 with 1M NaOH. This was sterilized in 
C for 30 min. The medium was freshly prepared and 
allowed to cool just prior to use.  
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an autoclave at 115 o
6.3.10.2 Test procedure 
Direct inoculation method was used. Here specified amount of niosome 
suspension was mixed with both medium and incubated. Simultaneously, 
positive and negative controls were also prepared and all the three tubes 
were incubated at specified temperatures. 
6.3.11 In vivo studies 
New Zealand rabbits of either sex weighing 2.5 to 3.1 kg were used for in vivo 
studies. The rabbits were housed singly in restraining cages during the 
experiment and allowed food and water ad libitum. Free lag and eye 
movement was allowed. The animals were housed at controlled temperature 
(25±2 °C), and humidity (60±5%), with a 12/12-h light-dark cycle. Institutional 
Animal Ethics Committee (IAEC) (Registration no. 1338/c/CPCSEA) approved 
the pharmacodynamic study. The animal experiment was conducted in full 
compliance with local, national, ethical, and regulatory principles and local 
licensing regulations, as per the spirit of ethics committee. 
C for 30 min. The medium was freshly prepared and 
allowed to cool just prior to use. 
6.3.11.1 Ocular safety study
 
 (29, 30) 
The ocular safety of administered delivery system can be tested based on the 
Draize Irritancy Test (as discussed in section 5.4.7.3). The observations 
based on scoring approach were used to establish the safety of the developed 
ocular inserts in rabbit eye. Three healthy albino rabbits (2.7–2.9 kg) were 
selected to evaluate the ocular safety of the optimized niosomal formulations. 
For feeding, conventional laboratory diets were used with an unrestricted 
supply of drinking water. A single dose of 100-μL niosomal formulation was 
instilled into the conjunctival sac of left eye of each animal (initially to one 
animal) and the untreated eye served as a control. Each of the animals was 
observed visually with a slit lamp for the severity of ocular reactions such as 
corneal ulceration, iritis, conjunctival redness, and conjunctival edema at 
various intervals of 1, 24, 48, and 72 hr. The animal experiment was 
conducted in full compliance with local, national, ethical, and regulatory 
principles and local licensing regulations, as per the spirit of ethics committee. 
This study was approved by IAEC (Registration no. 1338/c/CPCSEA). 
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6.3.11.2 In vivo anti-glaucoma activity evaluation 
i) Steroid induced model
(31, 32) 
Eyes of the 12 rabbits were treated 3 times daily by 0.5% dexamethasone eye 
drops for 2 weeks. Dexamethasone sodium phosphate (Taj Pharmaceuticals 
Ltd., Mumbai) was dissolved in phosphate buffer to a final concentration of 0.5 
% at pH 7.4. The intraocular pressure was measured at noon twice a week by 
Schiotz tonometer. 
 (33) 
ii) Antiglaucoma activity measurement on rabbit 
The optimized vesicular formulation was tested for its intraocular pressure 
lowering activity on albino rabbits (2.5–3.1 kg) and the results were compared 
to that of a marketed betaxolol solution (0.5%). The dispersions of niosomes, 
NS5 and NT6 were adjusted to a concentration of 0.5% betaxolol. The 
animals were divided into three groups (n=4). Group I received formulation 
NS5, Group II administered with formulation NT6 and Group III was treated 
with the marketed eye drops formulation. The IOP was measured at different 
intervals with a standardized tonometer (ShiØtz, Germany). A single 50-μl 
dose of 0.5% betaxolol preparation was instilled onto the corneal surface of 
rabbit’s left eye; (32) then after 30 min, and subsequently every 1 h interval, the 
IOP was measured for a period up to 24 hr. The right eye was left as a control 
in all the experimental animals. The ocular pressure lowering activity was 
expressed similarly to that reported by Winum and his associates 34( )
6.3.12 Ageing Study
 as the 
average difference in IOP between the treated and control eye. 
The prepared formulations were tested for stability by storing them at 4±1 °C, 
RT and at 40±2 °C. Formulations were assessed for vesicular fusion, pH 
variation, sterility testing, vesicles size and shape and number of vesicles per 
cubic millimeter before and after storage for 180 days. Residual drug content 
was also assessed every 60th day. Size of the vesicular systems was 
determined by dynamic light scattering method. The shape of the vesicle was 
observed under light microscope. The number of vesicles per cubic millimeter 
was calculated by method described elsewhere 
 (20) 
(35) using a hemocytometer by 
applying the following formula.  Number of niosomes per mm3 = Total number of niosomes × dilution × 400Total number of small squares counted                   [6.4] 
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6.4 Results and discussion 
In the present study niosomes of Betaxolol HCl were prepared using 
surfactants (Span 60 and Tween 60). A 32
 
Figure 6.1: IR Spectra of (A) Betaxolol HCL (B) Mixture of 
BX/span60/tween60/cholesterol 
 
Interpretation of IR spectrum of Betaxolol (Figure 6.1A) shows characteristic 
peaks at 3237 cm
 full factorial design was employed 
and so nine formulations were obtained for each surfactant. Niosomes were 
evaluated for their use as ocular delivery systems with a view to obtain 
sustained release. 
 
6.4.1 Drug-excipients compatibility study 
 
-1 (hydroxyl group O-H stretching), 2928 cm-1 (methyl C-H 
stretching), 2858 cm-1 (methylene C-H stretching), 1612 cm-1 (aromatic ring 
C=C-C stretching ), 1557 cm-1 and 1513 cm-1 (secondary amine N-H 
bending), 1474 cm-1 (methylene C-H bending ), 1376 cm-1 (methyl C-H sym. 
bending ), 1246 cm-1 (alkyl aryl ether c-o-c stretching), 1179 cm-1 (aromatic in 
plane C-H bending), 1087 cm-1 (aliphatic ether c-o-c stretching) and 1050 
(amine C-N stretching). FTIR spectrum of mixture (Figure 6.1B), in 
comparison to IR spectrum of pure drug, shows no substantial shifting of the 
position of the functional groups, indicating no major interaction between drug 
and polymers.  
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6.4.2 Appearance and morphology 
All niosomes appeared as translucent white dispersions without 
sedimentation, indicating that the niosomes were physically stable due to 
small and uniform vesicle sizes obtained after the sonication process. The 
formulations with an addition of the membrane additive-PEO were more turbid 
and whitish. 
The photomicrographs (×40) of betaxolol hydrochloride niosomes before 
sonication are shown in Figures 6.2a, 6.2b and 6.2c. Niosomes were 
spherical large unilamellar vesicles. It is also clear that the vesicles containing 
more amount of PEO are larger in size than those having fewer amounts or 
no PEO indicating that inclusion of PEO may have increased the internal 
space of niosomes, which is coherent to the entrapment efficiency results.  
 
 
  
 
Figure 6.2: Photomicrographs of Betaxolol niosomes before sonication 
(a) without PEO-NS4 (b) with 5 mg PEO-NS5 (c) with 10 mg PEO-NS6  
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Similar results were observed in other formulations (data not shown). Under 
the optical microscope, aggregation/fusion of the vesicles could be 
occasionally observed before size reduction as depicted in Figure 6.2. After 
sonication process, nonaggregated niosomes were obtained. Unfortunately, 
information concerning microstructure of niosomes could not be visualized by 
the low magnification power of optical microscope (lower of detection ∼200 
nm); therefore TEM was employed to elucidate niosome morphology. 
Negative stain transmission electron micrographs of betaxolol niosomes (NS4 
and NS5) are shown in Figure 6.3a and 6.3b respectively. It is demonstrated 
that the vesicles are well identified and present in a nearly perfect sphere-like 
shape having a large internal aqueous space. 
  
 
Figure 6.3: TEM images of (a) Niosome NS4 (b) Niosome NS5 
 
Moreover, by comparison of both the structures, it could be concluded that 
NS4 niosomes has less internal aqueous volume than NS5 and the structure 
of NS4 is like polygonal/irregular while that of NS5 is like perfect sphere. 
Aggregation was seen in NS4 niosomes while NS5 niosomes remained as 
separate entity. This may be attributed to the addition of small amount of PEO 
which acted as membrane stabilizer with probable mechanism of steric 
hindrance. 
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6.4.3 Optimization (PDE and MVD) 
The vesicles were characterized for drug entrapment efficiency, size, zeta 
potential and polydispersity index. 
It was observed that increase in surfactant/cholesterol ratio from 2:1 to 1:1 
increased the drug entrapment efficiency from 36.21% (NT1) to 43.84% (NT4) 
in case of tween niosomes; however, above the ratio of 1:1, the drug 
entrapment efficiency of the vesicles decreased to 33.52% for NT7 (Table 
6.5). Similar results were observed in case of span niosomes also. Such 
differences in drug entrapment efficiencies as well as drug content were found 
to be statistically significant (p<0.05). Guinedi and his co-workers(36) reported 
that an increase in span 60/ cholesterol ratio from 7:4 to 7:6 increased 
acetazolamide entrapment efficiency from 21.48% to 32.21%; however, the 
same was decreased to 21.36% with further increase in Span 60/cholesterol 
ratio to 7:7. However, cholesterol content beyond a certain extent starts 
disrupting the regular bilayer structure leading to lower drug entrapment 
efficiency 37( )
Batch 
Code 
. 
 
Table 6.5: Characterization of span60 niosomes of betaxolol 
A B PDE±SD* 
Vesicle size 
Zeta 
potential PDI Before SC(µm) 
After 
SC(nm)* 
NS1 2:1 0 30.12±0.36 <2 43.21±1.21 -33.1±0.3 0.411 
NS2 2:1 5 36.64±1.02 3.2 102.7±2.62 -24.7±0.7 0.254 
NS3 2:1 10 34.82±0.52 3.4 117.27±1.38 -17.8±0.3 0.268 
NS4 1:1 0 38.42±1.62 <2 60.84±1.48 -34.9±1.2 0.428 
NS5 1:1 5 51.64±1.14 3.6 124.21±3.21 -21.2±0.8 0.385 
NS6 1:1 10 48.63±0.73 3.7 134.82±0.98 -18.8±0.6 0.208 
NS7 1:2 0 29.24±1.53 <2 49.32±0.84 -31.6±1.1 0.276 
NS8 1:2 5 37.54±0.68 <2 108.65±1.25 -20.4±0.4 0.218 
NS9 1:2 10 36.64±2.15 3.12 118.87±1.15 -16.5±0.8 0.352 
* Average ± SD of three determinations has been reported 
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Table 6.6: Characterization of tween60 niosomes of betaxolol 
Batch 
Code A 
 
B PDE±SD* 
Vesicle size 
Zeta 
potential PDI Before SC(µm) 
After 
SC(nm)* 
NT1 2:1 0 36.21±0.48 <2 68.65±0.84 -35.3±1.3 0.398 
NT2 2:1 5 48.42±1.24 3.3 92.38±2.38 -24.2±1.1 0.224 
NT3 2:1 10 47.94±0.84 3.2 115.87±2.78 -13.6±0.6 0.262 
NT4 1:1 0 43.84±2.12 <2 77.37±1.83 -39.2±0.8 0.408 
NT5 1:1 5 57.28±1.82 3.5 108.57±2.34 -26.4±1.2 0.415 
NT6 1:1 10 58.48±0.75 3.7 121.96±2.38 -15.7±0.5 0.213 
NT7 1:2 0 33.52±2.15 <2 66.82±1.24 -29.6±1.4 0.292 
NT8 1:2 5 42.63±0.38 <2 95.52±2.35 -19.2±0.8 0.253 
NT9 1:2 10 41.97±1.12 3.2 118.21±3.15 -14.1±1.1 0.418 
* Average ± SD of three determinations has been reported 
 
Maximum and minimum PDE observed in niosomes were 29.24% and 
51.64% in span niosomes and 58.58% and 33.52% in tween niosomes 
respectively. This shows wide variation, which indicates that dependent 
variable is strongly affected by the independent variables selected for the 
study which was further confirmed by statistical optimisation using ANOVA. 
6.4.4 Statistical analysis 
6.4.4.1 ANOVA for percentile drug entrapment of span 60 niosomes 
ANOVA for response surface quadratic model was generated by software. 
Below is the ANOVA table for PDE of niosomes of Span 60. 
The Model F-value of 22.01 implies the model is significant.  There is only 
a 1.43% chance that a "Model F-Value" this large could occur due to noise. 
Values of "Prob > F" less than 0.05 indicate model terms are significant.   
In this case B, A2, B2 are significant model terms.   
Values greater than 0.1000 indicate the model terms are not significant.The 
polynomial equation derived from the coefficients of estimate in term of coded 
factor is  
PDE = 49.98 – 0.31A + 3.72B - 0.67AB - 12.07A2 - 5.63B2
The value of correlation coefficient R
             [6.5] 
2 = 0.9735 indicating  the good fit of the 
model. 
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Table 6.7: Result of ANOVA for measured response PDE of span 
niosomes 
Source Sum of squares df 
Mean 
square 
F 
value 
p-value 
Prob > 
F 
Full Model 439.93 5 87.99 22.01 0.0143 
A-Span 60: 
cholesterol Molar  
Ratio 
0.57 1       0.57 
 
0.14 
 
0.7307 
B-Amount of PEO 83.03 1 83.03 20.77 0.0198 
AB 1.81 1 1.81 0.45 0.5493 
A2 291.13 1 291.13 72.84 0.0034 
B2 63.39 1 63.39 15.86 0.0283 
Residual 11.99 3 4.00   
Cor Total 451.92 8    
Reduced Model 437.55 3 145.85 50.75 0.0004 
B-Amount of PEO 83.03 1 83.03 28.89 0.0030 
A2 291.13 1 291.13 101.30 0.0002 
B2 63.39 1 63.39 22.06 0.0054 
Residual 14.37 5 2.87   
Cor Total 451.92 8    
 
Equation 6.5 represents the effects of individual and combined variables on 
PDE of betaxolol niosomes. Small values of coefficients of A and AB (having 
p >0.05) in equation 6.5  are regarded as the least contributing factors in the 
entrapment of betaxolol in the niosomes. Positive value of B factor indicates 
that entrapment of drug increases with increase in the PEO amount. Negative 
signs of coefficients of A terms indicate low to medium level of cholesterol 
favors the increased PDE of BX niosomes. When the coefficient values of two 
independent key variables (A and B) compared, the value of variable B (3.72) 
was found to be maximum and hence amount of PEO was considered to be a 
major contributing variables for PDE of BX niosomes. 
Prob > F less than 0.05 indicate that surfactant:cholesterol ratio and amount 
of PEO has significant effect on entrapment efficiency of Betaxolol HCl. 
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Following graph (Figure 6.4) shows the effect of significant interaction terms 
on PDE.  
                              
  
Figure 6.4: Effect of (a) amount of PEO and (b) span60:cholesterol ratio 
on PDE of betaxolol niosomes 
 
The relationship between the dependent and independent variables was 
further elucidated using contour and response surface plots (Figure 6.5). 
Response surface 3D plot shows that as amount of polymer increased, PDE 
was increased. This may probably be due to increased internal aqueous 
volume with high amt of polymer. 
                               
   
Figure 6.5: (a) Response surface plot (3D) and (b) Contour plot showing 
the effect of molar ratio of span60: cholesterol and amount of PEO on 
the percentage drug entrapment (PDE) 
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Same observations were also indicated by counter plot. Contour plot shows 
that at medium span60: cholesterol ratio, amount of PEO has more significant 
effect compared to low level and high level of ratio. It also shows that 
increasing ratio level has significant effect on PDE at high amount of PEO. It 
is well known that increase in cholesterol content in vesicles increases the 
entrapment of drug by increasing the rigidity of the membrane and hence 
reducing the leakage of the drug from it. 
6.4.4.2 ANOVA for percentile drug entrapment (PDE) of tween 60 
niosomes 
ANOVA for response surface quadratic model was generated by software. 
Below is the ANOVA table for PDE. 
Table 6.8: Result of ANOVA for response PDE of tween niosomes 
Source Sum of Squares df 
Mean 
Square 
F 
Value 
p-value 
Prob > F 
Full Model 567.21 5 113.44 44.06 0.0052 
A-Tween 60: 
cholesterol Molar  
Ratio 
34.80 1       34.80 13.52 0.0348 
B-Amount of PEO 202.07 1 202.07 78.48 0.0030 
AB        2.69 1 2.69 1.04 0.3820 
A2 260.76 1 260.76 101.27 0.0021 
B2 66.89 1 66.89 25.98 0.0146 
Residual 7.72 3 2.57   
C or Total 574.94 8    
Reduced Model 564.52 4 141.13 54.21 0.0010 
A-Tween 60: 
cholesterol Molar  
Ratio 
34.80 1       34.80 13.37 0.0217 
B-Amount of PEO 202.07 1 202.07 77.61 0.0009 
A2 260.76 1 260.76 100.15 0.0006 
B2 66.89 1 66.89 25.69 0.0071 
Residual 10.41 4 2.60   
C or Total 574.94 8    
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The Model F-value of 44.06 implies the model is significant. There is only 
a 0.52% chance that a "Model F-Value" this large could occur due to noise. 
Values of "Prob > F" less than 0.05 indicate model terms are significant.   
In this case A, B, A2, B2 are significant model terms.   
Values greater than 0.1000 indicate the model terms are not significant.The 
polynomial equation derived from the coefficients of estimate in term of coded 
factor is  
PDE = 57.06 - 2.41A + 5.80B - 0.82AB - 11.42A2 - 5.78B2              [6.6] 
PDE = 57.06 - 2.41A + 5.80B - 11.42A2 - 5.78B2                    [6.7] 
The values of correlation coefficient R2
  
 = 0.9866 for full model and 0.9836 for 
reduced model indicate the good fit of the model. Equation 6.6 represents the 
effects of individual and combined variables on PDE of betaxolol niosomes. 
Small values of coefficients of AB (having p >0.05) in equation 6.6 are 
regarded as the least contributing factors in the entrapment of betaxolol in the 
niosomes. Positive value of B factor indicates that entrapment of drug 
increases with increase in the PEO amount. Negative signs of coefficient of A 
term indicate low to medium level of cholesterol favors the increased PDE of 
BX niosomes. When the coefficient values of two independent key variables 
(A and B) compared, the value of variable B (5.80) was found to be maximum 
and hence amount of PEO was considered to be a major contributing 
variables for PDE of BX niosomes. 
 
Figure 6.6: Effect of (a) amount of PEO and (b) tween60:cholesterol ratio 
on PDE of betaxolol niosomes 
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Prob > F less than 0.05 indicate that surfactant:cholesterol ratio and amount 
of PEO has significant effect on entrapment efficiency of Betaxolol HCl. The 
graph (Figure 6.6) shows the effect of significant interaction terms on PDE.  
The relationship between the dependent and independent variables was 
further elucidated using contour and response surface plots (Figure 6.7). 
Response surface 3D plot shows that as amount of polymer increased, PDE 
was increased. This may probably be due to increased internal aqueous 
volume with high amt of polymer. Same observations were also indicated by 
counter plot. Contour plot shows that at medium span60: cholesterol ratio, 
amount of PEO has more significant effect compared to low level and high 
level of ratio. It also shows that increasing ratio level has significant effect on 
PDE at high amount of PEO. It is well known that increase in cholesterol 
content in vesicles increases the entrapment of drug by increasing the rigidity 
of the membrane and hence reducing the leakage of the drug from it.              
                
   
Figure 6.7: (a) Response surface plot (3D) and (b) Contour plot showing 
the effect of molar ratio of tween60: cholesterol and amount of PEO on 
the percentage drug entrapment (PDE) 
 
 
 
 
 
Chapter 6 Preparation and characterization of betaxolol niosomes 
 
Hitesh B. Gevariya        174                                                   Ph. D. Thesis 
 
6.4.4.3 ANOVA for mean volume diameter (MVD) of span 60 niosomes  
ANOVA for response surface quadratic model was generated by software. 
Below is the ANOVA table for MVD. 
 
Table 6.9: Result of ANOVA for response MVD of span niosomes 
Source Sum of squares df 
Mean 
square 
F 
Value 
p-value 
Prob > F 
Model 9676.61 5 1935.32 865.64 < 0.0001 
   A-Span60:chol ratio  31.10 1 31.10 13.91 0.0336 
B- Amount of   PEO 7890.90 1 7890.90 3529.49 < 0.0001 
AB 5.09 1 5.09 2.27 0.2286 
A2 552.45 1 552.45 247.10 0.0006 
B2 1197.07 1 1197.07 535.43 0.0002 
Residual 6.71 3 2.24   
Cor Total 9683.31   8    
  
The Model F-value of 865.64 implies the model is significant.  There is only 
a 0.01% chance that a “Model F-Value” this large could occur due to noise. 
Values of “Prob > F” less than 0.05 indicate model terms are significant.   
In this case A, B, A2, B2 are significant model terms.   
Values greater than 0.1000 indicate the model terms are not significant.   
The polynomial equation derived from the coefficients of estimate in term of 
coded factor is:  
MVD  = 122.93 + 2.28 A + 36.26B – 1.13AB – 16.62 A2- 24.46B2          [6.8] 
The value of correlation coefficient R2
Equation 6.8 represents the effects of individual and combined variables on 
PDE of betaxolol niosomes. Small values of coefficients of AB (having p 
>0.05) in equation 6.8 are regarded as the least contributing factor affectind 
MVD. Positive value of A and B factor indicates that vesicle size increases 
with increase in the the cholesterol as well as PEO amount. When the 
coefficient values of two independent key variables (A and B) compared, the 
value of variable B (36.26) was found to be maximum and hence amount of 
 = 0. 0.9993 indicating  the good fit of 
the model. 
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PEO was considered to be a major contributing variables for vesicle size of 
BX niosomes (Figure 6.8). 
 
 
Figure 6.8: Effect of (a) amount of PEO and (b) span60:cholesterol ratio 
on MVD of betaxolol niosomes 
 
Prob > F less than 0.05 indicate that surfactant:cholesterol ratio and amount 
of PEO has significant effect on entrapment efficiency of Betaxolol HCl. The 
graph (Figure 6.8) shows the effect of significant interaction terms on PDE.  
The relationship between the dependent and independent variables was 
further elucidated using contour and response surface plots (Figure 6.9. 
Response surface 3D plot shows that as amount of polymer increased, MVD 
was increased. This may probably be due to increased internal aqueous 
volume with entrapment of high amt of polymer and drug. Same observations 
were also indicated by counter plot. Contour plot shows that at medium 
span60: cholesterol ratio, amount of PEO has more significant effect 
compared to low level and high level of ratio. It also shows that increasing 
ratio level has significant effect on PDE at high amount of PEO. It is well 
known that increase in cholesterol content in vesicles increases the 
entrapment of drug by increasing the rigidity of the membrane and hence 
reducing the leakage of the drug from it. 
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Kapadia et al.(38)
 
Figure 6.9: (a) Response surface plot (3D) and (b) Contour plot showing 
the effect of span60:cholesterol ratio and amount of PEO on the MVD 
 
 reported that increase in Span 60/cholesterol ratio from 7:4 
to 7:6 increased the size of acyclovir-loaded vesicles from 3.69 to 3.76 μm; 
however at ratio of 7:7, the same was found to decrease to 3.73 μm.  
 
In this study, we noticed that the size of nanovesicles was gradually increased 
with the increase in cholesterol content. It has long been realized that 
incorporation of more cholesterol into the vesicles would yield larger particles 
because of the reduction in fluidity of the bilayer. This would enhance the 
rigidity of bilayer membrane above the phase transition temperature, resulting 
in an increased elastic modulus, which inhibited curving of the bilayer(39, 40). 
The larger size may also contribute to the higher drug entrapment efficiency of 
the vesicles 36( , 41)
The Model F-value of 64.06 implies the model is significant.  There is only 
a 0.30% chance that a “Model F-Value” this large could occur due to noise. 
Values of “Prob > F” less than 0.05 indicate model terms are significant.   
In this case B and A2 are significant model terms.   
Values greater than 0.1000 indicate the model terms are not significant.   
. 
6.4.4.4 ANOVA for mean volume diameter (MVD) of tween 60 niosomes 
ANOVA for response surface quadratic model was generated by software. 
Below is the ANOVA table for MVD. 
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Table 6.10: Result of ANOVA for response MVD of tween niosomes 
Source 
Sum of 
squares 
df 
Mean 
square 
F 
Value 
p-value 
Prob > F 
Model 3645.59 5 729.12 64.06 0.0030 
   A-Tween60:chol 
ratio  
2.22 1 2.22 0.20 0.6886 
B- Amount of   PEO 3417.71 1 3417.71 300.27 0.0004 
AB 435 1 4.35 0.38 0.5803 
A2 189.15 1 189.15 16.62 0.0266 
B2 32.16 1 32.16 2.83 0.1914 
Residual 34.15 3 11.38   
Cor Total 3679.73 8    
  
The polynomial equation derived from the coefficients of estimate in term of 
coded factor is:  
MVD  = 105.31 + 0.61 A + 23.87B + 1.04AB – 9.73 A2- 4.01B2        [6.9] 
The value of correlation coefficient R2 = 0.9907 indicating  the good fit of the 
model. 
Equation 6.9 represents the effects of individual and combined variables on 
MVD of betaxolol niosomes. Small values of coefficients of A, AB and B2 
(having p >0.05) in equation 6.9 are regarded as the least contributing factor 
affecting MVD. Positive value of A and B factor indicates that vesicle size 
increases with increase in the the cholesterol as well as PEO amount. When 
the coefficient values of two independent key variables (A and B) compared, 
the value of variable B (23.87) was found to be maximum and hence amount 
of PEO was considered to be a major contributing variables for vesicle size of 
BX niosomes (Figure 6.10). 
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Figure 6.10: Effect of (a) amount of PEO and (b) tween60:cholesterol 
ratio on MVD of betaxolol niosomes 
 
Prob > F less than 0.05 indicate that surfactant:cholesterol ratio and amount 
of PEO has significant effect on entrapment efficiency of Betaxolol HCl. The 
graph (Figure 6.10) shows the effect of significant interaction terms on PDE.  
The relationship between the dependent and independent variables was 
further elucidated using contour and response surface plots (Figure 6.11). 
Response surface 3D plot shows that as amount of polymer increased, MVD 
was increased. This may probably be due to increased internal aqueous 
volume with entrapment of high amt of polymer and drug.  
 
 
Figure 6.11: (a) Response surface plot (3D) and (b) Contour plot showing 
the effect of tween60: cholesterol ratio and amount of PEO on the MVD 
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Same observations were also indicated by counter plot. Contour plot shows 
that at medium span60: cholesterol ratio, amount of PEO has more significant 
effect compared to low level and high level of ratio. It also shows that 
increasing ratio level has significant effect on PDE at high amount of PEO. It 
is well known that increase in cholesterol content in vesicles increases the 
entrapment of drug by increasing the rigidity of the membrane and hence 
reducing the leakage of the drug from it. 
6.4.4.5 Checkpoint analysis 
To validate the evolved mathematical models, two checkpoints were selected. 
From the contour plot, two sets of A and B were selected and two batches 
were prepared using the same procedure keeping the other process variables 
constant with the amounts of A and B at the selected checkpoint. The 
experiment was repeated three times and experimentally obtained mean PDE 
and MVD values were compared with predetermined (predicted) values 
(Table 6.11). Good correlation was found between observed and predicted 
values. When compared with the predicted PDE and MVD using students t-
test the differences were found to be insignificant (P>0.05). Hence, it might be 
concluded that the evolved model is valid for theoretical prediction of 
responses within the factor space. 
 
Table 6.11: Observed and predicted results of checkpoint batches of 
betaxolol niosomes 
Batch A B 
PDE MVD 
Observed Predicted Observed Predicted 
CS1 0 0.5 49.29 50.44 113.63 116.24 
CS2 1 -0.5 34.92 34.65 80.31 82.73 
CT1 0.5 0 51.49 53 101.20 103.18 
CT2 -0.5 0.5 57.73 56.87 115.83 112.51 
CS- span niosomes, CT-tween niosomes 
 
Considering above results, formulations NS5 and NT6 were selected as 
optimized formulations and subjected for further studies. 
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Polydispersity index is a parameter that gives an estimate of the width of 
distribution of the vesicles. The higher the polydispersity index, the wider is 
the size distribution. This parametric value was in the range of 0.208–0.428, 
and was found to follow bimodal intensity size distribution irrespective of the 
ratio of Span 60 and cholesterol. Cholesterol generally abolishes the gel to sol 
transition (42) resulting in vesicles that are less leaky 43( ). Increase in cholesterol 
content results in higher microviscosity which is indicative of more rigidity of 
vesicular lamella 16( )
Zeta potential values for span niosomes were within -16.5±0.8 and -34.9±1.2 
and for tween niosomes between -13.6±0.6 and -39.2±0.8. This high negative 
zera-potential is important in preventing aggregation. It has been reported that 
a physically stable nanosuspension solely stabilized by electrostatic repulsion 
will have a minimum zeta-potential of 30mV.
.  
(13)
The viscosity of ophthalmic solutions is often increased to prolong their 
retention in precorneal area because the rate of solution drainage decreases 
with increasing viscosity. Part of the viscous solution is also incorporated in 
the precorneal tear film and in the marginal tear strip
 The decrease in zeta potential 
after inclusion of PEO was due to the absorption of polyoxyethylene chain of 
PEO on the surface of the niosomes, leading to the shift of shear plane and 
subsequently reduction of zeta potential values. 
(44). It is also true that the 
products with a high viscosity are not well tolerated in the eye, causing 
lacrimation and blinking until the original viscosity of tear is regained. The 
drug diffusion from a viscous formulation into eye becomes difficult. Finally, 
the ocular administration is not so easy. A recent report indicated that the 
niosomal suspension having an optimal viscosity of 1.20 cps could prolong 
the ocular residence time, compared to solutions; and will not create 
lacrimation and blinking or blurred vision 45( )
 
. 
We examined that the dispersion of niosomes in a merely viscous PEO 
(0.05%) solution offer viscosity in the range of 0.42±0.02 and 2.19±0.08 cps 
(Table 6.12), respectively, with their increasing cholesterol and PEO content 
and therefore, the ocular niosomal formulation obtained at the intermediate 
ratio could be most suitable for ocular administration.  
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Table 6.12: pH and viscosity of betaxolol niosomes 
Batch 
Code 
pH 
n=3 
Viscosity 
(cps) 
n=3 
Batch 
Code 
pH 
n=3 
Viscosity 
(cps) 
n=3 
NS1 7.22±0.06 0.42±0.02 NT1 7.32±0.03 0.47±0.03 
NS2 7.26±0.12 1.19±0.05 NT2 7.36±0.15 1.11±0.08 
NS3 7.32±0.05 1.94±0.04 NT3 7.32±0.09 1.72±0.05 
NS4 7.18±0.09 0.49±0.04 NT4 7.28±0.11 0.48±0.04 
NS5 7.42±0.11 1.28±0.09 NT5 7.42±0.08 1.23±0.06 
NS6 7.38±0.14 2.12±0.05 NT6 7.38±0.09 2.02±0.07 
NS7 7.29±0.02 0.47±0.06 NT7 7.39±0.11 0.52±0.06 
NS8 7.46±0.16 1.29±0.11 NT8 7.41±0.12 1.36±0.03 
NS9 7.37±0.04 2.19±0.08 NT9 7.37±0.08 2.16±0.05 
 
The pH values of the prepared formulations varied between 7.18 to 7.46, 
indicating that the niosomal suspension did not have an irritation potential as 
the pH values are within the accepted ocular range(46). 
6.4.5 In vitro drug release 
In this study, niosomes of Betaxolol HCl was prepared using two different 
surfactants in varying ratio of surfactant to cholesterol with or without PEO. All 
formulation prepared were subjected to in vitro release study to ensure the 
effect of both the factors. The data obtained for in-vitro study were tabulated 
and represented graphically. 
Tables 6.13 and 6.14 and Figures 6.12 and 6.13 show percentage cumulative 
drug release profiles for all formulations of span60 i.e. NS1 to NS9 and 
tween60 i.e. NT1 to NT9 respectively. All the formulations showed sustain 
release of betaxolol as compared to betaxolol eye drops. Batch NS6 showed 
lowest release (37.14%) and NS1 showed faster release (76.89%) within 12 
hr. In case of tween niosomes NT7 showed faster release (79.98%) and NT6 
showed 50.62% release within 12 hr. 
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Table 6.13: In vitro drug release profiles of betaxolol niosomes of 
span60 
Time 
(h) 
Eye 
drops 
NS1 NS2 NS3 NS4 NS5 NS6 NS7 NS8 NS9 
1 22.14 9.43 7.21 5.43 6.74 5.46 2.16 4.78 3.14 3.52 
2 84.53 16.2 13.41 9.45 12.45 9.27 5.92 7.98 8.25 7.26 
4 100.03 26.36 22.84 17.72 21.35 17.45 9.25 16.84 15.76 14.27 
6  41.28 33.24 28.43 32.18 23.34 15.24 30.65 24.33 21.62 
8  52.34 44.34 39.44 41.82 32.65 22.67 41.54 35.98 30.34 
10  65.87 58.45 50.15 51.84 41.79 31.24 56.87 48.73 39.26 
12  76.89 67.42 62.12 62.14 50.08 37.14 65.8 59.16 47.18 
 
Table 6.14: In vitro drug release profiles of betaxolol niosomes of 
tween60 
Time 
(h) 
Eye 
drop 
NT1 NT2 NT3 NT4 NT5 NT6 NT7 NT8 NT9 
1 22.14 11.32 9.86 7.25 9.82 7.82 6.83 11.84 10.14 7.12 
2 84.53 19.54 15.25 12.24 17.26 14.35 9.16 20.14 17.28 13.18 
4 100.03 29.62 26.22 21.82 26.89 20.14 14.25 31.26 28.42 21.16 
6  42.18 37.88 30.46 37.12 27.32 20.64 43.14 38.26 31.84 
8  52.84 46.42 39.28 48.32 34.24 25.92 54.48 49.25 42.36 
10  66.72 56.28 47.28 56.46 42.73 33.25 65.24 58.82 50.22 
12  75.97 64.64 55.28 65.11 50.62 42.83 79.98 67.18 61.62 
 
Order of cumulative drug released was found in following manner 
NS1> NS2 > NS7 > NS4 > NS3 > NS8 > NS5 > NS9 > NS6 
NT7> NT1 > NT8 > NT4 > NT2 > NT9 > NT3 > NT5 > NT6 
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Figure 6.12: Drug release profiles of eye drop and span niosomes 
 
 
Figure 6.13: Drug release profiles of eye drop and tween niosomes 
 
It was observed that, as the proportion of cholesterol increases, the release of 
betaxolol from niosomes decreases. This may be due to the fact that 
cholesterol increases the rigidity of the bilayer of niosomes. It also abolished 
the gel to liquid phase transition and promoted the formation of a less ordered 
liquid-crystalline state as vesicles(47). This is a desirable feature as the 
leakage of content from the niosomes can be prevented 48( ). 
In vitro drug release data also revealed that the increase in amount of PEO 
decreased the release of the drug from niosomes. 
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The time-point approach (Q12h) was adopted to compare the drug release 
potential. The Q12h values (i.e., the % cummulative amount of drug released 
at the end of 12 h) were 76.89%, 62.14% and 65.8% for NS1, NS4 and NS7 
respectively, for the formulations with their increasing surfactant:cholesterol 
ratio (Table 6.13). A statistically significant difference was observed in their 
Q12h values and, hence, in their drug-release potential (p<0.05). As compared 
to eye drop release, the vesicles continued to liberate its content 
comparatively at a slower rate up to 12 hr. The formulation with 1:1 ratio of 
span 60 and cholesterol (NS6) exhibited slower and extended drug-release 
profile. The trend was followed by vesicular formulation of span 60 and 
cholesterol in the molar ratios of 2:1 and 1:2, respectively. Similar results were 
found in case of tween 60 niosomes. This is in good agreement with the fact 
that cholesterol causes a decrease in density of head groups at the interfaces 
of bilayer, and an increase in the package of phospholipid tails in the middle 
of bilayer, thereby reducing their permeability to encapsulated compound(49). 
Moreover, it is reported that cholesterol in phospholipid vesicular preparations 
could reduce the leakage of encapsulated material by decreasing the 
membrane fluidity 50( )
The kinetic modeling of drug-release profiles of tween60 vesicles have been 
represented in Table 6.16. It was revealed that the release kinetics of drug 
appeared to follow the mixed release kinetics of zero order (r2>0.9875) as 
well as Higuchi’s release kinetics (r2>0.9802). However, zero-order release 
kinetics predominated at the medium and higher ratio of surfactant to 
cholesterol (Table 6.16). On the other hand, the best fit with higher correlation 
was found with the Higuchi’s equation at low and high ratios, i.e., the drug 
release were proportional to square root of time, indicating that the drug 
release from vesicles was diffusion controlled. 
. However, cholesterol beyond 50% starts disrupting the 
vesicular membrane which serves as the reason for faster drug release from 
the vesicles.  
In case of formulations with span60, it was revealed that the release kinetics 
of drug appeared to follow zero order release kinetics (r2>0.9881) because 
high correlation coefficient was observed in the zero-order plot rather than 
Higuchi’s and first-order models (Table 6.15). This indicated that the drug 
release was independent on concentration of drug entrapped.  
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Table 6.15:  Kinetics modeling of release profile of span 60 niosomes 
containing betaxolol 
Release 
Kinetic 
NS1 NS2 NS3 NS4 NS5 NS6 NS7 NS8 NS9 
Zero 
order 
0.9987 0.9974 0.9965 0.9997 0.9971 0.9881 0.9934 0.9928 0.9982 
First 
order 
0.9287 0.9263 0.9375 0.9186 0.9328 0.9101 0.9328 0.9035 0.9139 
Peppas 0.9958 0.9968 0.9946 0.9986 0.9956 0.9888 0.9908 0.9964 0.9993 
Higuchi 0.975 0.9672 0.9565 0.9758 0.9635 0.9401 0.9538 0.9483 0.964 
n 0.849 0.895 0.990 0.889 0.891 1.109 1.101 1.155 1.042 
 
Table 6.16: Kinetics modeling of release profile of tween 60 niosomes 
containing betaxolol 
Release 
Kinetic 
NT1 NT2 NT3 NT4 NT5 NT6 NT7 NT8 NT9 
Zero 
order 
0.9987 0.9971 0.9987 0.9964 0.9963 0.9875 0.9981 0.9969 0.9984 
First 
order 
0.9305 0.9194 0.9126 0.9104 0.9226 0.9757 0.9272 0.9106 0.9213 
higuchi 0.9754 0.988 0.9863 0.9886 0.9734 0.9373 0.9767 0.9895 0.9743 
peppa 0.9953 0.9975 0.9995 0.9984 0.9914 0.9717 0.9967 0.9995 0.9969 
n 0.757 0.771 0.822 0.755 0.720 0.732 0.749 0.759 0.856 
 
6.4.6 Differential scanning calorimetry 
From the overlay of the DSC thermograms, it has been observed that 
Betaxolol is crystalline in nature (Figure 6.14).  
Thermogram exhibited a sharp melting endotherm at an onset temperature of 
112.82 oC, a peak temperature of 119.76 oC and a heat of fusion of 6.97 J/g. 
While the thermogram of niosomes shows crystallization of betaxolol from 
glass at 67.18 oC followed by fusion at 116.89 oC. 
Chapter 6 Preparation and characterization of betaxolol niosomes 
 
Hitesh B. Gevariya        186                                                   Ph. D. Thesis 
 
 
Figure 6.14: DSC spectra of pure drug and NS5(mixture) 
The thermal behavior of niosomes suggested that the drug is encapsulated in 
the niosomes as semicrystalline form as the fusion peak in the niosomes is 
very weak compared to the pure drug. 
6.4.7 X-Ray Diffraction (XRD) 
XRD spectrum of Betaxolol (Figure 6.15) revealed that the drug is crystalline 
in nature. XRD pattern of niosomes showed that characteristic peaks of 
betaxolol were reduced in number and intensity indicating that the drug 
crystallinity was decreased and drug was completely entrapped within the 
niosomes.  
 
 
Figure 6.15: XRD patterns of Betaxolol (BX) and NS5 (BX Niosomes) 
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6.4.8 Sterility testing 
The sterility testing of niosomes was performed for aerobic, anaerobic 
bacteria and fungi by using alternate thioglycollate medium and soyabean 
casein digest medium as per the IP’07 procedure.  
6.4.8.1 Test for aerobic bacteria 
Here, Bacillus subtilis was used as a test organism. As shown in Table 6.17, 
there was no evidence of growth found in the ‘test’ and ‘negative control’  
tubes and there was macroscopic evidence of microbial growth in ‘positive 
control’  tube. The results suggest that the niosomes tested for aerobic 
bacteria were passed the test for sterility. 
6.4.8.2 Test for anaerobic bacteria 
Here, Bacterioides vulgatus was used as test organism. As shown in Table 
6.17, there was no evidence of growth found in the ‘test’ and ‘negative control’  
tubes and there was macroscopic  evidence of microbial growth in ‘positive 
control’  tube. The results suggest that the niosomes tested for anaerobic 
bacteria were passed the test for sterility. 
 
Table 6.17: Sterility test observations in ATGM 
Sr. no. Samples 
Days 
1 2 3 5 7 14 
1 Negative Control - - - - - - 
2 Positive control √ √ √ √ √ √ 
3 Test - - - - - - 
(-) Absence of microbial growth,  (√) Presence of microbial growth 
 
6.4.8.3 Test for fungi 
Here, Candida albicans was used as test organisms. As shown in Table 6.18, 
there was no evidence of growth found in the ‘test’ and ‘negative control’ 
tubes and there was macroscopic evidence of microbial growth in ‘positive 
control’ test tube. The results suggest that the niosomes tested for fungi were 
passed the test for sterility. 
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Table 6.18: Sterility test observations in SBCD medium 
Sr. no. Samples 
Days 
1 2 3 5 7 14 
1 Negative Control - - - - - - 
2 Positive control √ √ √ √ √ √ 
3 Test - - - - - - 
(-) Absence of microbial growth, (√) Presence of microbial growth 
 
The overall results of the sterility test showed that the niosomes passed the 
sterility test and hence they were sterile preparations. 
6.4.9 In vivo studies 
6.4.9.1 Corneal residence evaluation 
The precorneal residence data of betaxolol after application of equivalent 
doses containing niosomes and eye drops in rabbit eyes is shown in Table 
6.19 and Figure 6.16. There was a significant improvement in precorneal 
resident of betaxolol after application of the formulated niosomes as 
compared to eye drops. In case of niosomes, the levels of drug concentration 
in tear fluid were maintained for 12 hr while for eye drops concentration was 
very less after 6 hr. The increase in corneal residence may be attributed to the 
sustained release of drug from the niosomes as proved by in vitro studies.  
Table 6.19: Tear fluid concentration of betaxolol 
Time (h) Tear fluid concentration (µg/mL) NT6 NS5 Eye drop 
0.1 0.1 0.12 20.48 
1 1.02 1.08 10.42 
2 3.24 2.73 6.85 
4 4.12 3.84 2.14 
6 3.82 3.8 1.24 
8 3.12 2.62 0.18 
10 2.13 1.62 0.02 
12 1.1 0.42 0 
22 0.2 0.14 0 
24 0.05 0.04 0 
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Figure 6.16: Tear fluid concentration of betaxolol  
 
6.4.9.2 Ocular safety studies  
The ocular safety score of the formulation NS5 and NB6 was found to be 1 
and 0 at the end of 24 hr respectively and therefore, considered as non 
irritating(30). Thus, it can be concluded that they were safe for ocular 
administration. 
6.4.9.3 In vivo antiglaucoma efficacy evaluation 
In vivo antiglaucoma activity was carried out on rabbit eyes using steroid 
induced glaucoma model. The data obtained was represented graphically as 
shown in Figure 6.17. The graph (Figure 6.17) shows that both selected 
niosomal formulations NS5 and NT6 showed better control over IOP as 
compared to eye drops. Both formulations showed peak effect (tmax
 
Figure 6.17: IOP lowering activity of betaxolol niosomes and eye drop 
) at 5 hr as 
compared to eye drops (3 hr). On administration of niosomes, IOP was under 
control for the period of 12 hr while eye drops was effective in controlling IOP 
for the period of 9 hr. 
-5
0
5
10
15
20
25
0 5 10 15 20 25 30
Te
ar
 fl
ui
d 
co
nc
en
tr
at
io
n 
(µ
g/
m
L)
Time (h)
Eye drop
NS5
NT6
-5
0
5
10
15
0 5 10 15 20 25 30IO
P 
ch
an
ge
 (m
m
hg
)
Time (h)
Control ED Eye drops NT6 Control NT6 NS5 Control NS5
Chapter 6 Preparation and characterization of betaxolol niosomes 
 
Hitesh B. Gevariya        190                                                   Ph. D. Thesis 
 
The interesting finding of the study was that IOP was also lowered effectively 
in control eyes of eye drop treated group, which was not the case for niosome 
treated group. This can be an indirect measure of systemic absorption of the 
drug following eye drops treatment, indicating that niosomes provide better 
control over systemic side effects.  
6.4.10 Ageing study 
Ageing study of the betaxolol niosomes was performed at R.T., 4 oC and 40 
oC for the period of 6 months. The results showed that there was no change in 
physical appearance of formulations. 
The drug content of the formulations were determined and it was observed 
that the percentage of drug leaching (percent of un-entrapped drug) was 
increased by 5.43%, 22.13% and 31.5% respectively (Table 6.20), for the 
preparations stored at refrigerated temperature, room temperature and 40 oC 
for NS5. Similar results were observed for NT6 niosomes. 
The formulation stored at cold temperature was subjected to vesicular size 
analysis. The z-average diameter of the vesicles was found to increase from 
124.21 to 211.8 nm and 121 nm to 222.48 for NS5 and NT6 respectively, the 
PDI increased from 0.387 to 0.598 and 0.213 to 0.568 indicating vesicle 
aggregation at RT and 40 oC. However, at refrigerated temperature no 
evidence of vesicular fusion was seen because an increase in vesicle size 
and PDI did not vary widely. Thus, we could suggest that the nanovesicular 
formulation should be stored at refrigerated temperature to maintain its better 
physical stability. Both formulations complied test for sterility at the end of 180 
days. Sedimentation data revealed that both the optimized formulations had 
shown complete sedimentation at the end of 120 days at RT and 40 oC. 
In addition, the pH shifted from 7.41 to 6.64 and from 7.38 to 6.51 for the 
formulations NS5 and NT6 respectively stored at 40oC. No appreciable 
change in pH was noted for the formulation stored at cold temperature and 
room temperature; however, the formulation stored at 40o
 
C exhibited a 
considerable shift in pH of the nanovesicular suspension.  
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Table 6.20: Ageing study results of niosomes  
  NS5  
(days) 
NT6  
(days) 
  0 60 120 180 0 60 120 180 
R
D
C
 
4o 100 C 98.92 99.18 94.57 100 98.48 97.86 95.14 
RT 100 97.42 89.74 77.87 100 97.32 88.42 75.50 
40o
100 
C 
93.18 79.26 68.5 100 93.65 78.32 68.26 
pH 
4o 7.42 C 7.42 7.40 7.38 7.38 7.41 7.37 7.35 
RT 7.41 7.38 7.15 7.01 7.38 7.19 7.06 6.84 
40o
7.41 
C 
7.13 7.06 6.64 7.38 7.02 6.95 6.51 
M
VD
 
4o
124.2
1 
C 
128.2
1 
125.6
5 
132.4
1 
121.9
6 
120.2
8 
124.6
1 
124.4
1 
RT 124.21 128.32 159.84 198.48 121.96 138.21 198.86 214.28 
40o 124.2
1 C 
156.6
3 
198.4
8 
211.2
6 
121.9
6 
188.8
1 
204.6
4 
222.4
8 
Se
di
m
en
ta
tio
n 4o - C - + ++ - - + ++ 
RT - + ++ +++ - + ++ +++ 
40o
- 
C 
++ +++ +++ - ++ +++ +++ 
- no sedimentation, +(1-25%) partial sedimentation, ++ (26-75%) nearly 
complete sedimentation, +++ complete sedimentation 
 
These results concluded that niosomes was chemically, physically and 
microbiologically stable at refrigeration temperature for six months. However, 
further studies at different temperatures and humidity conditions are needed 
to establish their shelf life. 
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6.5 Conclusion 
Betaxolol containing niosomes were prepared using two different surfactants 
span and tween and evaluated for in vitro and in vivo tests. Morphological 
studies revealed that all the formulations were spherical in shape and existed 
as separate particles. Drug entrapment was higher enough to incorporate 
required dose of drug in minimum possible concentrated niosomal 
suspension. The release of drug from niosomes was controlled by diffusion for 
a prolonged period of time. Both the optimized formulations showed better 
control of IOP over eye drops, indicating that niosomes can be a choice of 
drug delivery for the treatment of glaucoma as a sustained ocular drug 
delivery system. 
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7. FORMULATION AND EVALUATION OF BETAXOLOL 
NIOSERTS 
7.1 Aim of present investigation 
There are many potentially effective drug delivery systems and vehicles. They 
differ in their drug capacities, structure, in vivo and storage stability, modes of 
administration and possible applications. Each of them has favorable 
attributes and limitations(1)
Recent trend in ocular research is to formulate a dosage form which not only 
prolongs the residence of system in eye but also helps to reduce the 
elimination of the drug. In the same area many drug delivery systems 
including insitu gel
. 
(2), microemulsions 3( ), nanoparticles 4( ), liposome 5( ), 
niosomes 6( ), ocular inserts 7( )
Ophthalmic inserts offer many advantages over conventional dosages forms, 
like increased ocular residence, possibility of releasing drug at a slow and 
constant rate, accurate dosing, exclusion of preservatives and increased shelf 
life. Design, construction and technology of ocular insert in a controlled and 
sustained ocular delivery device are gaining rapid improvement to overcome 
these constraints
 etc. are being investigated worldwide by many 
researchers. The developmental technology of new ocular dosage forms has 
witnessed tremendous improvement during last few decades and its use is 
expected to increase in near future. 
(7,8).Niosomal vesicular system is one of the potential 
approaches, which can be suitably used 9( ). 
In our last attempt (chapter 6), we developed niosomal suspension of 
betaxolol. It showed sustained release of betaxolol for 24 hr (in vitro) but in 
vivo antiglaucoma activity was only upto 12-14 hr due to precorneal washout 
of niosomes from cul-de-sac. Stability data of this formulations suggested that 
on a longer storage of niosomes, physical instability (agglomeration) and drug 
leakage had occurred. This may cause dose inaccuracy and therapeutic 
inefficiency. 
Owing to these disadvantages, ocular inserts containing Betaxolol Niosomes 
– NIOSERT was designed and developed, in order to prolong the residence of 
drug/niosome in tear fluid as well as to enhance physical and chemical 
stability of niosomes. 
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Hence this investigation has been designed to study the drug release kinetics 
of betaxolol from a niosert developed by incorporating niosomes in matrix 
system of PEO and PVP. In the present investigation two different polymers 
have been blended to combine the advantages of the individual polymer. 
Advantages of polymer blends include easy fabrication of devices, controlling 
drug release, manipulation of drug loading and other devices properties such 
as hydration, degradation rate and mechanical strength. Formulation was 
designed for 24 hr therapy.  
It was our aim to develop nioserts that: 
1. Release the drug for prolonged period of time preferably 24 hr, in vitro as 
well as in vivo. 
2. Provide an increased ocular residence time resulting in prolonged drug 
delivery in eye. 
3. Deliver a drug at a controlled rate over a period of time.   
4. Show better in-vivo performance than conventional dosage forms. 
5. Improve stability of niosomes. 
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7.2 Experimental 
7.2.1 Preliminary screening  
Preliminary study was carried out for screening of various polymers. 
7.2.1.1 Selection of polymers  
Polymers were selected from among Sodium alginate, PVP, PEO and HPMC 
based on the type of films formed at different concentrations, the strength of 
the films formed and appearance of the films. Bearing in mind all these 
factors, it was concluded that PVP and PEO form very good films. 
 
Table 7.1: Formulation compositions for preliminary screening for films 
incorporating betaxolol niosomes 
Ingredients F1 F2 F3 F4 F5 F6 F7 
NS5 (mL) 10 10 10 10 10 10 10 
PEO* 240 120 --- --- 180 120 --- 
PVP* --- 120 100 240 --- --- 200 
HPMC* --- --- 140 --- --- 120 --- 
SA* --- --- --- --- 100 --- 100 
*All values are in mg. PEG400 (30% w/w) added as plasticizer 
 
This investigation was aimed to use composite polymer in matrix type ocular 
formulation. For screening the polymers and polymer blend a formulation 
study was carried out. Above Table 7.1 shows some of the important 
formulations screened for actual study.  
Formulation F2, F5 and F6 were prepared using PEO with PVP, SA and 
HPMC respectively. It was found that film was not good in case of F5 and F6; 
whereas F2 gave good uniform, smooth surfaced film as compared to rest 
other formulations. F1, F3, F4 and F7 films were more sticky and soft, so 
being difficult to handle. Considering above results, it was decided to prepare 
the ocular film by using the PEO in combination with PVP in equal 
proportions. 
7.2.1.2 Water absorption test for polymers(10)
Water uptake measurement was performed by using an apparatus consisting 
of G15 Buchner sintered glass filter of 3.8 cm diameter with one end 
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connected to a graduated 1 mL pipette via silicone rubber tube. The lower 
part of the filter and pipette were filled with distilled water at room temperature 
just before the experiment. The evaporation of water was minimized with 
aluminum foil wrapped around the filter. 
Polymer discs of PEO and PVP were prepared by directly compressing 200 
mg of the dried polymer in a hydraulic press. The prepared discs were placed 
at the center of the filter and the uptake of water for 24 hr was determined by 
obtaining the change in volume of water in the graduated pipette. The mean 
of 5 determinations were taken to represent the water uptake for the polymer. 
7.2.1.3 Drug-excipients compatibility studies 
Infrared spectra matching approach was used for detection of any possible 
chemical interaction between the drug and the polymer. The drug and 1:1 
physical mixtures of drug and polymer (each 10 mg) were prepared and 
mixed with 400 mg of potassium bromide. About 100 mg of this mixture was 
compressed to form a pellet using a hydraulic press at 10 tones pressure. It 
was scanned from 4000 to 400 cm-1
The matrix films of Betaxolol HCl using equal proportions of PEO and PVP 
(1:1) were prepared by solvent evaporation technique
 in a FTIR spectrophotometer. The IR 
spectrum of physical mixture was compared with those of pure drug and 
polymers to detect any appearance or disappearance of peaks.  
7.2.2 Formulation of nioserts 
(11). In the present study 
PBS (pH 7.4) was used as solvent.  
The weighed quantities of polymers were dissolved in 10 mL of niosomal 
suspension and plasticizer (30% w/w of polymer amount) was incorporated. 
Polymeric suspension was sonicated for 2 min under vacuum to remove the 
air. Polymeric suspension was then poured into a petridish (6.8 cm diameter) 
placed on a flat even surface. The rate of evaporation was controlled by 
inverting the funnel over the petridish. After drying at 40 o
 
C for 24 hr keeping 
in desiccator, circular ocular inserts of diameter 6 mm were cut using 
fabricated mould and packed in aluminum foils and stored in desiccators until 
further use. The composition of ocular films of Betaxolol HCl is shown in Table 
7.2. 
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Table 7.2: Formulation compositions for ocular inserts of betaxolol 
Formulation 
Betaxolol 
(0.5mg) 
Total polymer 
(% w/v) 
Loading dose 
(%) 
BNS1 Drug 1 0 
BNS2 NS5 1              0  
BNS3 NS5 1 20 
BNS4 Drug 2 0 
BNS5 NS5 2 0 
BNS6 NS5 2 20 
BNS7 Drug 3 0 
BNS8 NS5 3 0 
BNS9 NS5 3 20 
All formulations contain PEG400 as plasticizer 30 % w/w of 
polymer weight 
 
Formulations BNS1, BNS4 and BNS7 were containing pure drug while rest of 
formulations incorporated niosome NS5 formulation containing equivalent (5 
mg) of betaxolol.  
 
7.2.3 Evaluation 
7.2.3.1 Physicochemical evaluation of nioserts 
i) Physical appearance  
All the ocular films were visually inspected for color, clarity and smoothness. 
ii) pH (12)
iii) Thickness
 
pH of the inserts was determined by allowing them to dissolve in a test tube 
containing 5 mL of distilled water at room temperature for 30 min. pH was 
measured using calibrated pH meter. 
Thickness of the film is an important factor while considering its drug release 
from ocular delivery systems. If thickness varies from one film to another, the 
drug release from the film also varies. So it is must to keep the thickness of 
the film uniform to get reproducible results. In the present study, the thickness 
of the formulated films was measured using digital micro meter of sensitivity of 
 (12) 
Chapter 7 Formulation and evaluation of betaxolol nioserts 
 
Hitesh B. Gevariya        203                                                   Ph. D. Thesis 
 
0.01mm (mitutoyo, Japan). Average of 10 films was taken and standard 
deviation values were calculated. 
iv) Weight uniformity (12)
v) Tensile strength and percentage elongation at break 
  
As weight variation between the formulated films can lead to difference in 
drug content and in vitro behavior, evaluation was carried out by weighing 10 
films by an electronic balance (least count – 0.1 mg). The average weight and 
standard deviation were then calculated and reported. 
(13)
% 𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 𝑒𝑒𝑒𝑒 𝑏𝑏𝑏𝑏𝑒𝑒𝑒𝑒𝑏𝑏 =  IB − Io × 100                          [7.1] 
                    Where Io is the original length of the film and  
                    IB
 
Percentage elongation at break and tensile strength was calculated using the 
following formulae (Refer section 5.4.1.5). 
 
                     Where a, b and L are width, thickness and length of the strip   
respectively and ∆L is the elongation at break. 
                           Break force = weight required to break the film (Kg). 
is the length of the film at break when stress was applied.  Tensile strength =   Break forceab(1 + ∆L/L)                                      [7.2] 
vi) Folding endurance (14)
vii) Moisture uptake 
 
The flexibility of polymeric films can be measured quantitatively in terms of 
folding endurance. Folding endurance was determined by repeatedly folding a 
small strip of ocular film (2×2 cm) at the same place till it breaks. The number 
of times film could be folded at the same place, without breaking gives the 
value of folding endurance. 
(11, 14) 
The percentage moisture uptake test was carried out to check the physical 
stability or integrity of the film. Ocular films were weighed individually and 
placed in a desiccator containing 100 mL of saturated solution of sodium 
chloride (~ 75 % humidity). After three days, films were taken out and 
reweighed; the percentage moisture uptake was calculated by using following 
formula. Percentage moisture uptake =  Final weight –  Initial Weight Initial weight  × 100           [7.3] 
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viii) Percentage of moisture content (11, 13)
ix) Water vapor transmission studies 
 
The percentage moisture loss test was carried out to check the integrity of the 
film at dry condition. Ocular films were weighed individually and placed in a 
desiccator containing anhydrous calcium chloride. After three days, films were 
taken out and reweighed; the percentage moisture loss was calculated by 
using following formula. Percentage moisture content =   Initial weight –  Final weight Initial weight × 100           [7.4] 
(15) 
The glass vials of 5 mL capacity were washed thoroughly and dried to 
constant weight in an oven. Fused calcium chloride (1 g) was taken in vials 
and the polymer films were fixed over the brim with the help of an adhesive. 
These pre-weighed vials were stored in humidity chamber at RH 80% with 
temperature of 25 o
x) Determination of drug content 
C for a period of 24 hr. The weight gain was determined 
every hour up to a period of 24 hr to note the weight gain. Water vapour 
transmission (WVT) was calculated by taking the difference in weight of film 
before and after the study for a total period of 24 hr.  
(12) 
Polymeric films were dissolved in 5 mL distilled water in separate volumetric 
flasks and stirred using magnetic stirrer. Nioserts were dissolved in 1mL 
chloroform and drug was extracted with PBS (pH 7.4) which was kept at 60 o
 
C 
to remove chloroform. The volume was adjusted to 100 mL with phosphate 
buffer pH 7.4 and the solutions were filtered through filter. The drug content in 
each formulation was determined spectrophotometrically at 274 nm. Similarly, 
a blank solution was prepared using dummy film. Average drug content of 
three films was determined. 
xi) Scanning Electron Microscopy 
Films were mounted on an aluminum stub using double-sided adhesive 
carbon tape and coated with gold palladium using JEOL JFC 1600 auto fine 
coater for 90 seconds. Samples were examined using scanning electron 
microscope JSM-6380 LV (Jeol Ltd., Tokyo, Japan) at 20 kv accelerating 
voltage. 
 
Chapter 7 Formulation and evaluation of betaxolol nioserts 
 
Hitesh B. Gevariya        205                                                   Ph. D. Thesis 
 
7.2.3.2 In vitro drug release study (16)
i) Data treatment and analysis 
 
The in vitro drug release from different ophthalmic inserts were studied by 
using the classical standard cylindrical tube which has the diameter of 15 mm. 
Dialysis membrane (Dialysis membrane 110, mwc 12000-14000, Hi Media, 
India), immersed in water for one hour to remove the preservatives followed 
by rinsing in phosphate buffered saline (PBS) solution, acted as corneal 
epithelium, was tied to one end of open cylinder which acted as donor 
compartment. An ocular insert was placed inside this compartment with 0.7 
mL of simulated tear fluid (STF). Then, the glass tube was suspended in the 
dissolution flask of a USP dissolution apparatus such that entire surface of the 
membrane was in contact with the receptor compartment containing 250 mL 
of STF (pH 7.4). The content of the receptor compartment was stirred 
continuously at 25 rpm. Samples of 1 mL were withdrawn from the receptor 
compartment at periodic intervals and replaced by equal volume of fresh 
solution. The samples were analyzed spectrophotometrically at 274 nm 
against reference standard using STF as blank. 
The following parameters were determined from the in vitro data obtained for 
the diffusion of Betaxolol hydrochloride through the membrane. 
Diffusion rate 
Flux 
(17) 
(18)
Permeability coefficient 
 
(18)
ii) Kinetics of permeation 
 
For finding out the mechanism of drug release from Ocular system, the 
diffusion data obtained from the above experiments was treated with the 
different release kinetic equations(19).  
Zero order release equation    Q = K0 t                                             [7.5] 
Higuchi’s square root of time equation   Q = KH t1/2                           [7.6] 
Where, Q is amount of drug release at time t, K0 is zero order release rate 
constant, KH
iii) Mechanism of release 
 is Higuchi’s square root of time release rate constant. 
Using Korsmeyer and Peppas equation (20, 21) 
F = (Mt/M) = Km tn                                                  [7.7] 
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Where, Mt is drug release at time t, M is total Amount of drug in dosage form, 
F is fraction of drug release at time t, Km
7.2.3.3 Sterility testing 
 is constant depend on geometry of 
dosage form and n is diffusion exponent indicating the mechanism of drug 
release. 
(22)
Precorneal resident time of ocular drugs has been assessed by certain 
invasive technique
 
Sterility is one of the most vital requirements for an ophthalmic preparation. 
The tests for sterility are intended for detecting the presence of viable forms of 
microorganisms in ophthalmic preparations. The principle governing these 
tests is that if the microorganisms are placed in a medium which provides 
nutritive material and water, kept at a favorable temperature, the organisms 
will grow and their presence can be indicated by turbidity in the originally clear 
medium. In the present study, two media namely, alternative thioglycolate 
medium (ATGM) and soyabean-casein digest medium (SBCD) were used to 
investigate the presence/absence of aerobic, anaerobic bacteria and fungi, in 
the formulated sterilized ocular inserts. 
Sterilized inserts were dissolved in fluid A and directly inoculated in above 
medium aseptically as described in IP 2007 and labeled as ‘Test’. 
Simultaneously, positive and negative controls were also prepared and all the 
three tubes were incubated at specified temperatures. 
7.2.3.4 In vivo studies 
Approval for the use of animals in the study was obtained from the 
Institutional Animal Ethics Committee (1338/c/CPCSEA). New Zealand rabbits 
of either sex weighing 2.5 to 3.1 kg were used for in vivo studies. The rabbits 
were housed singly in restraining cages during the experiment and allowed 
food and water ad libitum. Free lag and eye movement was allowed. No 
ocular abnormalities were found on external and slit-lamp examination prior to 
beginning of the study. 
i) Corneal residence time evaluation 
(23) and non-invasive technique 24( , 25). These approaches 
however, require isolation of ocular tissues or the use of radioisotopes. In the 
present study, an effort was therefore made to develop a non-invasive method 
to assess the precorneal residence of the drug from the formulated delivery 
system based on HPLC technique. 
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a) Tear sampling and analysis 
Tear samples equivalent to 1 µL were collected from the left eye after 
application of test delivery system at 0, 0.10, 1, 2, 4, 6, 10, 22, 24 hr post 
dosing. Glass capillary tubes having 320 µm internal diameter and 1 µL 
Premark were placed near the canthus of the eye without applying pressure. 
Tear fluid was drained into the tubes due to capillary action. Samples 
equivalent to 1 µL were mixed with 50 µL of mobile phase and injected into 
HPLC chamber. Data were collected and interpreted and results were 
tabulated. 
b) HPLC Condition (26)
Mobile phase: methanol:acetonitrile:0.1% diethylamine (pH adjusted to 3 with   
orthophosphoric acid) (30:60:10, %v/v) 
Flow Rate: 1.0 mL/min 
Column: Phenomenex C18 Column. (Luna C, 25034.6 mm, 5 mm) 
Detector:  SPD-M20A Prominence Diode array detector 
Retention Time: 4.08 min 
Injection Volume: 20 µl by Rheodyne 7725i injector 
Standard solution:  2 μg/mL of Betaxolol in HPLC grade water. 
 
ii) Ocular safety study (27, 28)
The ocular safety of administered delivery system can be tested based on the 
Draize Irritancy Test (as discussed in section 5.4.7.3). The observations 
based on scoring approach were used to establish the safety of the developed 
ocular inserts in rabbit eye. Three healthy albino rabbits (2.7–2.9 kg) were 
selected to evaluate the ocular irritancy effects of the optimized formulations. 
For feeding, conventional laboratory diets were used with an unrestricted 
supply of drinking water. A single formulation was instilled into the conjunctival 
sac of left eye of each animal (initially to one animal) and the untreated eye 
served as a control. Each of the animals was observed visually with a slit 
lamp for the severity of ocular reactions such as corneal ulceration, iritis, 
conjunctival redness, and conjunctival edema at various intervals of 1, 24, 48, 
and 72 hr. The animal experiment was conducted in full compliance with local, 
national, ethical, and regulatory principles and local licensing regulations, as 
per the spirit of ethics committee. This study was approved by IAEC (Approval 
no. 1338/c/CPCSEA). 
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iii) In vivo anti-glaucoma activity evaluation (9, 29)
a) Animal care and handling 
 
The animals were acclimatized to the standard laboratory conditions in cross 
ventilated animal house at temperature 25±2 °C relative humidity 44–56% and 
light and dark cycles of 12:12 hr,  fed with standard pallet diet and  water ad 
libitum during experiment. The experiment was approved by the institutional 
ethics committee and as per CPCSEA guidelines (approval no. 
1338/c/CPCSEA). 
b) Steroid induced model (30)
Eyes of the 12 rabbits were treated 3 times daily by 0.5% dexamethasone eye 
drops for 2 weeks. Dexamethasone sodium phosphate (Taj Pharmaceuticals 
Ltd., Mumbai) was dissolved in phosphate buffer saline to a final 
concentration of 0.5 % at pH 7.4. The intraocular pressure was measured at 
noon twice a week by Schiotz tonometer. 
 
c) Antiglaucoma activity 
For evaluation, the rabbits with induced glaucoma were randomly divided in 
three groups (n=3). First group was treated with marketed preparation of 
betaxolol HCl eye drops equivalent to 0.5 mg. In second group formulation 
BNS5 and in third group niosert BNS6 were inserted in to lower cul de sac of 
rabbits. The intraocular pressure (IOP) changes were recorded up to 26 hr at 
specified time intervals. The ocular hypotensive activity is expressed as the 
average difference in IOP according to the equation ΔIOP = IOP’0’ time – 
IOP’t’time (31)
7.2.3.5 Ageing study 
.  
(16) 
The optimized nioserts were stored in amber colored glass bottles at 3 
different temperatures 4 oC, Room temperature and 40±0.5 oC for a period of 
6 months.  The samples were withdrawn after 30, 60, 120 and 180 days and 
analyzed for physical appearance, drug content, folding endurance and 
sterility.  
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7.3 Results and discussion 
In the present study ocular films containing Betaxolol HCl niosomes were 
prepared using combination of polymers (PVP and PEO) and termed as 
nioserts. Nine formulations were prepared. Films were evaluated for their use 
as ocular delivery systems with a view to obtain sustained release. 
7.3.1 Water absorption test for polymers 
PVP and PEO were found to take up 2.1 folds and 1.5 folds of its own weight 
of water respectively over a period of 24 hr. This property is very much useful 
as it enhances the mucoadhesive behavior. The water absorption capacity of 
200mg of PVP and 200mg of PEO were found to be 0.42 g and 0.3 g 
respectively after 24 hr. 
7.3.2 Drug-excipients compatibility studies 
Interpretation of IR spectrum of Betaxolol (Figure 7.1) shows characteristic 
peaks at 3237 cm-1 (hydroxyl group O-H stretching), 2928 cm-1 (methyl C-H 
stretching), 2858 cm-1 (methylene C-H stretching), 1612 cm-1 (aromatic ring 
C=C-C stretching), 1557 cm-1 and 1513 cm-1 (secondary amine N-H bending), 
1474 cm-1 (methylene C-H bending ), 1376 cm-1 (methyl C-H sym. bending ), 
1246 cm-1 (alkyl aryl ether c-o-c stretching), 1179 cm-1 (aromatic in plane C-H 
bending), 1087 cm-1
 
 (aliphatic ether c-o-c stretching) and 1050 (amine C-N 
stretching). FTIR spectra of mixture, in comparison to IR spectra of pure drug, 
show no substantial shifting of the position of the functional groups, indicating 
no major interaction between drug and polymers.   
Figure 7.1: IR spectra overlay of pure drug (BX), Mixture (M) of 
drug/PEO/PVP and polymers (PEO, PVP) 
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7.3.3 Physicochemical evaluation 
In the present investigation solvent evaporation technique is adopted and it 
was found to be giving thin uniform films. All prepared ocular films have good 
appearance with slightly rough surface due to presence of niosomes on 
surface. Films prepared were translucent and pale whitish in color. 
Weight and thickness measurement of films was carried out and low 
standard deviation values in film weight and thickness measurements ensure 
the uniformity of weight and thickness in each film. A good weight uniformity 
of all formulation indicates an equal distribution of niosomes and the polymers 
in the matrix film prepared by solvent evaporation technique. It was also 
accounted that weight and thickness of films were increasing with increasing 
polymer concentration. Formulations were not thick enough to produce any 
irritation while placing and being in cul-de-sac. 
 
Table 7.3: Physical properties of prepared nioserts of betaxolol 
Nioserts 
Weight of 
films(mg)*  
Thickness 
(mm)a  
Tensile 
strengtha 
Kg/cm2 
%Elongation   
at breaka 
(%EB)  
Folding 
endurancea     
BNS1 3.79±0.048 0.122±0.022 0.55 ± 0.02 3.78± 0.11 103±2.5 
BNS2 4.81±0.053 0.140±0.015 0.46 ± 0.03 2.63± 0.21 95.6±2.8 
BNS3 4.74±0.077 0.138±0.029 0.43 ± 0.01 2.56± 0.14 82.5±3.4 
BNS4 5.53±0.061 0.163±0.038 0.64 ± 0.03 5.29± 0.08 112.3±4.16 
BNS5 6.59±0.057 0.188±0.009 0.52 ± 0.02 4.02± 0.16 104±3.41 
BNS6 6.67±0.063 0.187±0.007 0.51 ± 0.03 4.09± 0.24 94.3±2.18 
BNS7 8.62±0.048 0.216±0.013 0.71 ± 0.05 6.49± 0.07 121.2±3.52 
BNS8 9.29±0.039 0.241±0.008 0.62 ± 0.02 5.04± 0.31 108.8±2.28 
BNS9 9.24±0.072 0.238±0.014 0.64 ± 0.04 4.87± 0.09 98.5±3.53 
a Average ± SD of three determinations has been reported 
*Average ± SD of ten determinations has been reported 
 
The pH values of the prepared inserts were found in between 7 to 7.5, 
indicating that the inserts did not have an irritation potential as the pH is within 
the accepted ocular range(32). 
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Tensile strength and %EB values of all inserts are shown in Table 7.3. It 
shows that formulation BNS7 showed highest tensile strength and % EB 
among all batches i.e. 0.71 ± 0.05 kg/cm2 and 6.49± 0.07% respectively. It 
was also found that films containing more amount of polymer show higher 
tensile strength. 
Folding endurance values shows that maximum folding endurance was 
found at high concentration of polymer. Formulation BNS7 shows highest 
folding endurance. Decrease in folding endurance of nioserts may be due to 
presence of niosomes causing the reduction in flexibility of films.  
Ocular films were also evaluated for % moisture content, % moisture uptake 
and water vapour transmission rate. Results were tabulated (Table 7.4).  
 
Table 7.4: Evaluation of prepared ocular films of betaxolol 
Nioserts 
% Moisture 
content 
(%MC ± SD)a 
% Moisture 
uptake 
(%MU ± SD)a 
Water vapor 
transmission 
ratea× 10-3 
gm/cm2h 
Drug 
contenta 
(% ± SD) 
BNS1 4.50 ± 0.03  03.37 ± 0.14  3.95 ± 0.09 100.75±1.32 
BNS2 4.78 ± 0.08 03.20 ± 0.09 3.08 ± 0.12 101.14±1.08 
BNS3 4.67 ± 0.09 03.18 ± 0.16 3.04 ± 0.04 100.42±1.62 
BNS4 6.84 ± 0.11  04.83 ± 0.12   4.83 ± 0.17 101.13±0.48 
BNS5 6.77 ± 0.13 04.75 ± 0.08 4.18 ± 0.05 99.85±0.85 
BNS6 6.67 ± 0.08 04.72 ± 0.12 4.12 ± 0.19 101.07±1.22 
BNS7 7.85 ± 0.12  06.23 ± 0.07  6.02 ± 0.12 100.27±1.09 
BNS8 7.81 ± 0.06 06.14 ± 0.09 5.22 ± 0.06 99.73±0.92 
BNS9 8.05 ± 0.14 06.10 ± 0.11 5.28 ± 0.04 98.88±1.24 
a Average ± SD of three determination has been reported 
 
Moisture content values of films were found in range of 4.50 ± 0.03 to 8.05 ± 
0.14 percent. It also shows that moisture content of inserts increase with 
increasing amount of polymers. This is due to Hydrophilic properties of 
polymer. Same observation was also found in water vapor transmission rate 
of inserts. Water vapour transmission rate was found in range of 3.04 × 10-3 to 
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6.02 × 10-3 gm/cm2h. The results showed that presence of niosomes in 
polymer matrix offers resistance to water transmission. The water uptake or 
absorption behavior of the polymeric film plays an important role at the 
beginning stage of drug release from dosage form(33)
 
Figure 7.2: Comparative WVT rate of nioserts 
 
Good uniformity in the drug content among the batches was observed for all 
the formulations. % Drug content was found in the range of 98.88±1.24% to 
101.14±1.08%. The drug content analysis of the prepared formulations have 
shown that the process employed to prepare films in this study was capable of 
giving films with uniform drug content and minimum batch variability. 
Scanning electron microscopy 
. Thus, the film with 
higher moisture uptake supposed to give higher drug release rate initially. 
 
 
Figure 7.3: SEM image of niosert BNS6 
SEM image of Niosert indicated that niosomes were found uniformly 
distributed throughout the matrix bed of polymer. 
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7.3.4 In vitro drug release studies 
In this study, Matrix-type inserts were prepared using polymer blend (PVP and 
PEO). All formulations prepared were subjected to in vitro diffusion study to 
ensure the effect of variables. The data obtained for in- vitro study were 
tabulated and represented graphically. 
Table 7.5 shows percentage cumulative drug release (average of 3 readings) 
profile for all formulation BNS1 to BNS9. The Maximum drug release was 
found at lower polymer concentration and as the polymer amount was 
increased from 1% to 3% w/v, the release was found to be decreased. Niosert 
BNS8 shows minimum drug release i.e. 69.48% in 24 hr. Initial rapid rate of 
drug release was observed with nioserts with loading dose as predicted. Initial 
rate of release affects onset of action. 
 
Table 7.5: Percent cumulative amount of betaxolol permeated through 
membrane 
Time 
(hr) 
BNS1 BNS2 BNS3 BNS4 BNS5 BNS6 BNS7 BNS8 BNS9 
% CP % CP %CP % CP % CP % CP % CP %CP % CP 
0.5 8.8 1.2 3.25 6.9 0.9 2.68 5.11 0.64 2.16 
1 15.42 2.86 7.62 13.26 1.96 7.12 10.43 1.08 6.74 
1.5 27.84 3.78 11.42 22.43 3.16 10.86 15.22 1.98 9.32 
2 42.32 7.21 18.42 35.92 5.85 17.16 22.43 4.09 15.32 
4 72.65 13.18 26.68 60.21 11.08 24.14 45.27 8.46 22.08 
6 89.36 19.84 34.98 75.23 16.82 32.43 66.14 13.87 29.32 
8 100.78 27.12 43.18 89.21 22.82 40.42 80.18 19.28 36.87 
10  33.82 51.26 100.21 29.14 47.82 90.12 25.82 44.24 
12  41.26 58.25  36.38 54.12 100.32 32.29 51.12 
22  74.32 93.26  68.14 89.32  63.29 83.86 
24  82.46 101.14  74.55 96.28  69.48 90.59 
 
Order of cumulative drug permeated was found in following manner: 
BNS1>BNS4>BNS7>BNS3>BNS6>BNS9>BNS2>BNS5>BNS8 
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Figure 7.4: In vitro release of betaxolol from nioserts 
 
Drug permeation profile of all formulations is shown in Figure 7.4. It shows 
that formulation BNS1, BNS4 and BNS7 showed almost 100 percent drug 
release within just 12 hr. Lowest drug release was found in case of BNS8 as it 
contained more amount of polymer compare to all others. 
Diffusion parameters like Diffusion rate, flux and permeability coefficient were 
also determined.  
In vitro permeation profile shows that concentration of polymer in the film 
plays a very important role on drug permeation. Results show that as 
concentration of polymer increased there was decrease in drug permeation.   
The Maximum average diffusion rate found was 0.0715 mg/hr in case of 
formulation BNS1 whereas BNS8 shows minimum drug release with diffusion 
rate of 0.0159 mg/hr. Flux values attained for all formulation are shown in 
Table 7.6. Result of flux also favors that drug release was inversely 
proportional to polymer concentration. Diffusion of molecule through inserts 
was rate limiting step for permeation of molecule. The process of drug release 
in most controlled release devices is governed by diffusion, and the polymer 
matrix has a strong influence on the diffusivity as the motion of a small 
molecule is restricted by the three-dimensional network of polymer chains. It 
has been reported that diffusion rate of molecule is inversely proportional to 
diffusion path(34). Thickness of inserts increases with increasing the amount of 
polymer. This lead to an increase in diffusion path of molecules and so less 
0
20
40
60
80
100
120
0 5 10 15 20 25 30
D
ru
g 
re
le
as
e 
(%
)
Time (h)
EYE Drop
BNS1
BNS2
BNS3
BNS4
BNS5
BNS6
BNS7
BNS8
BNS9
Chapter 7 Formulation and evaluation of betaxolol nioserts 
 
Hitesh B. Gevariya        215                                                   Ph. D. Thesis 
 
release was observed in case of formulation containing high concentration of 
polymer. 
 
Table 7.6: Permeation parameters of betaxolol through membrane 
Nioserts 
Diffusion rate 
Dr 
Flux 
JS 
Permeability coefficient 
KP 
mg/h mg/cm2h cm/h 
BNS1 0.0715 0.040515289 0.081031 
BNS2 0.0175 0.009937712 0.019875 
BNS3 0.0254 0.014399773 0.028800 
BNS4 0.0567 0.03211778 0.064236 
BNS5 0.0168 0.009535674 0.019071 
BNS6 0.0237 0.013413647 0.026827 
BNS7 0.0379 0.021479049 0.042958 
BNS8 0.0159 0.009048698 0.018097 
BNS9 0.0221 0.012539638 0.025079 
 
The drug release was found to increase on increasing the concentration of 
hydrophilic polymer in the polymer matrix. This is due to the fact that 
dissolution of aqueous soluble fraction of the polymer matrix leads to the 
release of niosomes which release the drug for prolonged period of times. 
Diffusion profiles of all formulation were subjected to data treatment. Diffusion 
data were treated with zero order, first order, Higuchi and Peppas equation. 
The diffusion data treatment of different batches is shown in Table 7.7. It can 
be concluded from the results that zero order release model fit the best for all 
the niosert batches as correlation coefficient values for all the inserts were 
more than 0.99. This is followed by korsemeyer-peppas model and higuchi 
equation. From the n value it can be seen that all the formulations followed 
non fickian diffusion of drug release(19)
 
. Nioserts BNS2, BNS5 and BNS8 
shows super case-II transport mechanism of release. All other formulations 
showed anomalous transport of drug release.  
From the above results, BNS5 and BNS6 were taken as optimised 
formulations for further evaluations. 
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Table 7.7: Kinetic modeling for release profiles of betaxolol nioserts 
Insert Zero order 
First 
order Higuchi 
Korsmeyer
-Peppas n Release mechanism 
BNS1 0.9309 0.7789 0.9819 0.9492 0.8859 Anomalous transport 
BNS2 0.9997 0.8066 0.9606 0.9976 1.032 Super Case-II transport 
BNS3 0.9920 0.7919 0.985 0.9877 0.7650 Anomalous transport 
BNS4 0.9506 0.7806 0.9927 0.9574 0.8429 Anomalous transport 
BNS5 0.9994 0.7945 0.9534 0.9948 1.106 Super Case-II transport 
BNS6 0.9942 0.8023 0.9812 0.9884 0.7729 Anomalous transport 
BNS7 0.9700 0.8297 0.9968 0.9885 0.9184 Anomalous transport 
BNS8 0.9983 0.7719 0.9447 0.9912 1.260 Super Case-II transport 
BNS9 0.9958 0.8158 0.9792 0.9919 0.7792 Anomalous transport 
 
7.3.5 Sterility testing 
The sterility testing of nioserts was performed for aerobic, anaerobic bacteria 
and fungi by using alternative thioglycollate medium and soyabean casein 
digest medium as per the IP’07 procedure.  
7.3.5.1 Test for aerobic bacteria: Here, Bacillus subtilis was used as a test 
organism. As shown in Table 7.8, there was no evidence of growth found in 
the ‘test’ and ‘negative control’  tubes and there was macroscopic evidence of 
microbial growth in ‘positive control’  tube. The results suggest that the 
nioserts tested for aerobic bacteria were passed the test for sterility. 
7.3.5.2 Test for anaerobic bacteria: Here, Bacterioides vulgatus was used 
as test organism. As shown in Table 7.8, there was no evidence of growth 
found in the ‘test’ and ‘negative control’ tubes and there was macroscopic 
evidence of microbial growth in ‘positive control’ tube. The results suggest that 
the nioserts tested for anaerobic bacteria were passed the test for sterility. 
 
Table 7.8: Sterility test observations in ATGM 
Sr. no. Samples Days 1 3 5 7 14 
1 Negative control - - - - - 
2 Positive control √ √ √ √ √ 
3 Surface sterilized 
10 min 
30 min 
 
- 
- 
 
- 
- 
 
√ 
- 
 
√ 
- 
 
√ 
- 
(-) Absence of microbial growth, (√) Presence of microbial growth 
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7.3.5.3 Test for fungi: Here, Candida albicans was used as test organisms. 
As shown in Table 7.9, there was no evidence of growth found in the ‘test’ and 
‘negative control’ tubes and there was macroscopic evidence of microbial 
growth in ‘positive control’ test tube. The results suggest that the nioserts 
tested for fungi were passed the test for sterility. 
The overall results of the sterility test showed that the surface sterilized (for 30 
min) nioserts passed the sterility test and hence they were sterile 
preparations. 
Table 7.9: Sterility test observations in SBCD medium 
Sr. no. Samples Days 1 3 5 7 14 
1 Negative Control - - - - - 
2 Positive contol √ √ √ √ √ 
3 Surface Sterilized 
10 min 
30 min 
 
- 
- 
 
- 
- 
 
√ 
- 
 
√ 
- 
 
√ 
- 
(-) Absence of microbial growth, (√) Presence of microbial growth 
 
7.3.6 In vivo studies 
7.3.6.1 Corneal residence evaluation 
The precorneal residence of betaxolol after application of equivalent doses 
containing nioserts and eye drops in rabbit eyes is shown in Table 7.10 and 
Figure 7.5.  
Table 7.10: Tear fluid concentration of betaxolol 
Time (h) Tear fluid concentration (µg/mL) Eye drop BNS5 BNS6 
0.1 31.18 0 0.75 
1 12.35 0.12 3.16 
2 6.85 0.68 4.42 
4 2.14 1.24 6.36 
6 1.24 2.12 6.88 
8 0.18 4.22 6.46 
10 N.D. 5.28 5.82 
12 N.D. 5.02 5.12 
22 N.D. 4.78 4.02 
24 N.D. 4.32 3.23 
N.D. - Not detectable 
    
There was a significant improvement in precorneal residence of betaxolol 
after application of the formulated nioserts as compared to eye drops. In case 
of nioserts, the levels of drug concentration in tear fluid were maintained for 
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24 hr while for eye drops concentration was very less after 6 hr. It was also 
observed that in case of BNS5, significant tear concentration of drug was 
found after 2 hr. This may ultimately affect onset as well as peak effect time of 
the drug. The increase in corneal residence may be attributed to the 
controlled release of drug from the nioserts as proved by in vitro release 
studies.  
 
Figure 7.5: Tear fluid concentration of betaxolol 
 
7.3.6.2 Ocular safety studies  
The ocular safety score of the formulation BNS6 and BNS5 was found to be 
1.5 and 2 at the end of 24 hr respectively and therefore, considered as 
practically non irritating(27)
In vivo antiglaucoma activity was carried out on rabbits using steroid induced 
glaucoma model. The data obtained was represented graphically as shown in 
Figure 7.6. Niosert BNS 6 showed faster peak effect (t
. Thus, it can be concluded that they were safe for 
ocular administration. 
7.3.6.3 In vivo antiglaucoma efficacy evaluation 
max) at 6 hr as 
compared to BNS5 which showed peak effect at 10 hr, this is due to the fact 
that BNS6 contains free drug as loading dose which started releasing fast due 
to polymer matrix erosion after insert administration followed by release of 
niosome encapsulated drug. The results indicate that nioserts showed better 
control over IOP as compared to eye drops. On the administration of nioserts, 
IOP was under control for the period of 24 hr while eye drops was effective in 
controlling IOP for the period of 10 hr. 
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Figure 7.6: IOP lowering activity of betaxolol nioserts and eye drops 
 
Important finding of the study was that control eyes of eye drops treated 
rabbits also showed reduction in IOP after 4 hr indicating systemic absorption 
of betaxolol due to nasolachrymal drainage of eye drops supporting the 
possibilities of side effects on long term use of eye drops. However, no such 
IOP reduction in control eyes were seen in case of niosert treated rabbits 
indicating no systemic absorption and hence side effects. Thus nioserts were 
also found better than eye drops in terms of preventing side effects of 
betaxolol. 
7.3.7 Ageing study 
Ageing study of the optimized nioserts was performed at R.T., 4 oC and 40 oC 
for the period of 6 months. The results showed that there was no change in 
physical appearance of ocuserts. The drug content (Tables 7.11 and 7.12) 
showed no marked change after six months. Folding endurance values were 
also comparable to initial values indicating good physical integrity after six 
months of storage at R.T. and 4 oC but at 40 oC, folding endurance was 
reduced by 40 to 50 % at the end of study possibly due to loss of moisture 
level of nioserts at high temperature. All the nioserts complied the test for 
sterility. These results concluded that nioserts were chemically, physically and 
microbiologically stable at RT for six months. It is better to store nioserts at 
refrigeration temperature to increase stability. However, further studies at 
different temperatures and humidity conditions are needed to establish their 
shelf life. 
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Table 7.11: Ageing studies of niosert BNS5 
 
 
Table 7.12: Ageing studies of niosert BNS6 
 
 
7.4 Conclusion 
Attempt has been made to incorporate niosomes in blend of polymers to 
design sustained release ocular delivery system of betaxolol. The ocular 
inserts prepared and evaluated in the current study were translucent and 
uniform in physicochemical properties. Due to use of mucoadhesive polymer, 
the surface of inserts was hydrophilic enough to be easily wetted by tear film 
and adhere to corneal surface. Niosomes were found to be uniformly 
distributed throughout the matrix of polymer as revealed from SEM. Thus the 
present work showed that incorporation of niosomes into polymeric matrix 
system can be successfully done in order to model ocular inserts providing 
promising controlled release delivery system. Niosome loaded ocuserts 
(Nioserts) showed sustained drug release for 24 hr. The control of IOP, 
systemic absorption and hence possible side effects using inserts was found 
to be better than conventional eye drops. Thus, on the basis of In vivo 
antiglaucoma activity, ocular safety test and ageing studies, it can be 
concluded that this betaxolol nioserts can be a promising once-a-day 
controlled release formulation. 
 
 
Time 
(days) 
4 o R.T. C           40 oC 
RDC FE RDC FE RDC FE 
0 99.85±0.85 103±2 99.85±0.85 103±2 99.85±0.85 103±2 
60 99.98±1.05 99.6±3.5 100.12±0.24 94.3±2.5 99.62±0.64 75.3±2.5 
90 99.48±0.79 96±1.5 99.81±0.69 91.6±2 98.94±1.08 60.6±2.6 
120 99.85±1.13 95.3±3 99.85±0.92 88±2.5 99.18±0.77 54.6±2.5 
Time 
(days) 
           4 o R.T. C      40 oC 
RDC FE RDC FE RDC FE 
0 101.07±1.22 94.3±2.18 101.07±1.22 94.3±2.18 101.07±1.22 94.3±2.18 
60 100.92±0.85 96±3.5 99.98±1.25 90.33±2.5 101.28±0.63 74.6±2.5 
90 100.12±0.28 97.6±1.5 100.28±0.82 85.6±2.8 98.82±0.85 62±2.6 
120 99.80±1.68 93.3±3.4 100.52±1.09 80±2.5 99.68±1.77 52.6±2.5 
Chapter 7 Formulation and evaluation of betaxolol nioserts 
 
Hitesh B. Gevariya        221                                                   Ph. D. Thesis 
 
7.5 Reference 
 
1. Saettone MF, Salminen L. Ocular inserts for topical delivery. Advanced 
drug delivery reviews. 1995;16(1):95-106. 
2. Rathore KS. In situ gelling ophthalmic drug delivery system: An overview. 
Int J Pharm Sci. 2010;2(4):30-4. 
3. Chan J, Maghraby GMME, Craig JP, Alany RG. Phase transition water-in-
oil microemulsions as ocular drug delivery systems: In vitro and in vivo 
evaluation. International journal of pharmaceutics. 2007;328(1):65-71. 
4. De Campos AM, Diebold Y, Carvalho ELS, Sanchez A, Josa Alonso M. 
Chitosan nanoparticles as new ocular drug delivery systems: In vitro 
stability, in vivo fate, and cellular toxicity. Pharmaceutical research. 
2004;21(5):803-10. 
5. Budai L, Hajda M, Budai M, Graf P, Baoni S, Noszail B, et al. Gels and 
liposomes in optimized ocular drug delivery: Studies on ciprofloxacin 
formulations. International journal of pharmaceutics. 2007;343(1):34-40. 
6. Mehta A. Niosomes. 2008. www.pharmainfo.net. Accessed 21-9-2009. 
7. Attia MA, Kassem MA, Safwat SM. In vivo performance of dexamethasone 
ophthalmic film delivery systems in the rabbit eye. International journal of 
pharmaceutics. 1988;47(1):21-30. 
8. Bharath S, Hiremath SR. Ocular delivery systems of pefloxacin mesylate. 
Die Pharmazie. 1999;54(1):55. 
9. Kaur IP, Singh M, Kanwar M. Formulation and evaluation of ophthalmic 
preparations of acetazolamide. International journal of pharmaceutics. 
2000;199(2):119-27. 
10. Ceulemans J, Vermeire A, Adriaens E, Remon JP, Ludwig A. Evaluation of 
a mucoadhesive tablet for ocular use. Journal of controlled release. 
2001;77(3):333-44. 
11. Abhilash AS, Jayaprakash S, Nagarajan M, Dhachinamoorthi D. Design 
and evaluation of timolol maleate ocuserts. Indian journal of 
pharmaceutical sciences. 2005;67(3):311-4. 
12. Balasubramaniam J, Srinatha A, Pandit JK, Nath G. In vitro microbiological 
evaluation of polyvinyl alcohol-based ocular inserts of ciprofloxacin 
hydrochloride. Indian journal of pharmaceutical sciences. 2006;68(5):626. 
Chapter 7 Formulation and evaluation of betaxolol nioserts 
 
Hitesh B. Gevariya        222                                                   Ph. D. Thesis 
 
13. Dandagi PM, Manvi FV, Patil MB, Mastiholimath VS, Rathod R. 
Development and evaluation of ocular films of cromolyn sodium. Indian 
journal of pharmaceutical sciences. 2004;66(3):309-12. 
14. Manvi FV, Dandagi PM, Gadad AP, Mastiholimath VS, Jagadeesh T. 
Formulation of atransdermal drug delivery system of ketotifen fumarate. 
Indian journal of pharmaceutical sciences. 2003;65(3):239-43. 
15. Gupta R, Mukherjee B. Development and in vitro evaluation of diltiazem 
hydrochloride transdermal patches based on povidone-ethylcellulose 
matrices. Drug development and industrial pharmacy. 2003;29(1):1-7. 
16. Sankar V, Chandrasekaran AK, Durga S, Geetha G, Ravichandran V, 
Vijayakumar A, et al. Desion and evaluation of diclofenac somun 
ophthalmic inserts. The Indian Pharmacist. 2005;4(41):98-100. 
17. Sanap GS, Dama GY, Hande AS, Karpe SP, Nalawade SV, Kakade RS, 
et al. Preparation of transdermal monolithic systems of indapamide by 
solvent casting method and the use of vegetable oils as permeation 
enhancer. International Journal of Green Pharmacy. 2008;2(2):129. 
18. Ceschel GC, Maffei P, Gentile M. Design and evaluation of a new 
transdermal formulation containing chlorpheniramine maleate. Drug 
development and industrial pharmacy. 1999;25(9):1035-9. 
19. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. 
European journal of pharmaceutical sciences. 2001;13(2):123-33. 
20. Ritger PL, Peppas NA. A simple equation for description of solute release 
ii. Fickian and anomalous release from swellable devices. Journal of 
controlled release. 1987;5(1):37-42. 
21. Ritger PL, Peppas NA. A simple equation for description of solute release 
i. Fickian and non-fickian release from non-swellable devices in the form of 
slabs, spheres, cylinders or discs. Journal of controlled release. 
1987;5(1):23-36. 
22. Sterility testing.  Indian pharmacopoeia 2007. New Delhi: Indian 
Pharmacopoeia Commission, Ministry of Health and Family Welfare, Gov 
of India; 2007. p. 52-9. 
23. Lee VHL, Swarbrick J, Stratford Jr RE, Morimoto KIMW. Disposition of 
topically applied sodium cromoglycate in the albino rabbit eye. Journal of 
Pharmacy and Pharmacology. 1983;35(7):445-50. 
Chapter 7 Formulation and evaluation of betaxolol nioserts 
 
Hitesh B. Gevariya        223                                                   Ph. D. Thesis 
 
24. Greaves JL, Wilson CG, Birmingham AT. Assessment of the precorneal 
residence of an ophthalmic ointment in healthy subjects. British journal of 
clinical pharmacology. 1993;35(2):188. 
25. Felt O, Furrer P, Mayer JM, Plazonnet B, Buri P, Gurny R. Topical use of 
chitosan in ophthalmology: Tolerance assessment and evaluation of 
precorneal retention. International journal of pharmaceutics. 
1999;180(2):185-93. 
26. Mahalaxmi D, Samarth MM, Shiravadekar HS, Sanghavi NM. Stability-
indicating hplc method for betaxolol hcl and its pharmaceutical dosage 
forms. Drug development and industrial pharmacy. 1996;22(9-10):1037-9. 
27. Wilhelmus KR. The draize eye test. Survey of ophthalmology. 
2001;45(6):493-515. 
28. Draize JH, Woodard G, Calvery HO. Methods for the study of irritation and 
toxicity of substances applied topically to the skin and mucous 
membranes. Journal of pharmacology and Experimental Therapeutics. 
1944;82(3):377-90. 
29. Jani A, Goyal RK, Shah GB, Mehta AA. Effect of calcium channel blockers 
on intraocular pressure in rabbits. Iranian Journal of Pharmacology and 
Therapeutics. 2005;4(2):95-9. 
30. Knepper PA, Collins JA, Frederick R. Effects of dexamethasone, 
progesterone, and testosterone on iop and gags in the rabbit eye. 
Investigative ophthalmology & visual science. 1985;26(8):1093-100. 
31. Gupta SK, Saxena R, Agarwal R, Galpalli ND, Srivastava S, Agrawal SS. 
Estimation of intraocular pressure in rabbits using noncontact tonometer: A 
comparative evaluation with schiotz tonometer. Methods and findings in 
experimental and clinical pharmacology. 2007;29(6):405-10. 
32. Gonnering R, Edelhauser HF, Van Horn DL, Durant W. The ph tolerance 
of rabbit and human corneal endothelium. Investigative ophthalmology & 
visual science. 1979;18(4):373-90. 
33. Golomb G, Fisher P, Rahamim E. The relationship between drug release 
rate, particle size and swelling of silicone matrices. Journal of controlled 
release. 1990;12(2):121-32. 
34. Fan L, Singh SK. Controlled release: A quantitative treatment: Springer-
Verlag Berlin; 1989. 
  
 
 
 
CHAPTER 8 
SUMMARY 
Chapter 8                                                                                                                                      Summary 
Hitesh B. Gevariya                                                   224                                                    Ph. D. Thesis 
             
 
 
 
8. SUMMARY 
Eye being a most delicate organ, ocular drug delivery is a challenge for the 
formulator. Recent trend in ocular research is to formulate a dosage form 
which not only prolongs the residence of system in eye but also helps to 
reduce the elimination of the drug and side effects. In the present study, 
successful efforts were made to develop such dosage forms. 
The ocular inserts were prepared using composite polymeric blend of PMMA 
and PEO by solvent casting technique. A 32 full factorial design was employed 
to optimize the formulation. Inserts prepared in the current study were 
semitransparent and uniform in physicochemical properties. Blending of PEO 
into PMMA matrix was uniform. All the inserts showed drug release for the 
period of 24 hr in vitro. The control of IOP, systemic absorption and hence 
possible side effects using inserts was found to be better than conventional 
eye drops.  
Betaxolol containing niosomes were prepared using two different surfactants 
span and tween and evaluated for in vitro and in vivo tests. A 32 full factorial 
design was employed to study the effects of independent variables on 
selected responses. Morphological studies revealed that all the formulations 
were spherical in shape and existed as separate particles. Drug entrapment 
was higher enough to incorporate required dose of drug in minimum possible 
concentrated niosomal suspension. The release of drug from niosomes was 
controlled by diffusion for a prolonged period of time. Both the optimized 
formulations showed better control of IOP as compared to eye drops. 
In nioserts, niosomes were found to be uniformly distributed throughout the 
matrix of polymer as revealed from SEM. Thus the present work showed that 
incorporation of niosomes into polymeric matrix system can be successfully 
done in order to provide promising controlled release delivery system. 
Nioserts showed sustained drug release for 24 hr. In vivo study showed that 
the control of IOP using nioserts was found to be better than conventional eye 
drops. 
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Long Acting Betaxolol Ocular Inserts based on Polymer Composite 
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Abstract: Poor bioavailability and therapeutic response of conventional therapy due to many pre-corneal constraints ne-
cessitate the development of novel controlled and sustained ocular drug delivery to become a standard one in modern 
pharmaceutical era. This investigation aimed to study the drug release kinetics of betaxolol hydrochloride from a hydro-
phobic matrix system of PMMA cast with incorporating different proportions of polyethylene oxide (PEO) and evaluate 
its ability to improve ocular bioavailability and duration of action for the drug. Matrix type ocular inserts were prepared 
by the film casting technique and characterized in vitro by drug release studies using a flow through apparatus that simu-
lated the eye conditions. All the formulations were subjected to physicochemical evaluation. Rabbit model with steroid 
induced glaucoma was used to establish in vivo efficacy of inserts. Polymer composition and concentration significantly 
affected the drug release based on change in diffusional path length and formation of gelaneous pores by polymer erosion. 
Formulations released the drug by non-fickian diffusion including anomalous transport (0.5<n<1) and super case II trans-
port (n>1). It was also observed that increasing the proportion of PEO in to PMMA does not affect the blend miscibility. 
IVIVC suggested no significant difference (P< 0.001) between in vitro and in vivo release of drug from inserts. In vivo 
IOP lowering activity was better for optimized insert F8 (for 24 h) as compared to eye drops (10 h). This ocular insert 
could be a promising once-a-day sustained release formulation for treating glaucoma. 
Keywords: Betaxolol hydrochloride, ocular delivery, once-a-day ocuserts, polymer composite, release kinetics, sustained  
release. 
INTRODUCTION 
 Continuous delivery of drugs to the eye offers major ad-
vantages over conventional therapies that involve admini-
stration of drug solutions or suspensions as eye drops. Eye 
drop administration often results in poor bioavailability and 
therapeutic response due to rapid precorneal elimination of 
the drug and is also associated with patient compliance prob-
lems [1, 2]. After instillation of an eyedrop, typically less 
than 5% of an applied dose reaches the intraocular tissues. 
This is due to tightness of the cornea1 barrier and rapid loss 
of the instilled solution from the precorneal area [3-5]. 
 There are two main strategies for improvements of ocular 
drug delivery: increasing the corneal permeability and pro-
longing the contact time on the ocular surface. Most formu-
lation efforts aim at maximizing the absorption through pro-
longation of the drug residence time in the conjunctival sac 
[6, 7]. Many colloidal drug carriers like nanoparticles, 
liposomes, niosomes have been investigated as an alternative 
approach to deliver the drug at right dosage to right target 
organ, to prevent degradation, metabolism and cellular efflux 
in the course of drug delivery [8-10]. A basic concept in oph-
thalmic research and development is that the therapeutic ef-
ficacy of an ophthalmic drug can be greatly improved by 
prolonging its contact with the corneal surface. Ophthalmic 
inserts offer many advantages over conventional dosages 
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forms, like increased ocular residence, possibility of releas-
ing drug at a slow and constant rate, accurate dosing, exclu-
sion of preservatives and increased shelf life. Design, con-
struction and technology of ocular insert in a controlled and 
sustained ocular delivery device are gaining rapid improve-
ment to overcome these constraints [11, 12]. 
 Betaxolol is selective beta-1-adrenegic receptor blocker 
and used in the treatment of ocular hypertension and chronic 
open angle glaucoma. There are only a few ocular inserts 
available on the market, made of EVA as a rate controlling 
membrane [13, 14]. Likewise, poly (methyl methacrylate) 
(PMMA) is also an excellent film-forming polymer but the 
films of PMMA alone are brittle [15]. It offers more resis-
tance to the diffusion of drug molecules, and is less explored 
as a polymer for ocular delivery of drugs. The current litera-
tures indicate that no inserts are made of hydrophobic mono-
lithic systems using betaxolol. Hence this investigation has 
been designed to study the drug release kinetics of betaxolol 
from a hydrophobic matrix system of PMMA cast with in-
corporating different proportions of polyethylene oxide 
(PEO). With the addition of hydrophilic polymer to PMMA, 
the films become resilient and do not break easily and it was 
ascertained that the diffusion might improve. 
MATERIALS AND METHODS 
 Betaxolol HCL was obtained as a complimentary gift 
sample from Ciron Drugs and Pharmaceuticals Pvt. Ltd., 
Mumbai, India. PMMA (molecular weight 120,000) was 
purchased from Loba Chemie, Mumbai, India. PEO powder 
2    Current Drug Delivery, 2013, Vol. 10, No. 2 Gevariya and Patel 
(molecular weight 1000,000) was purchased from Alfa Aesar 
Inc., USA. Other reagents and chemicals used in the research 
were of analytical grade. 
Preparation of Ocular Inserts 
 The matrix films were prepared by film casting method 
from PEO and PMMA using 32 full factorial design (Table 1 
and 2). Briefly, weighed quantities of the drug and polymers 
were solubilized in chloroform with continuous mixing using 
magnetic stirrer at 25 rpm. The solutions were then sonicated 
for 30 seconds to remove the air. Polymeric drug solutions 
were poured on to Teflon coated petridish. The matrix films 
were dried constantly under the ambient conditions. In all the 
films DBP (30% w/w) was incorporated as a plasticizer [16-
18]. Inserts were sterilized under UV for 1hr [19] and inserts 
were packed individually in sterilized aluminum foils which 
were further stored in amber colored glass bottles at room 
temperature. 
Physicochemical Evaluation of Ocular Inserts 
 Prepared inserts were evaluated for physical appearance, 
surface pH, thickness, weight variation, folding endurance, 
tensile strength, moisture content, water transmission rate, 
water uptake and drug content uniformity.  
 Surface pH was determined by allowing inserts to swell 
in a closed petridish at room temperature for 30 minutes in 
0.1ml of distilled water [20]. PH paper was kept on surface 
and after one minute the color developed was compared with 
the standard colour scale. Thickness was evaluated using a 
micro meter of sensitivity of 0.001mm (mitutoyo, Japan); the 
average of ten readings was taken [21]. From each batch ten 
inserts were weighed individually using digital balance 
(Shimadzu, Japan) and mean weight was recorded [22]. 
Folding endurance was determined by repeatedly folding a 
small strip of ocular film at the same place till it broke. Drug 
content was estimated by triturating ocular inserts in 20 ml 
of phosphate buffer pH 7.4 with the help of mortar and pes-
tle. The solution was filtered and one ml solution was with-
drawn, diluted and measured by UV-Visible Spectropho-
tometer at 274 nm [23]. 
 Tensile strength was determined with an instrument as-
sembled in the laboratory. A small strip of ocular film meas-
uring 5 cm?1 cm was cut with a sharp blade. One end of the 
film was fixed by placing in the film holder. Another end of 
the film was fixed with the help of forceps having triangular 
ends to keep the strip straight while stretching and a hook 
was inserted. A thread was tied to the hook, passed over the 
pulley and a small pan attached to the other end to hold 
weights. A small pointer was attached to the thread that trav-
els over the graph paper affixed on the base plate. 
 To determine elongation and tensile strength, the film 
was pulled by means of a pulley system. Weights were 
gradually added (5gms/min) to the pan to increase the pull-
ing force till the film was broken. Elongation was deter-
mined simultaneously by noting the distance traveled by the 
Table 1. Independent Factors for Formulation of Betaxolol Ocular Inserts. 
Factor A 
Drug to Polymer Ratio (Drug : Total Polymer) 
Factor B 
Polymer to Polymer Ratio (PMMA : PEO) Independent Variable 
Low Medium High Low Medium High 
Coded Levels -1 0 1 -1 0 1 
Actual Levels 1:2 1:4 1:6 9:1 8:2 7:3 
 
Table 2. 3
2 
Full Factorial Design of Betaxolol Ocular Inserts. 
Factor A 
Drug to Polymer Ratio 
Factor B 
Polymer to Polymer Ratio (PMMA:PEO) Formulation 
Coded Actual Coded Actual 
F1 -1 1:2 -1 9:1 
F2 -1 1:2 0 8:2 
F3 -1 1:2 1 7:3 
F4 0 1:4 -1 9:1 
F5 0 1:4 0 8:2 
F6 0 1:4 1 7:3 
F7 1 1:6 -1 9:1 
F8 1 1:6 0 8:2 
F9 1 1:6 1 7:3 
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pointer on the graph paper before the film was broken. The 
weight necessary to break the film was noted as break force. 
Percentage elongation at break and tensile strength was cal-
culated using the following formulae [24]. 
% elongation at break = IB  – Io ? 100  
Where Io is the original length of the film and  
 IB is the length of the film at break when stress was applied.  
Tensile strength =
Break force
ab (1 + ?L / L)  
Where a, b and L are width, thickness and length of the strip 
respectively  
?L is the elongation at break. 
 Break force = weight required to break the film (Kg). 
 Percentage moisture content, moisture uptake [24] and 
water vapor transmission studies [25] were carried as per the 
methods prescribed elsewhere. 
Surface Morphology 
 Surface characteristics of polymer blend were studies by 
Scanning electron microscopy. Films were mounted on an 
aluminum stub using double-sided adhesive carbon tape and 
coated with gold palladium using JEOL JFC 1600 auto fine 
coater for 90 seconds. Samples were examined using scan-
ning electron microscope JSM-6380 LV (Jeol Ltd., Tokyo, 
Japan) at 20 kv accelerating voltage. 
Hydrophilicity 
 The measurement of contact angle was performed at R.T. 
by optical tensiometry using contact-angle meter (Theta op-
tical tensiometer, Biolin scientific AB, Sweden) equipped 
with T200 60 fps digital camera. Drops of STF (pH 7.4) 
were prepared with a precision syringe (1 ml, Hamilton 
1001TPLT) and were dropped onto the surface of the poly-
mer. The static contact angle was measured at contact time 
t= 10 s. 
Drug-Excipients Compatibility Study 
Fourier Transform Infrared (FTIR) Spectroscopy 
 The FTIR spectra of the pure drug and physical mixture 
(betaxolol, PEO and PMMA) were taken as KBr pellets in 
the range of 4000–650 cm–1 (FT/IR-4100 type A spectropho-
tometer, Jasco, Japan). The infrared analysis of optimized 
insert was carried out in the same range by ATR-IR spec-
troscopy (Perkin Elmer Model 1600 FT-IR spectrophotome-
ter with ATR mode Perkin Elmer, USA). 
Physical State of Drug 
Differential Scanning Calorimetry (DSC) 
 Differential scanning calorimetry (DSC) scans of pure 
drug and drug loaded ocular insert were performed using 
DSC 1/700 (Mettler Toledo, Germany). The analysis was 
performed with a heating range of -20 0C to 250 °C and at a 
rate of 10°C per minute in nitrogen atmoshere. The sample 
weight was approximately 6 mg. 
X-Ray Diffraction 
 X-Ray diffraction (XRD) patterns of pure betaxolol and 
ocular film were recorded using a powder X-Ray diffracto-
meter (XRD-D8 Advance, Bruker, Germany) over the inter-
val10-90° 2?-1. The experimental condition were: generator 
tension (voltage) of 38 kV, generator current of 34 mA, scan 
step time of 30.6 sec-1 and scan step size of 0.049° 2?-1. 
In Vitro Drug Permeation Study 
 Since there was no specific official method prescribed for 
in vitro studies of ocular inserts, we fabricated an open flow 
through assembly, simulating the condition of the ocular 
cavity, by using the classical standard cylindrical tube which 
has the diameter of 15 mm. Dialysis membrane (Dialysis 
membrane 110, mw cut-off 12000-14000, Hi Media, India), 
immersed in water for one hour to remove the preservatives 
followed by rinsing in phosphate buffered saline (PBS) solu-
tion, acted as corneal epithelium, was tied to one end of open 
cylinder which acted as donor compartment. An ocular insert 
was placed inside this compartment with 0.7 ml of simulated 
tear fluid (STF pH 7.4). Then, the glass tube was suspended 
in the dissolution flask of a USP dissolution apparatus such 
that entire surface of the membrane was in contact with the 
receptor compartment containing 100 ml of STF. The con-
tent of the receptor compartment was stirred continuously at 
25 rpm. Samples of 1 ml were withdrawn from the receptor 
compartment at periodic intervals and replaced by equal vol-
ume of fresh solution. The samples were analyzed spectro-
photometrically using STF as blank [26, 27].  
 From the drug permeation data, diffusion rate, steady 
state flux and permeability coefficient were derived [28]. 
The results of diffusion study were also fitted to zero-order 
(%release Vs time), higuchi (%release Vs sq. root of time) 
and Korsmeyer and Peppas (log %release Vs log time) equa-
tion [29]. 
In Vivo Release Study 
 Approval for the use of animals in the study was obtained 
from Institutional Animal Ethics Committee 
(1338/c/CPCSEA). On the day of experiments, the sterilized 
ocular inserts were inserted into one eye of seven rabbits at 
the same time and contralateral eye served as control. After 
1, 2, 4, 6, 10, 22 and 24 hrs, the inserts were carefully re-
moved and analyzed for remaining drug content by UV spec-
trophotometer [26, 27].  
Ocular Safety Study 
 The ocular safety of administered delivery system was 
studied based on the Draize Eye Test. The observations 
based on scoring approach established the safety of the de-
veloped ocular inserts in rabbit eye [30]. 
In Vivo Antiglaucoma Activity  
 In vivo intra ocular pressure lowering activity of opti-
mized Ocular insert of Betaxolol was studied in normoten-
sive albino rabbits of either sex. The animals were housed 
under well controlled conditions of temperature, humidity 
and 12/12 – h, light-dark cycle, with free access to food and 
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water. No ocular abnormalities were found on external and 
slit-lamp examination prior to beginning of the study. 
 Glaucoma was induced using topical steroid (dexametha-
sone) by the method prescribed elsewhere [31]. The basal 
intraocular pressure was measured by schiotz tonometer. The 
drug formulation was placed in cul-de-sac of rabbits. Total 
12 rabbits were divided in to three groups each containing 4 
rabbits. First group was treated with marketed preparation of 
betaxolol HCL eye drop equivalent to 0.50 mg. In second 
group placebo film and in third group medicated film (F8) of 
betaxolol HCL was inserted in to lower cul de sac of rabbits. 
The intraocular pressure (IOP) changes were recorded up to 
26 h at specified time intervals. The ocular hypotensive ac-
tivity is expressed as the average difference in IOP according 
to the equation ?IOP = IOP’0’ time – IOP’t’time [32].  
Stability Study 
 Stability studies were carried out according to ICH 
guidelines [33]. Ocular inserts (F8) were stored in amber 
colored glass bottles at 3 different temperatures 4oC, Room 
temperature (R.T.) and 40±0.5 oC for a period of 6 months. 
The samples were withdrawn after 30, 60, 120 and 180 days 
and analyzed for physical appearance, drug content and fold-
ing endurance. 
RESULTS AND DISCUSSION 
Physico-Chemical Evaluation 
 In the present investigation solvent evaporation technique 
is adopted & it was found to be giving thin uniform films. 
The films were transparent with smooth surface indicating 
good miscibility of both the polymers. The physicochemical 
evaluation data presented in Table 3 indicates that the thick-
ness of the matrix films varies from 0.118±0.06 mm to 
0.25±0.054 mm. All the formulations exhibited thickness 
with low standard deviation values ensuring the uniformity 
of the films prepared by film casting method. Formulations 
were not thick enough to produce any irritation while placing 
and being in cul-de-sac as inferred from ocular irritancy test. 
 The results showed that weights of formulations ranged 
from 4.09±0.069 mg to 9.09±0.04 mg. The drug content of 
all the formulations was found to be within the range of 
0.495±0.002 mg to 0.51±0.007 mg for matrix films. The 
minimum intrabatch variations revealed the suitability of the 
process used to prepare the ocular inserts.  
 The folding endurance for all formulations was good. 
The maximum folding endurance of formulation F3 was 
99.3±2.51 foldings and formulation F7 showed minimum 
folding endurance of 61.3±2.08 foldings. This showed that as 
the concentration of polymer increased in the formulation, 
folding endurance was decreased. It was also observed that 
as the proportion of PEO in PMMA increases, flexibility of 
films increases as indicated by increasing folding endurance 
values. High tensile strength values indicate good physical 
strength of the films. As polymer ratio increases, tensile 
strength decreases. The surface pH of the prepared inserts 
varied between 6.5 to 7.5, indicating that the inserts did not 
have an irritation potential as the pH is within the accepted 
ocular range [34]. 
Surface Morphology (SEM) 
 SEM study (Fig. 1) revealed that surface of the ocular 
films are smooth indicating the complete miscibility of PEO 
with PMMA. This finding is similar to that of J.baldrian [35] 
who suggested that when the concentration of PEO is less 
than or equal to 20wt. %, the polymers are completely mis-
cible and the blend is amorphous. This result is also sup-
ported by DSC and XRD studies (Figs. 2 & 3). 
Hydrophilicity 
 Static STF Contact angles (?s) of films were below 50 
(data not shown) indicating increasing hydrophilicity of the 
surface as the concentration of PEO increased in the matrix. 
As ?s is only related to the outermost 10Å of each samples, 
the surface composition of blend is greatly correlated with ?s 
[36]. This result also reveals that PEO was uniformly dis-
tributed throughout the bulk of PMMA and concentration of 
PEO at surface increases with bulk concentration, making 
Table 3. Physicochemical Evaluation Data of Different Batches of Ocular Films. 
Formulation Weight of Films (mg)*  Thickness (mm)
#
  
Tensile Strength
# 
Kg/cm
2
 
%Elongation at Break
#
  Folding Endurance
#
 
F1 4.09± 0.069 0.118± 0.06 0.75 ± 0.03  3.26± 0.21 69±2  
F2 4.2± 0.046  0.13± 0.0063 0.68 ± 0.01  8.13± 0.23 90.3±2.08  
F3 4.11± 0.052 0.148± 0.0075 0.57 ± 0.01  12.63± 0.4 99.3±2.51  
F4 6.43± 0.094 0.19 ± 0.05 0.84 ± 0.02  2.95± 0.32 65.3±3.51  
F5 6.49± 0.082 0.20± 0.007  0.72 ± 0.01  7.18± 0.43 81±2.61  
F6 6.44± 0.044 0.21± 0.0054  0.65 ± 0.01 12.17± 0.21 94.6±2.08  
F7 8.89± 0.057 0.24± 0.003  1.84 ± 0.05  2.28± 0.32 61.3±2.08  
F8 9.09± 0.04 0.248± 0.004  0.92 ± 0.02  7.89± 0.46 73.3±2.52  
F9 8.91± 0.052 0.25± 0.054 0.80 ± 0.02  11.93± 0.54 89.6±3.78 
All readings are in the form of Mean±SD,   # Average of 3 runs,   *Average of 10 determinations. 
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the insert hydrophilic enough to be wetted by tear fluid and 
adhere to corneal surface for longer duration. 
Drug-Excipients Compatibility Study 
 Interpretation of IR spectrum [37, 38] of Betaxolol  
(Fig. 2A) shows characteristic peaks at 3237 cm-1 (Hydroxyl 
group O-H stretching), 2928 cm-1 (Methyl C-H stretching), 
2858 cm-1 (Methylene C-H stretching), 1612 cm-1 (Aromatic 
ring C=C-C stretching ), 1557 cm-1 and 1513 cm-1 (Secon-
dary amine N-H bending), 1474 cm-1 (Methylene C-H bend-
ing ), 1376 cm-1 (Methyl C-H sym. bending ), 1246 cm-1 
(alkyl aryl ether c-o-c stretching), 1179 cm-1 (aromatic in 
plane C-H bending), 1087 cm-1 (aliphatic ether c-o-c stretch-
ing) and 1050 (Amine C-N stretching). FTIR spectra of mix-
ture (Fig. 2B) and insert F8 (Fig. 2C), in comparison to IR 
spectra of pure drug, show no substantial shifting of the posi-
tion of the functional groups, indicating no major interaction 
between drug and polymers. However, broadening and re-
duced intensity of peaks in IR spectra of inserts indicates 
encapsulation of betaxolol in polymeric matrix. Although 
shifting and broadening of drug peak at 3237 cm-1in the IR 
spectra of Insert F8 indicate that hydrogen bonding has oc-
curred between the lone electron pairs of the oxygen atom of 
polymers and the hydrogen atom of the hydroxyl group of 
the drug. 
Physical State of Drug 
DSC 
 From the overlay of the DSC thermograms, it has been 
observed that Betaxolol is crystalline in nature (Fig. 3).  
 Thermogram exhibited a sharp melting endotherm at an 
onset temperature of 112.82 0 C, a peak temperature of 
119.76 0 C and a heat of fusion of 6.97 J/g. While the ther-
mogram of film shows crystallization of betaxolol from glass 
at 67.18 0 C followed by fusion at 116.89 0 C. The thermal 
behavior of film suggested that the drug is present in the film 
as semicrystalline form as the fusion peak in the film is very 
weak compared to the pure drug. 
XRD 
 XRD spectrum of Betaxolol (Fig. 4) revealed that the 
drug is crystalline in nature. XRD pattern of film showed 
that characteristic peaks of betaxolol were reduced in num-
ber and intensity indicating that the drug crystallinity was 
decreased in the inserts. 
 
 
Fig. (1). Scanning electron microscopy (SEM) images of inserts F7 and F8. Experimental condition: magnification= ?1000, Acc. V 20 kV, 
signal SEI, ___ 10 ?m. 
 
 
 
Fig. (2). IR Spectra of (A) Betaxolol HCL (B) Mixture of PMMA/ PEO/BX (C) Ocular Insert F8. 
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Fig. (3). DSC spectra of pure drug and ocular film. 
 
 
 
Fig. (4). XRD patterns of Betaxolol (black line) and Insert F8(red line). 
 
In Vitro Diffusion Study 
 In vitro results revealed that drug release from inserts 
was influenced by both the factors namely polymer concen-
tration and polymer composition.  
Effect of Polymer Concentration 
 In vitro permeation profile shows that concentration of 
polymer in the film plays a very important role on drug per-
meation. ANOVA study shows that factor A (drug to poly-
mer ratio) has significant effect on maximum drug perme-
ated i.e. (Fig. 5) shows that as concentration of polymer in-
creases there was decrease in drug permeation. 
 Result of flux (Table 4) also favors that drug release was 
inversely proportional to polymer concentration. Among all 
batches, maximum flux was found in case of F3 i.e. 0.01730 
mg/cm2hr.  
 Diffusion of molecule through polymer matrix was rate 
limiting step for permeation of molecule. The process of 
drug release in most controlled release devices is governed 
by diffusion, and the polymer matrix has a strong influence 
on the diffusivity as the motion of a small molecule is re-
stricted by the three-dimensional network of polymer chains. 
It has been reported that diffusion rate of molecule is in-
versely proportional to diffusion path [39]. Thickness of in-
serts increases with increasing the amount of polymer. This 
lead to an increase in diffusion path of molecules and so less 
release was observed in case of formulation containing high 
concentration of polymer. Descending order of cumulative 
drug permeated was found in following order: 
Eye drops>F3> F6 > F2 > F5 > F1 > F9 > F4 > F8 > F7 
Effect of Polymer Composition 
 In vitro permeation study shows that change in polymer 
blend will alter the drug permeation profile. ANOVA study 
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shows that factor B (HPMC to EC ratio) has significant ef-
fect on drug permeation profile. 
 Average diffusion rate of formulation F1 to F3 was found 
0.0247, 0.0273 & 0.0306 mg/h respectively. This shows that 
diffusion rate was increased with increase in PEO concentra-
tion. Similar observations were also found in case of batches 
F4 to F6 and F7 to F9. Result of flux also indicates that drug 
release was directly proportional to PEO concentration.  
 Results showed that increasing concentration of PMMA 
will retard the drug release and so drug permeation. Release 
rates were increased when the concentration of PEO in-
creased in the formulations. This is because as the proportion 
of this polymer in the matrix increased, there was an increase 
in the amount of water uptake and hydration of the polym-
eric matrix and thus more drugs was released [40]. The poly-
ether chains of PEO can form strong hydrogen bonds with 
water, therefore, when inserts are brought into contact with 
an aqueous medium, the polymer tends to hydrate, forming a 
superficial gel which eventually erodes as the polymer dis-
solves [41]. This is due to the fact that dissolution of aqueous 
soluble fraction of the polymer matrix leads to the formation 
of gelaneous pores. The formation of such pores leads to 
decrease in the mean diffusion path length of drug molecules 
to release into the diffusion medium and hence, to cause 
higher release rate. 
 The kinetic treatment of diffusion data is shown in Table 5. 
It can be concluded that Korsemeyer and Peppas model fit 
the best for all the formulations as correlation coefficient 
value for all the inserts were more than 0.98. This is 
followed by Higuchi and zero order equation. Inserts F4, F5 
and F7 released drug according to super case II transport 
mechanism while drug release from rest formulations 
followed anomalous transport. Drug release from such ma-
trices may be controlled by polymer swelling or erosion, or 
drug diffusion in the hydrated gel, or by these processes al-
together [41]. 
In Vivo Studies 
 The ocular insert showed 99.87% of drug release in vivo 
at the end of 24 hours which was comparable to in vitro drug 
 
 
Fig. (5). In vitro drug release profile of ocusert. 
 
Table 4. Permeation Parameters of Betaxolol Through Membrane. 
Diffusion Rate Dr Flux JS Permeability Coefficient KP 
Formulation 
mg/h mg/cm
2
h cm/h 
F1 0.0247 0.013958 2.79?10-2 
F2 0.0273 0.015459 3.09?10-2 
F3 0.0306 0.017299 3.46?10-2 
F4 0.0236 0.013364 2.67?10-2 
F5 0.0252 0.014275 2.86?10-2 
F6 0.0286 0.016195 3.24?10-2 
F7 0.0170 0.009609 1.92?10-2 
F8 0.0221 0.012514 2.50?10-2 
F9 0.0256 0.014499 2.90?10-2 
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release (Fig. 6). Thus there was good in vitro – in vivo corre-
lation for the ocular insert F8 indicating the effectiveness of 
the formulation to be used in vivo. Difference factor of 
0.0004 and similarity factor of 80.29 for the in vitro-in vivo 
release data of formulation F8 indicates no significant differ-
ence between in vitro release and in vivo performance of the 
inserts. 
 
 
 
Fig. (6). In vitro – in vivo correlation for formulation F8. 
 
 The ocular safety score of the formulation F8 was found 
to be 3 at the end of 24 hours and therefore, considered as 
minimally irritating [30]. This irritation might be due to the 
organic solvent used in the preparation of inserts. Thus, it can be 
concluded that inserts were safe for ocular administration. 
 In vivo IOP lowering study results (Fig. 7) revealed that 
in comparison to eye drops, formulation F8 showed better 
control of IOP up to 24h (P< 0.001).  
 A single instillation of one drop of 0.5% betaxolol eye 
drops controlled IOP well to the base level up to the period 
of 8 h and then after IOP was increased, while same dose of 
betaxolol from insert F8 controlled IOP up to 24 h. Peak 
effect was observed at 4 h and 6 h in case of eye drops and 
F8 respectively. The interesting finding of the study was that 
IOP was also lowered effectively in control eyes of eye drop 
treated group, which was not the case for inserts treated 
group. This can be an indirect measure of systemic absorp-
tion of the drug following eye drops treatment, indicating that 
ocusert provides better control over systemic side effects.  
 
 
 
Fig. (7). IOP lowering study. 
 
Stability Study 
 Stability study of the ocular insert F8 was performed at 
R.T., 4oC and 40oC for the period of 6 months. The results 
showed that there was no change in physical appearance of 
ocular inserts. The drug content showed no marked change 
after six months and folding endurance were good indicating 
no change in flexibility of the films. These results concluded 
that ocular insert F8 was chemically and physically stable at 
RT for 6 months. However, further studies at different tem-
peratures and humidity conditions are needed to establish 
their shelf life. 
 
Table 5. Kinetic Treatment of Release Study Data of Ocular Inserts. 
Zero Order Higuchi Korsmeyer – Peppas 
 Formulation  
 R
2
  R
2
 R
2
 N 
F1 0.9869 0.9789 0.995 0.9573 
F2 0.9714 0.9869 0.9944 0.8522 
F3 0.933 0.9836 0.9867 0.7785 
F4 0.9904 0.9721 0.9937 1.095 
F5 0.9752 0.9826 0.9871 1.024 
F6 0.9517 0.9891 0.9881 0.8423 
F7 0.9951 0.9445 0.9935 1.107 
F8 0.9986 0.9552 0.9963 0.9215 
F9 0.9859 0.9847 0.9979 0.8661 
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CONCLUSION 
 The ocular inserts prepared and evaluated in the current 
study are transparent and uniform in physicochemical prop-
erties. Due to addition of hydrophilic polymer, the surface of 
inserts was hydrophilic enough to be easily wetted by tear 
film. The blend of PEO in PMMA matrix was found to be 
homogenous and blend was amorphous in nature. No phase 
separation was observed in polymer composite as revealed 
from SEM, DSC and XRD studies. Thus the present work 
showed that incorporation of hydrophilic polymer into hy-
drophobic matrix system can be successfully done in order to 
model ocular inserts providing promising controlled release 
delivery system. Blending of PEO into PMMA matrix was 
uniform and it was observed that increasing the proportion of 
PEO in to PMMA increases the rate of release of betaxolol. 
The control of IOP, systemic absorption and hence possible 
side effects using inserts was found to be better than conven-
tional eye drops. Thus, on the basis of In vivo antiglaucoma 
activity, ocular safety test and stability studies, it can be con-
cluded that this betaxolol ocular insert can be a promising 
once-a-day controlled release formulation after due consid-
erations of human in vivo studies. 
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ANNEXURE 
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Scores for Grading the Severity of the Ocular Irritation (As per Draize Eye Irritancy Test) 
Sr. No. Observations Rabbit No 
1 CORNEA 1 2 3 
A Opacity - Degree of density (area which is more dense taken for reading) 
 
   Scattered or diffused area-details of iris clearly visible    
   Easily discemible translucent `areas, details of iris slightly obscured    
   Opalescent areas, no details of iris visible, size of pupil barely discemible    
   Opaque, iris invisible    
B Area of cornea involved 
    One quarter (or less) but not zero    
   Greater than one quarter-less than one-half    
   Greater than one half less than three quarters    
   Greater than three quarters up to whole area    
           Score equals – A×B×5        Total possible maximum = 80                                                                                    Total Score    
2 IRIS 
A Values 
 Folds above normal, congestion, swelling, circumcorneal injection (any one or all of these or combination of any thereof), iris still 
reacting to light (sluggish reaction is positive)    
No reaction to light hemorrhage; gross destruction (if any or all of these)     
           Score equals – A×5        Total possible maximum = 10                                                                                        Total Score    
3 CONJUNCTIVA 
A Redness (refers to palpebral conjunctiva only) 
 
   Vessels definitely injected above normal    
   More diffuse, deeper crimson red, individual vessel not easily discernible    
   Diffuse beefy red    
B Chemosis 
 
   Any swelling above normal (include nictitating membrane)    
   Obvious swelling with partial aversion of the lids    
   Swelling with lids about half closed    
   Swelling with lids about half closed to completely closed    
C Discharge 
    Any amount different from normal (doesn’t include small amount observed in inner cul-de-sac)     
   Discharge with moistening of the lids and hairs just adjacent to the lids    
   Discharge with moistening of the lids and considerable area around the eye    
             Score equals – (A+B+C)×2        Total possible maximum = 20                                                                           Total Score    
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